

Request Jan Delaval

Access DB# 158214

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha Qaz (STIC) Examiner #: 74141 Date: 7/5/05
Art Unit: 1616 Phone Number: 20622 Serial Number: 091091665
Mail Box and Bldg/Room Location: 4C70 Rm, 4A45 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Contraception process + kit

Inventors (please provide full names): Jan Enderikat et al

Earliest Priority Filing Date: 9/2/1998

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Ch 3-7, 14-30 + 36-77 are pending
All needs to be searched.

Please note

- 1) Crestagen is used first
- 2) Claim 14 is one of the main claims

Please see attached sheet

Thank you

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN <input checked="" type="checkbox"/>
Searcher Phone #: <u>22504</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>7/17/05</u>	Bibliographic <input checked="" type="checkbox"/>	Dr. Link _____
Date Completed: <u>7/17/05</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>20</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>6</u>	Other _____	Other (specify) _____

=> d his

(FILE 'HOME' ENTERED AT 13:45:37 ON 07 JUL 2005)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:45:57 ON 07 JUL 2005

L1 1 S (DE95-19549264 OR WO96-DE2486)/AP,PRN
E ENDRIKAT J/AU
L2 22 S E3,E4
E DUESTERBERG B/AU
L3 35 S E3,E4
E DUSTERBERG B/AU
L4 13 S E3
E DEUSTERBERG B/AU
E REILHAD P/AU
E REILHAC P/AU
L5 6 S E3,E5
SEL RN L1

FILE 'REGISTRY' ENTERED AT 13:50:36 ON 07 JUL 2005

L6 13 S E1-E13
SEL RN
L7 349 S E14-E26/CRN

FILE 'HCAPLUS' ENTERED AT 13:52:09 ON 07 JUL 2005

L8 88422 S L6
L9 66447 S GESTODENE OR PROGESTERONE OR LEVONORGESTREL OR CYPROTERONE AC
L10 197 S DIENOGEST OR 3 KETODESOGRESTREL OR 3 KETO DESOGRESTREL
L11 173 S DIENOGESTRIL OR SHB 331 OR WL 70 OR ZK 30595 OR CCRIS 6523 OR
L12 96 S ORG 2969 OR DICROMIL OR CYCLOSA OR CERAZETTE OR MARVELON OR (
L13 3423 S NORGESTREL OR DEXNORGESTREL OR NORPLANT OR NORGESTRELEM OR AN
L14 1714 S CHLOROMADINONE OR CHRONOSYN OR FERTILETTEN OR GESTAFORTIN OR
L15 105972 S L8-L14
L16 798 S GESTAGEN
L17 106265 S L15,L16
E ESTROGEN/CT
E E41+ALL
L18 9208 S E7-E9
L19 33901 S E6
L20 1273 S E18,E19
L21 19561 S L17 AND L18-L20
L22 40424 S L17 AND (ESTROGEN? OR OESTROGEN?)
L23 40464 S L21,L22
E CONTRACEPT/CT
L24 529 S E10
L25 6873 S E11,E12,E13,E15,E16,E17,E19
L26 954 S L23 AND L24,L25
E E8+ALL
L27 1310 S E5 AND L23
L28 1310 S L26,L27
L29 1688 S L23 AND CONTRACEPT?
L30 1690 S L23 AND ?CONTRACEPT?
L31 2 S L30 NOT L29
L32 2690 S L23 AND ?IMPLANT?
E BIRTH CONTROL/CT
E E4+ALL
E E2+ALL
L33 79 S L23 AND (ANTIIMPLANT? OR ANTIOVUL? OR ANTI() (IMPLANT? OR OVUL
L34 1 S L33 AND PROGESTOGEN/TI
E QUE L18

```

L35      622 S L19 AND L29
          E PROGEST/CT
          E E56+ALL
L36      876 S E7,E8
L37      5144 S E6
L38      275 S L35 AND L36,L37
L39      2466 S L18-L20 AND L36,L37
L40      433 S L39 AND CONTRACEPT?
L41      286 S L39 AND L24,L25
L42      433 S L40,L41,L38
L43      254 S L42 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)
L44      10 S L1-L5 AND L23,L39
          SEL DN AN 10
L45      9 S L44 NOT E1-E3
L46      9 S L45 AND L1-L5,L8-L45
L47      7 S L46 NOT (ESTRIOL OR TUMOR)/TI
L48      251 S L43 NOT L44
L49      146 S L48 AND (COMBIN? OR COMPOSITION OR SYNERG? OR MIX? OR COTHERA
          SEL DN AN L49 1 2 5 6 8-10 14-16 18 12 22-26 28-31 34 36 37 40
L50      64 S L49 AND E4-E193
L51      105 S L48 NOT L49
          SEL DN AN 44 54 81
L52      3 S L51 AND E194-E202
L53      74 S L47,L50,L52
L54      74 S L53 AND L1-L5,L8-L53
L55      74 S L54 AND (?ESTROGEN? OR ?PROGEST? OR ?GESTAG?)
L56      74 S L55 AND (?IMPLANT? OR ?OVUL? OR ?UTER? OR ?CONTRACEPT?)
L57      6 S L56 AND (?MULTIPHAS? OR ?MULTI PHAS?)
L58      0 S L56 AND (?DIPHAS? OR DI PHAS?)
L59      5 S L56 AND (?TRIPHAS? OR TRI PHAS?)
L60      11 S L57,L59
L61      63 S L56 NOT L60
          SEL HIT RN L56

```

FILE 'REGISTRY' ENTERED AT 14:47:17 ON 07 JUL 2005

L62 13 S E203-E215

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:47:30 ON 07 JUL 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2005 HIGHEST RN 853990-77-9

DICTIONARY FILE UPDATES: 6 JUL 2005 HIGHEST RN 853990-77-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```

*****
*
* The CA roles and document type information have been removed from *

```

* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide can tot 162

L62 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 67392-87-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, [6R-(6 α ,7 α ,8 β ,9 α ,10-
beta.,13 β ,14 α ,15 α ,16 α ,17 β)]-

OTHER NAMES:

CN 1,2-Dihydrospirorenone

CN 3-Oxo-6 β ,7 β :15 β ,16 β -dimethylene-17 α -pregn-4-en-
21,17-carbolactone

CN BRN 4765500

CN CCRIS 6523

CN Dihydrospirorenone

CN Drospirenona

CN Drospirenone

CN ZK 30595

FS STEREOSEARCH

MF C24 H30 O3


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN,
DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,
IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

143 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 143 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487431
 REFERENCE 2: 142:476356
 REFERENCE 3: 142:404258
 REFERENCE 4: 142:349202
 REFERENCE 5: 142:341950
 REFERENCE 6: 142:328889
 REFERENCE 7: 142:310089
 REFERENCE 8: 142:69384
 REFERENCE 9: 142:49378
 REFERENCE 10: 141:406204

L62 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 65928-58-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
 (CA INDEX NAME)

OTHER NAMES:

CN Dienogest

CN Dienogestril

CN STS 557

FS STEREOSEARCH


MF C20 H25 N O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CIN, DDFU,
 DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR,

RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

234 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
234 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487431
REFERENCE 2: 142:457193
REFERENCE 3: 142:441924
REFERENCE 4: 142:404258
REFERENCE 5: 142:341950
REFERENCE 6: 142:49618
REFERENCE 7: 142:17088
REFERENCE 8: 141:289431
REFERENCE 9: 141:289430
REFERENCE 10: 141:271711

L62 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 60282-87-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17 α)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN Gestodene

CN SHB 331

CN WL 70


FS STEREOSEARCH

DR 110541-55-4

MF C21 H26 O2

CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


406 REFERENCES IN FILE CA (1907 TO DATE)
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 408 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:20193
 REFERENCE 2: 142:487431
 REFERENCE 3: 142:404258
 REFERENCE 4: 142:360870
 REFERENCE 5: 142:349202
 REFERENCE 6: 142:341950
 REFERENCE 7: 142:310089
 REFERENCE 8: 142:255156
 REFERENCE 9: 142:204625
 REFERENCE 10: 142:168893

L62 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 54048-10-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 17-Ethynyl-17β-hydroxy-18-methyl-11-methyleneestr-4-en-3-one

CN 3-keto-Desogestrel
 CN 3-Keto-Org 2969
 CN 3-Ketodesogestrel
 CN 3-Oxodesogestrel
 CN Etonogestrel
 CN Implanon
 CN Org 3236
 FS STEREOSEARCH
 DR 165050-21-5
 MF C22 H28 O2
 CI COM
 LC STN Files: ADISNEWS, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
 CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, DDFU,
 DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IMPATENTS, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR,
 RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

256 REFERENCES IN FILE CA (1907 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 256 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 142:487431
 REFERENCE 2: 142:457230
 REFERENCE 3: 142:457214
 REFERENCE 4: 142:360870
 REFERENCE 5: 142:255156
 REFERENCE 6: 142:233472
 REFERENCE 7: 142:225453
 REFERENCE 8: 142:33111
 REFERENCE 9: 142:17092

REFERENCE 10: 142:11597

L62 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 54024-22-5 REGISTRY

ED Entered STN: 16 Nov 1984

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 13-Ethyl-11-methylene-18,19-dinor-17 α -4-pregnen-20-yn-17-ol

CN 17-Ethynyl-18-methyl-11-methyleneestr-4-en-17 β -ol

CN Cerazette

CN Cyclosa

CN Desogestrel

CN Dicromil

CN Marvelon 150/320

CN Org 2969

FS STEREOSEARCH

MF C22 H30 O

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

433 REFERENCES IN FILE CA (1907 TO DATE)

12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

433 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:20193

REFERENCE 2: 142:487431

REFERENCE 3: 142:469206

REFERENCE 4: 142:457214

REFERENCE 5: 142:424053
REFERENCE 6: 142:424040
REFERENCE 7: 142:349202
REFERENCE 8: 142:341950
REFERENCE 9: 142:310091
REFERENCE 10: 142:310089

L62 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 35189-28-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN D 138

CN d-(17 α)-17-Acetoxy-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one oxime

CN Dexnorgestrel acetate

CN Norgestimate

CN ORF 10131

CN RWJ 10131

FS STEREOSEARCH

MF C23 H31 N O3

CI COM


LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU,
DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA,
MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

224 REFERENCES IN FILE CA (1907 TO DATE)

7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

224 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 143:20193
REFERENCE 2: 142:487431
REFERENCE 3: 142:404258
REFERENCE 4: 142:367872
REFERENCE 5: 142:360884
REFERENCE 6: 142:349202
REFERENCE 7: 142:341950
REFERENCE 8: 142:255156
REFERENCE 9: 142:148835
REFERENCE 10: 142:148750

L62 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 797-63-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 18,19-Dinor-17 α -pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy- (7CI,
8CI)

OTHER NAMES:

CN (-)-Norgestrel

CN 13-Ethyl-17-ethynyl-17 β -hydroxy-4-gonen-3-one

CN 13-Ethyl-17-hydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one

CN 13-Ethyl-17 α -ethynyl-17-hydroxygon-4-en-3-one

CN 13-Ethyl-17 α -ethynylgon-4-en-17 β -ol-3-one

CN 13 β -Ethyl-17 α -ethynyl-17 β -hydroxygon-4-en-3-one

CN 17 α -Ethynyl-13-ethyl-19-nortestosterone

CN 17 α -Ethynyl-13 β -ethyl-3-oxo-4-estren-17 β -ol

CN 17 α -Ethynyl-17-hydroxy-18-methylestr-4-en-3-one

CN 17 α -Ethynyl-18-homo-19-nortestosterone

CN 17 α -Ethynyl-18-methyl-19-nortestosterone

CN 17 β -Hydroxy-18-methyl-19-nor-17 α -pregn-4-en-20-yn-3-one

CN 18-Methyl-17 α -ethynyl-19-nortestosterone

CN 18-Methylnorethindrone

CN 19-Nortestosterone, 17-ethynyl-18-methyl-

CN D-(-)-Norgestrel

CN d-(17 α)-17-Hydroxy-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-one

CN D-Norgestrel

CN Dexnorgestrel

CN Follistrel

CN Jadelle

CN Levonorgestrel

CN Levonova

CN Lng-IUS

CN Microlut

CN Microluton

CN Microval

CN Mirena


CN Norgeston

CN Norgestrelem

CN Norlevo

CN Norplant
 CN Norplant 2
 CN Norplant II
 CN Postinor 2
 CN Wy 5104
 FS STEREOSEARCH
 DR 797-62-6, 121714-72-5, 4222-79-1
 MF C21 H28 O2
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
 CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU,
 DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PROMT, PROUSDDR, PS,
 RTECS*, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1521 REFERENCES IN FILE CA (1907 TO DATE)
 26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1527 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE	1:	143:20193
REFERENCE	2:	143:20179
REFERENCE	3:	143:20098
REFERENCE	4:	143:1119
REFERENCE	5:	142:487431
REFERENCE	6:	142:476549
REFERENCE	7:	142:475241
REFERENCE	8:	142:469206
REFERENCE	9:	142:457214
REFERENCE	10:	142:457193

L62 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 427-51-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 6-chloro-1 β ,2 β -dihydro-17-hydroxy-, acetate (8CI)
CN Cyclopropa[1,2]cyclopenta[a]phenanthrene, 3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione deriv.
CN Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-1 α ,2 α -methylene-, acetate (7CI)
OTHER NAMES:
CN 1,2 α -Methylene-6-chloro- Δ 4,6-pregnadien-17 α -ol-3,20-dione acetate
CN 1,2 α -Methylene-6-chloro-17 α -acetoxy-4,6-pregnadiene-3,20-dione
CN 1,2 α -Methylene-6-chloro-pregna-4,6-diene-3,20-dione 17 α -acetate
CN 17 α -Acetoxy-6-chloro-1 α ,2 α -methylenepregna-4,6-diene-3,20-dione
CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione
CN 6-Chloro-1,2 α -methylene-17 α -hydroxy- Δ 6-progesterone acetate
CN 6-Chloro-1,2 α -methylene-6-dehydro-17 α -hydroxyprogesterone acetate
CN 6-Chloro-17-hydroxy-1 α ,2 α -methylenepregna-4,6-diene-3,20-dione acetate
CN Androcur
CN CPA
CN Cyprostat
CN Cyproterone 17-O-acetate
CN Cyproterone 17 α -acetate
CN Cyproterone acetate
CN Cyproviron
CN NSC 81430
CN SH 714
FS STEREOSEARCH
MF C24 H29 Cl O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK*, NIOSHTIC, PATDPASPC, PROMT, PS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1629 REFERENCES IN FILE CA (1907 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1631 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:21052
 REFERENCE 2: 143:19781
 REFERENCE 3: 142:487431
 REFERENCE 4: 142:475518
 REFERENCE 5: 142:468857
 REFERENCE 6: 142:463732
 REFERENCE 7: 142:457298
 REFERENCE 8: 142:443193
 REFERENCE 9: 142:442048
 REFERENCE 10: 142:441924

L62 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 302-22-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pregna-4,6-diene-3,20-dione, 6-chloro-17-hydroxy-, acetate (6CI, 7CI, 8CI)

OTHER NAMES:

CN 17-Acetoxy-6-chloro-6-dehydroprogesterone

CN 17-Acetoxy-6-chloropregna-4,6-diene-3,20-dione

CN 17 α -Acetoxy-6-chloro-4,6-pregnadiene-3,20-dione

CN 17 α -Acetoxy-6-chloro-6,7-dehydroprogesterone

CN 6-Chloro- Δ 4,6-pregnadien-17 α -ol-3,20-dione 17-acetate

CN 6-Chloro- Δ 6-17-acetoxyprogesterone


CN 6-Chloro- Δ 6-dehydro-17-acetoxyprogesterone

CN 6-Chloro- Δ 6-[17 α]acetoxyprogesterone

CN 6-Chloro-17-acetoxy-4,6-pregnadiene-3,20-dione

CN 6-Chloro-17-hydroxypregna-4,6-diene-3,20-dione acetate
CN 6-Chloro-17 α -acetoxy-4,6-pregnadiene-3,20-dione
CN 6-Chloro-17 α -hydroxy- Δ 6-progesterone acetate
CN 6-Chloro-17 α -hydroxy-4,6-pregnadiene-3,20-dione 17-acetate
CN 6-Chloro-17 α -hydroxypregna-4,6-diene-3,20-dione acetate
CN 6-Chloro-6,7-dehydro-17-acetoxypregesterone
CN 6-Chloro-6-dehydro-17-acetoxypregesterone
CN 6-Chloro-6-dehydro-17 α -acetoxypregesterone
CN 6-Chloro-pregna-4,6-dien-17 α -ol-3,20-dione acetate
CN 6-Dehydro-6-chloro-17 α -acetoxypregesterone
CN Ay 13390-6
CN Bovisynchron
CN CAP
CN Cero
CN Chloramdinone acetate
CN Chlormadinon acetate
CN Chlormadinone acetate
CN Chronosyn
CN Clordion
CN Cyclonorm
CN Fertiletten
CN Gestafortin
CN Lormin
CN Luteran
CN Lutinyll
CN Lutoral
CN Lutoral (Syntex)
CN Matrol
CN Menstridyl
CN Natrol
CN Normenon
CN NSC 92338
CN Prostal
CN Retex
CN RS 1280
CN Skedule TM
CN Synchrosyn
CN Synchrosyn P
CN Traslan
CN Verton
FS STEREOSEARCH
MF C23 H29 Cl O4
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB,
IFIPAT, IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PIRA, PROMT,
PS, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

950 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 950 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:20175
 REFERENCE 2: 142:487431
 REFERENCE 3: 142:404258
 REFERENCE 4: 142:341950
 REFERENCE 5: 142:309325
 REFERENCE 6: 142:233433
 REFERENCE 7: 142:214819
 REFERENCE 8: 142:211450
 REFERENCE 9: 142:193196
 REFERENCE 10: 142:183446

L62 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 68-22-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17 α -pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)

OTHER NAMES:

CN (17 α)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one

CN 17-Hydroxy-19-nor-17 α -pregn-4-en-20 yn-3-one

CN 17 α -Ethynyl-17 β -hydroxy- Δ 4-estren-3-one

CN 17 α -Ethynyl-19-nortestosterone

CN 17 α -Ethynylestr-4-en-17 β -ol-3-one

CN 17 α -Ethynyl-17-hydroxy-4-estrene-3-one

CN 17 α -Ethynyl-17-hydroxyest-4-en-3-one

CN 17 α -Ethynyl-17-hydroxyestr-4-en-3-one

CN 17 α -Ethynyl-17 β -hydroxy-19-norandrost-4-en-3-one

CN 17 α -Ethinyl-17 β -hydroxyestr-4-en-3-one
CN 17 α -Ethinyl-19-nor-androst-4-en-17 β -ol-3-one
CN 17 α -Ethinyl-19-nortestosterone
CN 17 α -Ethinyl-3-oxo-4-estren-17 β -ol
CN 17 β -Hydroxy-17 α -ethynylestr-4-en-3-one
CN 19-Nor-17 α -ethynyl-17 β -hydroxy-4-androsten-3-one
CN 19-Nor-17 α -ethynylandrosten-17 β -ol-3-one
CN 19-Nor-17 α -ethynyltestosterone
CN 19-Norandrost-4-en-3-one, 17 α -ethynyl-17 β -hydroxy-
CN 19-Nortestosterone, 17-ethynyl-
CN Anovule
CN Conludaf
CN Conludag
CN Estr-4-ene-17 α -ethynyl-17 β -ol-3-one
CN Ethinylnortestosterone
CN Ethynylnortestosterone
CN Gestest
CN Menzol
CN Micronett
CN Micronor
CN Micronovum
CN Mini-Pe
CN Mini-pill
CN Nor-QD
CN Noralutin
CN Norcolut
CN Norethindrone
CN Norethisteron
CN Norethisterone
CN Norethynodrone
CN Noretisterone Dak
CN Norfor
CN Norgestin
CN Norluten
CN Norlutin
CN Norluton
CN Normapause
CN Norpregneninolone
CN NSC 9564
CN Primolut N

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH

MF C20 H26 O2

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB,
IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR,
PIRA, PROMT, PS, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2,
USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2341 REFERENCES IN FILE CA (1907 TO DATE)
 68 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2341 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:21052
 REFERENCE 2: 143:20193
 REFERENCE 3: 143:3753
 REFERENCE 4: 142:487431
 REFERENCE 5: 142:469206
 REFERENCE 6: 142:457214
 REFERENCE 7: 142:457193
 REFERENCE 8: 142:451759
 REFERENCE 9: 142:442084
 REFERENCE 10: 142:441828

L62 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 57-83-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Δ4-Pregnene-3,20-dione
 CN Agolutin
 CN Bio-luton
 CN CIDR
 CN Corlutin
 CN Corlutina
 CN Corluvite
 CN Corporin
 CN Corpus luteum hormone
 CN Crinone
 CN Cyclogest
 CN Duraprogen
 CN Estima
 CN Flavolutan

CN Fologenon
CN Gesterol
CN Gestiron
CN Gestone
CN Gestormone
CN Gestron
CN Glanducorpin
CN Gynlutin
CN Gynolutone
CN Hormoflaveine
CN Hormoluton
CN Lipo-Lutin
CN Lucortum Sol
CN Lugesteron
CN Luteal Hormone
CN Luteinique
CN Luteocrin normale
CN Luteodyn
CN Luteogan
CN Luteohormone
CN Luteol
CN Luteopur
CN Luteosan
CN Luteostab
CN Luteovis
CN Luteum
CN Lutex
CN Lutidon
CN Lutin
CN Lutociclina
CN Lutocucclin M
CN Lutocyclin
CN Lutocyclin M
CN Lutocyclin
CN Lutoform
CN Lutogyl

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH

DR 753497-20-0, 8012-32-6, 8023-13-0, 257630-50-5

MF C21 H30 O2

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT,
IFIUDB, IMSCOSEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC,
PHAR, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT,
USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



****PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT****

45834 REFERENCES IN FILE CA (1907 TO DATE)
 508 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 45880 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:37705
 REFERENCE 2: 143:31993
 REFERENCE 3: 143:25810
 REFERENCE 4: 143:24715
 REFERENCE 5: 143:23928
 REFERENCE 6: 143:23760
 REFERENCE 7: 143:23584
 REFERENCE 8: 143:23561
 REFERENCE 9: 143:23339
 REFERENCE 10: 143:22529

L62 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN

RN 51-98-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17 α -pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate (6CI, 8CI)

OTHER NAMES:

CN 17-Acetoxy-19-nor-17 α -pregn-4-en-20-yn-3-one

CN 17 α -Ethynyl-19-nortestosterone 17 β -acetate

CN 17 α -Ethynyl-19-nortestosterone acetate

CN 17 α -Ethynyl-4-estrene-17 β -ol-acetate-3-one

CN 17 α -Ethynyl-19-nortestosterone acetate

CN 17 β -Acetoxy-17 α -ethynyl-4-estren-3-one

CN 17 β -Acetoxy-19-nor-17 α -pregn-4-en-20-yn-3-one

CN 17 β -Hydroxy-19-nor-17 α -pregn-4-en-20-yn-3-one acetate


CN 19-Norethisterone acetate

CN 19-Norethynyltestosterone acetate

CN Aygestin

CN Gynophase
 CN Gynovlane
 CN Milli-Anovlar
 CN Milligynon
 CN Miniphase
 CN Norethindrone 17-acetate
 CN Norethindrone acetate
 CN Norethisteron acetate
 CN Norethisterone 17-acetate
 CN Norethisterone acetate
 CN Norethynyltestosterone acetate
 CN Norethysterone acetate
 CN Norlutate
 CN Norlutin A
 CN Norlutin acetate
 CN NSC 22844
 CN Orlutate
 CN Primolut-Nor
 CN Progylut
 CN SH 420
 FS STEREOSEARCH
 MF C22 H28 O3
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
 CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIADB,
 IMSPATENTS, IPA, MRCK*, MSDS-OHS, NIOSHTIC, PATDPASPC, PHAR, PROMT, PS,
 RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

961 REFERENCES IN FILE CA (1907 TO DATE)
 11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 961 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 53 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:489
 REFERENCE 2: 142:476356
 REFERENCE 3: 142:451882

REFERENCE 4: 142:442084
REFERENCE 5: 142:442026
REFERENCE 6: 142:404258
REFERENCE 7: 142:341950
REFERENCE 8: 142:341949
REFERENCE 9: 142:303640
REFERENCE 10: 142:162670

L62 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2005 ACS on STN
RN 50-28-2 REGISTRY
ED Entered STN: 16 Nov 1984
CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estradiol (8CI)
OTHER NAMES:
CN (+)-3,17 β -Estradiol
CN β -Estradiol
CN 13 β -Methyl-1,3,5(10)-gonatriene-3,17 β -ol
CN 17 β -Estradiol
CN 17 β -Oestradiol
CN 3,17-Epidihydroxyestratriene
CN 3,17 β -Dihydroxyestra-1,3,5(10)-triene
CN 3,17 β -Estradiol
CN Absorlent Matrix
CN Aerodiol
CN Altrad
CN Aquadiol
CN Bardiol
CN Beta-estradiol
CN Climaderm
CN Climara
CN Compudose
CN Compudose 200
CN Compudose 365
CN Corpagen
CN Dermestril
CN Dihydrofollicular hormone
CN Dihydrofolliculin
CN Dihydromenformon
CN Dihydrotheelin
CN Dihydroxyestrin
CN Dimenformon
CN Diogyn
CN Diogynets
CN Divigel
CN E 2
CN Encore
CN Epiestriol 50
CN Estra-1,3,5(10)-triene-3,17-diol, (17 β) -
CN Estra-1,3,5(10)-triene-3,17 β -diol
CN Estrace
CN Estraderm
CN Estraderm TTS
CN Estraderm TTS 100

CN Estraderm TTS 50
 CN Estradot
 CN Estraldine
 CN Estring Vaginal Ring
 CN Estroclim
 CN Estroclim 50
 CN Estrogel
 CN Estrogel HBF
 CN Estrovite
 CN Evorel

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
 DISPLAY

FS STEREOSEARCH

MF C18 H24 O2

CI COM


LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
 CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
 CSNB, DDFU, DETHERM*, DIOGENES, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*,
 IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC,
 PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SPECINFO, SYNTHLINE,
 TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

55154 REFERENCES IN FILE CA (1907 TO DATE)
 999 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 55235 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 143:37705

REFERENCE 2: 143:32415

REFERENCE 3: 143:31783

REFERENCE 4: 143:25685

REFERENCE 5: 143:24723

REFERENCE 6: 143:23928

REFERENCE 7: 143:23561

REFERENCE 8: 143:23339

REFERENCE 9: 143:21359

REFERENCE 10: 143:21308

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:47:42 ON 07 JUL 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2005 VOL 143 ISS 2
FILE LAST UPDATED: 6 Jul 2005 (20050706/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d all hitstr tot 160

L60 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:450930 HCAPLUS
DN 142:487431
ED Entered STN: 27 May 2005
TI Extended use combination comprising **estrogens** and
progestins
IN **Duesterberg, Bernd; Endrikat, Jan; Schuermann, Rolf**
PA Germany
SO U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-56
INCL 514170000
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 2
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005113350	A1	20050526	US 2003-721825	20031126
	EP 1535618	A1	20050601	EP 2003-90405	20031126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

jan delaval - 7 july 2005

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 WO 2005051400 A1 20050609 WO 2004-EP13545 20041120
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

PRAI EP 2003-90405 A 20031126
 US 2003-721825 A 20031126

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005113350	ICM	A61K031-56
	INCL	514170000
US 2005113350	NCL	514/170.000

US 2005113350	ICM	A61K031-56
	INCL	514170000
US 2005113350	NCL	514/170.000

AB A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one **estrogen** and/or at least one **progestin** in a predetd. amount to be administered in the first 21-28 days and a second composition which contains at least one **estrogen** and/or at least one **progestin** in a predetd. amount higher than the amount of the first composition and comprises a mono or **multiphase** sequence of pharmaceutical dosages.

ST extended drug delivery **estrogen progestin**
contraceptive

IT Packaging materials
 (blister; extended-use combination comprising **estrogens** and **progestins**)

IT Drug delivery systems
 (buccal; extended-use combination comprising **estrogens** and **progestins**)

IT Uterus, disease
 (endometriosis; extended-use combination comprising **estrogens** and **progestins**)

IT Equus caballus
 (**estrogens** of; extended-use combination comprising **estrogens** and **progestins**)

IT **Contraceptives**
 Drug delivery systems
 Human
 Menstrual disorder
 Packaging materials
 (extended-use combination comprising **estrogens** and **progestins**)

IT **Estrogens**
Progestogens
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)
 (extended-use combination comprising **estrogens** and **progestins**)

IT **Ovulation**
 (inhibitors; extended-use combination comprising **estrogens** and **progestins**)

- IT Headache
(migraine, menstrual; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(nasal; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(oral; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(parenterals; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(sublingual; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(transdermal; extended-use combination comprising **estrogens** and **progestins**)
- IT Drug delivery systems
(vaginal; extended-use combination comprising **estrogens** and **progestins**)
- IT Acne
(vulgaris; extended-use combination comprising **estrogens** and **progestins**)
- IT 50-27-1, Estradiol 50-28-2, Estradiol, biological studies
52-76-6, Lynestrenol 53-16-7, Estrone, biological studies 57-63-6,
Ethinylestradiol 57-83-0, **Progesterone**, biological
studies 57-83-0D, **Progesterone**, hydroxy Me derivs.
68-22-4, **Norethisterone** 68-23-5, Norethynodrel
68-96-2, **Hydroxyprogesterone** 68-96-2D, 17-
Hydroxyprogesterone, esters 79-64-1, Dimethisterone 152-62-5,
Dydrogesterone 297-76-7, Ethynodiol diacetate 302-22-7,
Chlormadinone acetate 427-51-0, **Cyproterone**
acetate 432-60-0, Allylestrenol 434-03-7, Ethisterone
472-54-8, 19-Norprogesterone 797-63-7,
Levonorgestrel 848-21-5, Norgestrienone 977-79-7, Medrogestone
1323-54-2, Acetoxypregnenolone 2137-18-0 2529-45-5, Flurogestone
acetate 2740-52-5, Anagestone 5630-53-5, Tibolone 5633-18-1,
Melengestrol 6533-00-2, dl-Norgestrel 7759-35-5, Nestorone
10116-22-0, Demegestone 10592-65-1, Quingestanol 15183-37-6, Estetrol
16320-04-0, Gestrinone 24356-94-3, Algestone acetophenide 24749-37-9,
Estrane 34184-77-5, Promegestone 35189-28-7 53016-31-2,
17-Deacetylnorgestimate 54024-22-5, **Desogestrel**
54048-10-1, 3-Ketodesogestrel 58691-88-6, Nomegestrol
60282-87-3, **Gestodene** 65928-58-7,
Dienogest 67392-87-4, **Drospirenone**
70805-85-5, 3- β -Hydroxydesogestrel 264186-52-9 475678-64-9
600730-96-9
RL: PEP (Physical, engineering or chemical process); PYP (Physical
process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
USES (Uses)
(extended-use combination comprising **estrogens** and **progestins**)
- IT 50-28-2, Estradiol, biological studies 57-83-0,
Progesterone, biological studies 57-83-0D,
Progesterone, hydroxy Me derivs. 68-22-4,
Norethisterone 302-22-7, Chlormadinone acetate
427-51-0, **Cyproterone acetate** 797-63-7
, **Levonorgestrel** 35189-28-7 54024-22-5,
Desogestrel 54048-10-1, 3-Ketodesogestrel

60282-87-3, Gestodene 65928-58-7,
Dienogest 67392-87-4, Drospirenone


RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(extended-use combination comprising **estrogens** and **progestins**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS


CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 60282-87-3 HCAPLUS
 CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
 (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 65928-58-7 HCAPLUS
 CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 67392-87-4 HCAPLUS
 CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2' (5'H)-
 furan]-3,5' (2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
 hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:864382 HCAPLUS

DN 137:333524

ED Entered STN: 14 Nov 2002

TI **Triphasic combination of progestin/
estrogen oral contraceptives**

IN Gast, Michael J.

PA Wyeth, John, and Brother Ltd., USA

SO U.S., 8 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61P015-18

ICS A61K031-567; A61K031-575

INCL 514170000

CC 2-3 (Mammalian Hormones)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6479475	B1	20021112	US 1997-887163	19970702 <--
PRAI	US 1996-22626P	P	19960726	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6479475	ICM	A61P015-18
	ICS	A61K031-567; A61K031-575
	INCL	514170000
US 6479475	NCL	514/170.000; 514/181.000; 514/182.000; 514/843.000
	ECLA	A61K031/567+M; A61K031/575+M <--

AB A method of **contraception comprises** administering to a female of child bearing age a **triphasic combination** of **progestin/estrogen oral contraceptive regimen** with good cycle control and min. side effects while greatly reducing the total **contraceptive steroid** administered. **Combinations** of a **progestin** at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg **dienogest**, or 250 µg-4 mg **drospirenone**, and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg ethinyl estradiol are administered for 24 days beginning on day 1 of the menstrual cycle. The first phase **combination** is administered for 7 days, the second phase **combination** is administered for 7 days, and the third phase

combination is administered for 10 days. The daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.

ST **estrogen progestin triphasic
combination oral female contraceptive**

IT **Estrogens**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; triphasic combination of
progestin/estrogen oral female contraceptives
)

IT **Contraceptives**

Drug delivery systems
(oral; triphasic combination of
progestin/estrogen oral female
contraceptives)

IT **Estrogens**

Progestogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triphasic combination of progestin/
estrogen oral female contraceptives)

IT **50-28-2, 17 β -Estradiol, biological studies 53-16-7,
Estrone, biological studies 57-63-6, Ethinyl estradiol 72-33-3,
Mestranol 65928-58-7, Dienogest 67392-87-4,
Drospirenone 74513-62-5, Trimegestone**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triphasic combination of progestin/
estrogen oral female contraceptives)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Anon; EP 0253607 1988 HCAPLUS
- (2) Anon; EP 0628312 1994 HCAPLUS
- (3) Anon; DE 4313926 1994 HCAPLUS
- (4) Anon; WO 9517194 1995 HCAPLUS
- (5) Anon; WO 9526730 1995 HCAPLUS
- (6) Anon; EP 0696454 1996 HCAPLUS
- (7) Barcomb; US 5547948 A 1996 HCAPLUS
- (8) Bennink; US 5418228 A 1995 HCAPLUS
- (9) Bergink; US 5262408 A 1993 HCAPLUS
- (10) Boissonneault; US 4962098 A 1990 HCAPLUS
- (11) Coussediere; US 4273771 A 1981 HCAPLUS
- (12) Edgren; US 4390531 A 1983 HCAPLUS
- (13) Ehrlich; US 5280023 A 1994 HCAPLUS
- (14) Gast; US 5858405 A 1999 HCAPLUS
- (15) Lachnit-Fixson; US 3957982 A 1976 HCAPLUS
- (16) Lachnit-Fixson; US 3969502 A 1976 HCAPLUS
- (17) Lachnit-Fixson; US 4621079 A 1986 HCAPLUS
- (18) Oettel; US 5633242 A 1997 HCAPLUS
- (19) Pasquale; US 4530839 A 1985 HCAPLUS
- (20) Pasquale; US 4628051 A 1986 HCAPLUS
- (21) Pasquale; US 4921843 A 1990 HCAPLUS
- (22) Ponsold; US 4248790 A 1981 HCAPLUS
- (23) Sartoretto; Clinica e Terapeutica 1974, V3, P399
- (24) Spona; US 5583129 A 1996 HCAPLUS

IT **50-28-2, 17 β -Estradiol, biological studies 65928-58-7**


, **Dienogest 67392-87-4, Drospirenone**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triphasic combination of progestin/

estrogen oral female contraceptives)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H) -
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:745952 HCAPLUS
 DN 128:26926
 ED Entered STN: 27 Nov 1997
 TI Oral **contraceptives**
 IN Gast, Michael Jay
 PA American Home Products Corporation, USA
 SO PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741871	A1	19971113	WO 1997-US7085	19970428 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9729269	A1	19971126	AU 1997-29269	19970428 <--
PRAI	US 1996-647086	A	19960508	<--	
	WO 1997-US7085	W	19970428		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741871	ICM	A61K031-565
WO 9741871	ECLA	A61K031/565+M

AB This invention provides a method of **contraception** which **comprises** administering to a female of child-bearing age for 28 consecutive days, a first phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 3-8 days beginning on day 1 of the menstrual cycle; a second phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 4-15 days; a third phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 4-15 days; and an **estrogen** phase **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 3-5 days. The daily dosage of the **combination** administered in the first phase is not the same as the daily dosage of the **combination** administered in the second phase and that the daily dosage of the **combination** administered in the second phase is not the same as the daily dosage of the **combination** administered in the third phase.

ST oral **contraceptive kit progestin estrogen triphase**; **levonorgestrel ethinylestradiol triphase oral contraceptive**


- IT **Estrogens**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugated; **progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- IT **Contraceptives**
 (oral; **progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- IT **Estrogens**
Progestogens
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- IT **Drug delivery systems**
 (tablets; **progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9, Norethisterone acetate 53-16-7, Estrone, biological studies 57-63-6, Ethinylestradiol 68-22-4, Norethindrone 72-33-3, Mestranol 797-63-7, Levonorgestrel 6533-00-2, Norgestrel 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9, Norethisterone acetate 68-22-4, Norethindrone 797-63-7, Levonorgestrel 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen bridged triphasic combination oral contraceptive kit for females**)
- RN 50-28-2 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 51-98-9 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L60 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:745951 HCAPLUS

DN 128:26925

ED Entered STN: 27 Nov 1997

TI Oral **contraceptives**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741870	A1	19971113	WO 1997-US7084	19970428 <--
	W:			AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9729268	A1	19971126	AU 1997-29268	19970428 <--
PRAI	US 1996-647087	A	19960508	<--	
	WO 1997-US7084	W	19970428		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741870	ICM	A61K031-565
WO 9741870	ECLA	A61K031/565+M <--

AB This invention provides a method of **contraception** which **comprises** administering to a female of child-bearing age for 23-25 consecutive days; a first phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 3-8 days beginning on day 1 of the menstrual cycle; a second phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 4-15 days; and a third phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent

in **estrogenic** activity to 10-20 µg ethinylestradiol for 4-15 days. The daily dosage of the **combination** administered in the first phase is not the same as the daily dosage of the **combination** administered in the second phase and that the daily dosage of the **combination** administered in the second phase is not the same as the daily dosage of the **combination** administered in the third phase.


- ST oral contraceptive kit triphase progestin
estrogen; levonorgestrel ethinylestradiol
triphasic oral contraceptive
- IT **Estrogens**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; **progestin-estrogen triphasic**
combination oral contraceptive kit for females)
- IT **Contraceptives**
(oral; **progestin-estrogen**
triphasic combination oral
contraceptive kit for females)
- IT **Estrogens**
Progestogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**progestin-estrogen triphasic**
combination oral contraceptive kit for females)
- IT Drug delivery systems
(tablets; **progestin-estrogen triphasic**
combination oral contraceptive kit for females)
- IT 50-28-2, 17β-Estradiol, biological studies 51-98-9,
Norethisterone acetate 53-16-7, Estrone, biological
studies 57-63-6, Ethinylestradiol 68-22-4, Norethindrone
72-33-3, Mestranol 797-63-7, **Levonorgestrel**
6533-00-2, **Norgestrel** 35189-28-7, **Norgestimate**
54024-22-5, **Desogestrel** 54048-10-1,
3-Ketodesogestrel 60282-87-3, **Gestodene**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**progestin-estrogen triphasic**
combination oral contraceptive kit for females)
- IT 50-28-2, 17β-Estradiol, biological studies 51-98-9,
Norethisterone acetate 68-22-4, Norethindrone
797-63-7, **Levonorgestrel** 35189-28-7,
Norgestimate 54024-22-5, **Desogestrel**
54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**progestin-estrogen triphasic**
combination oral contraceptive kit for females)
- RN 50-28-2 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 51-98-9 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 797-63-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS


CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 60282-87-3 HCAPLUS
 CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
 (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L60 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1997:384192 HCAPLUS
 DN 127:9115
 ED Entered STN: 20 Jun 1997
 TI **Multiphase contraceptive preparation based on natural
 estrogens**
 IN Dittgen, Michael; Fricke, Sabine; Hoffmann, Herbert; Moore, Claudia;
 Oettel, Michael; Ostertag, Monika
 PA Jenapharm GmbH, Germany
 SO Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 IC ICM A61K031-57
 ICI A61K031-57, A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 770388	A1	19970502	EP 1996-116919	19961022 <--
	EP 770388	B1	19980325		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	DE 19540253	A1	19970430	DE 1995-19540253	19951028 <--
	DE 19540253	C2	19980604		
	RU 2113849	C1	19980627	RU 1996-119803	19960927 <--
	CZ 290741	B6	20021016	CZ 1996-3043	19961017 <--

PL 186339	B1	20031231	PL 1996-316608	19961021 <--
AT 164312	E	19980415	AT 1996-116919	19961022 <--
ES 2116804	T3	19980716	ES 1996-116919	19961022 <--
SK 281709	B6	20010710	SK 1996-1352	19961022 <--
CA 2188907	AA	19970429	CA 1996-2188907	19961025 <--
CA 2188907	C	20010227		
JP 09169649	A2	19970630	JP 1996-285357	19961028 <--
JP 3020880	B2	20000315		
CN 1159917	A	19970924	CN 1996-123360	19961028 <--
PRAI DE 1995-19540253	A	19951028	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 770388	ICM	A61K031-57	
	ICI	A61K031-57, A61K031-565	
EP 770388	ECLA	A61K031/57+M	<--
DE 19540253	ECLA	A61K031/57+M	<--

AB A multiphase contraceptive kit comprises a

1st phase containing 2-4 daily dosage units of natural **estrogen**, a 2nd phase containing 22-16 daily dosage units of a **combination** of a natural **estrogen** and ≥ 1 natural or synthetic **gestagen**, a 3rd phase containing 2-4 daily dosage units of natural **estrogen**, and a 4th phase containing 2-4 daily dosage units of placebo. Use of this kit provides highly effective **contraception** through the entire menstrual cycle and control of menstruation at low **estrogen** and **gestagen** doses with minimal side effects. Thus, a **contraceptive** regimen used the following daily dosage schedule: days 1-3, 3 mg estradiol valerate; days 4-7, 2 mg estradiol valerate + 0.075 mg **desogestrel**; days 8-23, 2 mg estradiol valerate + 0.150 mg **desogestrel**; days 24-25, 1 mg estradiol valerate; days 26-28, placebo.

ST **contraceptive estrogen gestagen**

IT **Contraceptives**

(multiphase contraceptive preparation based on natural **estrogens**)

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(multiphase contraceptive preparation based on natural **estrogens**)

IT 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, metabolites 57-83-0, **Progesterone**, biological studies 71-58-9, **Medroxyprogesterone acetate** 979-32-8, Estradiol valerate 54024-22-5, **Desogestrel** 65928-58-7, **Dienogest**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(multiphase contraceptive preparation based on natural **estrogens**)

IT 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, metabolites 57-83-0, **Progesterone**, biological studies 54024-22-5, **Desogestrel** 65928-58-7, **Dienogest**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(multiphase contraceptive preparation based on natural **estrogens**)

RN 50-28-2 HCAPLUS


CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-28-2 HCAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 54024-22-5 HCAPLUS
CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:240103 HCAPLUS

DN 122:17220

ED Entered STN: 13 Dec 1994

TI **Multiphase** hormonal system for **contraception**

IN Moore, Claudia; Oettel, Michael

PA Jenapharm GmbH, Germany

SO Ger. Offen., 10 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4313926	A1	19941103	DE 1993-4313926	19930428 <--
PRAI DE 1993-4313926		19930428	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4313926	ICM	A61K031-565
DE 4313926	ECLA	A61K031/565+M

AB The title system **comprises combinations of estrogens** and a **gestagen** to be administered during the 1st 3 phases of the ovarian cycle and an **estrogen** preparation to be

applied in the 4th phase. Thus, film tablets were provided for administration on the following days of the ovarian cycle containing, in addition

to standard excipients, the following active agents (in mg): days 1-7, ethynylestradiol (I) 0.050, **levonorgestrel** (II) 0.010, estradiol valerate (III) 1.000; days 8-14, I 0.075, II 0.050, III 1.000; days 15-21, I 0.005, II 0.075, III 1.000; days 22-28, III 1.000.

ST **estrogen gestagen multiphase**
contraceptive

IT **Contraceptives**

(multiphase hormonal system for contraception)

IT **Estrogens**

Progestogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multiphase hormonal system for contraception)

IT 50-28-2, Estradiol, biological studies 57-63-6, Ethynylestradiol

72-33-3, Mestranol 481-97-0, Estrone sulfate 797-63-7,

Levonorgestrel 979-32-8, Estradiol valerate 65928-58-7

, **Dienogest**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multiphase hormonal system for contraception)

IT 50-28-2, Estradiol, biological studies 797-63-7,

Levonorgestrel 65928-58-7, **Dienogest**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multiphase hormonal system for contraception)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS


CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 65928-58-7 HCAPLUS
 CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:476530 HCAPLUS

DN 117:76530

ED Entered STN: 23 Aug 1992

TI Contraceptive regimen

IN Coelingh Bennink, Herman Jan Tijmen

PA AKZO N. V., Neth.

SO Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 491438	A1	19920624	EP 1991-203282	19911212 <--
	EP 491438	B1	19960403		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	ZA 9109770	A	19920930	ZA 1991-9770	19911211 <--
	AT 136219	E	19960415	AT 1991-203282	19911212 <--
	ES 2087965	T3	19960801	ES 1991-203282	19911212 <--
	AU 9189679	A1	19920618	AU 1991-89679	19911213 <--
	AU 645637	B2	19940120		
	CA 2057747	AA	19920618	CA 1991-2057747	19911216 <--
	CA 2057747	C	20030729		
	FI 9105914	A	19920618	FI 1991-5914	19911216 <--
	FI 98985	B	19970613		
	FI 98985	C	19970925		
	NO 9104969	A	19920618	NO 1991-4969	19911216 <--
	NO 179311	B	19960610		
	NO 179311	C	19960918		
	PT 99819	B	20010531	PT 1991-99819	19911216 <--
	CN 1062464	A	19920708	CN 1991-107996	19911217 <--
	CN 1036833	B	19971231		
	JP 04290830	A2	19921015	JP 1991-333718	19911217 <--
	US 5418228	A	19950523	US 1994-182304	19940114 <--
PRAI	EP 1990-203372	A	19901217	<--	
	US 1991-809724	B1	19911217	<--	


US 1993-53841

B1 19930427 <--

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 491438	ICM	A61K031-565	
EP 491438	ECLA	A61K031/565; A61K031/57+M	<--
US 5418228	NCL	514/182.000; 514/170.000; 514/179.000; 514/843.000	<--
AB	A contraceptive regimen includes a multiphase combination and contraceptive kit containing at least 21 daily dosage units divided into 3 phases. The first phase contains 6-8 dosage units, each containing a progestogen at a dosage equivalent in progestogenic activity to 75-150 µg desogestrel and an estrogen at 20-25 µg ethinylestradiol. The 2nd phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units. The 3rd phase contains 6-8 dosage units, each containing less progestogen than in the previous dosage units. Thus, tablets were prepared for all 3 phases.		
ST	contraceptive progestogen estrogen		
IT	Progestogens		
	RL: BIOL (Biological study)		
	(oral contraceptive tablets containing estrogens and)		
IT	Estrogens		
	RL: BIOL (Biological study)		
	(oral contraceptive tablets containing progestogens and)		
IT	Contraceptives		
	(oral, estrogen and progestogen tablets)		
IT	Pharmaceutical dosage forms		
	(tablets, estrogen and progestogen , as oral contraceptives)		
IT	54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel		
	RL: BIOL (Biological study)		
	(oral contraceptive tablets containing estrogens and)		
IT	50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17β)-, biological studies 57-63-6, Ethinylestradiol		
	RL: BIOL (Biological study)		
	(oral contraceptive tablets containing progestogens and)		
IT	54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel		
	RL: BIOL (Biological study)		
	(oral contraceptive tablets containing estrogens and)		
RN	54024-22-5 HCAPLUS		
CN	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)		

Absolute stereochemistry. Rotation (+).




RN 54048-10-1 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
 (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β)-, biological
 studies
 RL: BIOL (Biological study)
 (oral **contraceptive** tablets containing **progestogens**
 and)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1991:88652 HCAPLUS
 DN 114:88652
 ED Entered STN: 09 Mar 1991
 TI **Multi-phase contraceptive** preparation
 IN De Jager, Evert
 PA AKZO N. V., Neth.
 SO Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K031-57
 ICS A61K031-56
 ICI A61K031-57, A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
PI  EP 368373      A1      19900516      EP 1989-202543      19891009 <--
      R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE
      CA 2000438      AA      19900413      CA 1989-2000438      19891011 <--
      DK 8905076      A       19900414      DK 1989-5076        19891012 <--
      ZA 8907749      A       19900725      ZA 1989-7749        19891012 <--
      AU 8942879      A1      19900426      AU 1989-42879       19891013 <--
      AU 628397      B2      19920917
      JP 02174717      A2      19900706      JP 1989-267974      19891013 <--
PRAI NL 1988-2511      A       19881013      <--

```

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 368373	ICM	A61K031-57
	ICS	A61K031-56
	ICI	A61K031-57, A61K031-565


```

-----
AB  EP 368373      ICM      A61K031-57
      ICS      A61K031-56
      ICI      A61K031-57, A61K031-565
AB  A multiphase contraceptive has 22-30 dosage units, in
    ≥2 phases. The 1st phase which may have various subphases has
    20-22, preferably 21, dosage units containing effective amts. of
progestogens and estrogens. The 2nd phase has 2-10,
    preferably 7, dosage units containing only a progestogen. Fertility
    is controlled by orally administering the 1st dosage units daily, and
    administering the 2nd dosage units daily. Thus, a 1st phase was prepared
    from 21 soft gelatin capsules, each one containing desogestrel 0.150
    and estradiol 17β-cyclooctylacetate 0.250, both dissolved in peanut
    oil. The 2nd phase was prepared from 7 capsules, each containing
desogestrel 0.030 mg in peanut oil. Formulation of
    tablets and dragees is also described.
ST  multiphase oral contraceptive dosage unit;
    estrogen progestogen multiphase dosage unit
IT  Progestogens
    RL: BIOL (Biological study)
        (multiphase oral contraceptive dosage units containing
        estrogens and)
IT  Estrogens
    RL: BIOL (Biological study)
        (multiphase oral contraceptive dosage units containing
        progestogens and)
IT  Pharmaceutical dosage forms
        (capsules, soft, multiphase oral contraceptives in)
IT  Pharmaceutical dosage forms
        (dragees, multiphase oral contraceptives in)
IT  Contraceptives
        (oral, multiphase dosage units containing
        progestogens and estrogens 1)
IT  Pharmaceutical dosage forms
        (tablets, multiphase oral contraceptives in)
IT  797-64-8 54024-22-5, Desogestrel
    RL: BIOL (Biological study)
        (multiphase oral contraceptive dosage units containing
        estrogens and)
IT  50-28-2, 17β-Estradiol, biological studies 57-63-6, Ethinyl
    estradiol 66791-46-6, Estradiol 17β-cyclooctylacetate
    RL: BIOL (Biological study)
        (multiphase oral contraceptive dosage units containing
        progestogens and)
IT  54024-22-5, Desogestrel
    RL: BIOL (Biological study)
        (multiphase oral contraceptive dosage units containing
        estrogens and)

```


RN 54024-22-5 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 50-28-2, 17 β -Estradiol, biological studies
 RL: BIOL (Biological study)
 (multiphase oral contraceptive dosage units containing
 progestogens and)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1986:39773 HCAPLUS
 DN 104:39773
 ED Entered STN: 08 Feb 1986
 TI Triphasic oral contraceptive
 IN Pasquale, Samuel A.
 PA Ortho Pharmaceutical Corp., USA
 SO U.S., 5 pp. Cont.-in-part of U.S. Ser. No. 536,135.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-56
 INCL 514170000
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 21
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4544554	A	19851001	US 1984-607038	19840504 <--
	US 4530839	A	19850723	US 1983-536135	19830926 <--

CA 1226221	A1	19870901	CA 1984-462334	19840904 <--
US 4628051	A	19861209	US 1985-743344	19850611 <--
US 4616006	A	19861007	US 1985-744189	19850613 <--
PRAI US 1983-536135	A2	19830926	<--	
US 1984-607038	A	19840504	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 4544554	ICM	A61K031-56	
	INCL	514170000	
US 4544554	NCL	514/170.000; 514/177.000; 514/182.000	<--
US 4530839	NCL	514/171.000; 514/843.000	<--
US 4628051	NCL	514/170.000; 514/177.000; 514/182.000	<--
US 4616006	NCL	514/170.000	<--

AB The title **contraceptive composition** comprises 21 sep. daily dosage units adapted for successive daily oral ingestion, wherein the **estrogen** dosage is kept constant throughout the 21-day cycle, whereas the **progestogen** dosage is gradually increased in successive doses. The **combination** consists as the 1st, 2nd, and 3rd phases, 5-8, 7-11, and 3-7 dosage units, resp., of an **estrogen** and **progestogen**. Then, for 6-8 days either **estrogen** or **progestogen** was not administered. Thus, a 1st stage tablet contained 17- α -ethinylestradiol 0.035, norethindrone 0.50, lactose 88.9, pregelatinized starch 10.0, and Mg stearate 0.5 mg. The 2nd and 3rd stage tablets contained the same amount of each ingredient, except for norethindrone which was 0.75 and 1.0 mg, resp.

ST **triphasic oral contraceptive estrogen progestogen**

IT **Estrogens**

RL: BIOL (Biological study)
(**triphasic oral contraceptive containing progestogen and**)

IT **Progestogens**

RL: BIOL (Biological study)
(**triphasic oral contraceptives containing estrogens and**)

IT **Contraceptives**

(**oral, sequential, triphasic, estrogens and progestogens in**)

IT 68-22-4 6533-00-2 35189-28-7

RL: BIOL (Biological study)
(**triphasic oral contraceptives containing ethinylestradiol and**)

IT 57-63-6

RL: BIOL (Biological study)
(**triphasic oral contraceptives containing progestogen and**)


IT 68-22-4 35189-28-7

RL: BIOL (Biological study)
(**triphasic oral contraceptives containing ethinylestradiol and**)

RN 68-22-4 HCAPLUS


CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35189-28-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
 (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



L60 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1985:583572 HCAPLUS
 DN 103:183572
 ED Entered STN: 30 Nov 1985
 TI **Triphasic oral contraceptive**
 IN Pasquale, Samuel A.
 PA Ortho Pharmaceutical Corp., USA
 SO U.S., 4 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A01N045-00
 INCL 514171000
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4530839	A	19850723	US 1983-536135	19830926 <--
	US 4544554	A	19851001	US 1984-607038	19840504 <--
	CA 1226221	A1	19870901	CA 1984-462334	19840904 <--
	US 4628051	A	19861209	US 1985-743344	19850611 <--
	US 4616006	A	19861007	US 1985-744189	19850613 <--
PRAI	US 1983-536135	A2	19830926	<--	
	US 1984-607038	A	19840504	<--	

CLASS


PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

```

-----
US 4530839      ICM      A01N045-00
                  INCL      514171000
US 4530839      NCL      514/171.000; 514/843.000      <--
US 4544554      NCL      514/170.000; 514/177.000; 514/182.000      <--
US 4628051      NCL      514/170.000; 514/177.000; 514/182.000      <--
US 4616006      NCL      514/170.000      <--
AB  Triphasic oral contraceptives contain low concns. of
    estrogen and progestogen; a daily dose of 0.125-0.75 mg
    progestogen in combination with 0.02-0.05 mg
    estrogen for the first 7 d; 0.5-1.0 mg progestogen
    /0.02-0.50 mg estrogen for the next 7 d; 0.75-2.0 mg
    progestogen/0.02-0.05 mg estrogen for the last 7 d; and
    finally followed by 7 placebos comprise the administration
    regime. Thus, tablets were prepared containing 0.036 mg 17 $\alpha$ -
    ethynylestradiol (I) [57-63-6] and 0.050 mg norethindrone (II) [
    68-22-4] for 1st stage; 0.036 mg I and 0.75 mg II for 2nd stage;
    and 0.036 mg I and 1.0 mg II for 3rd stage. Clin. studies with 656 women
    showed an efficacy in preventing pregnancies and a decrease in the
    incidence of midcycle breakthrough bleeding and/or spotting.
ST  contraceptive triphase estrogen
    progestogen
IT  Progestogens
    RL: BIOL (Biological study)
        (triphasic oral contraceptives containing
        estrogen and)
IT  Estrogens
    RL: BIOL (Biological study)
        (triphasic oral contraceptives containing
        progestogen and)
IT  Contraceptives
        (oral, sequential, triphasic,
        estrogen-progestogen combinations for)
IT  57-83-0, biological studies 68-22-4 6533-00-2
    13732-69-9
    RL: BIOL (Biological study)
        (triphasic oral contraceptives containing
        estrogen and)
IT  50-27-1 50-28-2, biological studies 53-16-7, biological
    studies 57-63-6
    RL: BIOL (Biological study)
        (triphasic oral contraceptives containing
        progestogen and)
IT  57-83-0, biological studies 68-22-4
    RL: BIOL (Biological study)
        (triphasic oral contraceptives containing
        estrogen and)
RN  57-83-0 HCAPLUS
CN  Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


```

Absolute stereochemistry.




RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, biological studies
 RL: BIOL (Biological study)
 (triphasic oral contraceptives containing
 progestogen and)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L60 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:40915 HCAPLUS
 DN 96:40915
 ED Entered STN: 12 May 1984
 TI Multi-phase combination-type
 sequential preparation and method for oral contraception
 IN De Jager, Evert

PA AKZO N. V., Neth.
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC A61K045-06; A61K031-565; A61K031-57
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 36229	A1	19810923	EP 1981-200240	19810302 <--
	EP 36229	B1	19850123		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	NL 8001593	A	19811016	NL 1980-1593	19800318 <--
	AT 11371	E	19850215	AT 1981-200240	19810302 <--
	ZA 8101490	A	19820331	ZA 1981-1490	19810305 <--
	AU 8168210	A1	19810924	AU 1981-68210	19810310 <--
	AU 546010	B2	19850808		
	FI 8100805	A	19810919	FI 1981-805	19810316 <--
	FI 72649	B	19870331		
	FI 72649	C	19870710		
	US 4378356	A	19830329	US 1981-244071	19810316 <--
	DK 8101188	A	19810919	DK 1981-1188	19810317 <--
	DK 162474	B	19911104		
	DK 162474	C	19920406		
	JP 56140914	A2	19811104	JP 1981-38576	19810317 <--
	JP 01053252	B4	19891113		
	CA 1158981	A1	19831220	CA 1981-373188	19810317 <--
PRAI	NL 1980-1593	A	19800318	<--	
	EP 1981-200240	A	19810302	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 36229	IC	A61K045-06IC A61K031-565IC A61K031-57
US 4378356	NCL	514/170.000; 514/843.000 <--

AB A **multiphase combination type sequential** preparation for oral **contraception** consists of 20-22 tablets each containing a **gestagen** and an **estrogen**. The 1st phase consists of 5-8 tablets, each of which contains a low dosage of a **gestagen**, a relatively high dose of **estrogen**, and the 2nd phase consists of 5-8 tablets each having a **gestagen** dose greater and an **estrogen** dose smaller than that during the 1st phase, and a 3rd phase of 5-11 tablets each of which has a **gestagen** dose greater and an **estrogen** dose lower than that in the 2nd phase. Tablets for the 1st phase consisted of **desogestrel** (I) [54024-22-5] 0.025 and 17 α -ethinylestradiol (II) [57-63-6] 0.04 mg; tablets for the 2nd and 3rd phases contained I 0.125 and II 0.03 mg. Seven tablets were used for the 1st phase and 14 tablets for the 2nd and 3rd. The tablets contained the usual binders and additives. These were administered at 1 tablet/day for 20-22 days to a fertile female according to the prescribed sequence of phases.

ST **estrogen progestogen oral contraceptive**IT **Progestogens**


RL: BIOL (Biological study)
 (oral **contraceptives** containing **estrogen** and, for
multiphase administration)

IT **Estrogens**

RL: BIOL (Biological study)

(oral **contraceptives** containing **progesterone** and, for
multiphase administration)
 IT **Contraceptives**
 (oral, **estrogens** and **gestagen** for
multiphase)
 IT 57-63-6
 RL: BIOL (Biological study)
 (oral **contraceptive** containing **desogestrel** and, for
multiphase administration)
 IT **54024-22-5**
 RL: BIOL (Biological study)
 (oral **contraceptive** containing ethinyl estradiol and, for
multiphase administration)
 IT **54024-22-5**
 RL: BIOL (Biological study)
 (oral **contraceptive** containing ethinyl estradiol and, for
multiphase administration)
 RN 54024-22-5 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



```
=> d all hitstr tot 161
```

L61 ANSWER 1 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:517364 HCAPLUS

ED Entered STN: 16 Jun 2005

TI **Contraceptives** based on a **progestogen** and an **estrogen**

IN Paris, Jacques; Thomas, Jean Louis

PA Laboratoire Theramex, Monaco

SO U.S., 7 pp., Cont.-in-part of U.S. 6,831,073.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-56

ICS C07J001-00

INCL 514170000; 514171000; 514177000; 514178000; 514182000; 514841000;
514843000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s) : 2

FAN.CNT 4

PATENT NO.

KIND

DATE _____

APPLICATION NO.

DATE _____

PI US 6906049

B1

20050614

US 1999-423108

```
19991025 <--
```

jan delaval - 7 july 2005

FR 2754179 A1 19980410 FR 1996-12239 19961008 <--
 FR 2754179 B1 19981224
 WO 9815279 A1 19980416 WO 1997-FR1792 19971008 <--
 W: AU, BR, CA, CN, CU, CZ, HU, ID, IL, JP, KR, MG, MX, NO, NZ, PL,
 RO, RU, SG, SK, TR, US, VN, YU
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG
 EP 1334725 A2 20030813 EP 2003-8979 19971008 <--
 EP 1334725 A3 20040121
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 US 6831073 B1 20041214 US 1999-284147 19990317 <--
 WO 2001030355 A1 20010503 WO 1999-FR2587 19991025
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE
 US 2004220163 A1 20041104 US 2004-753073 20040108 <--
 PRAI FR 1996-12239 A 19961008 <--
 WO 1997-FR1792 W 19971008
 US 1999-284147 A2 19990317
 WO 1999-FR2587 W 19991025
 EP 1997-944940 A3 19971008
 US 1999-423108 A2 19991025

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6906049	ICM	A61K031-56
	ICS	C07J001-00
	INCL	514170000; 514171000; 514177000; 514178000; 514182000; 514841000; 514843000
US 6906049	NCL	514/170.000; 514/171.000; 514/177.000; 514/178.000; 514/182.000; 514/841.000; 514/843.000 <--
FR 2754179	ECLA	A61K031/57+M <--
WO 9815279	ECLA	A61K031/57+M <--
EP 1334725	ECLA	A61K031/57+M <--
US 6831073	NCL	514/169.000; 514/170.000; 514/171.000; 514/177.000; 514/178.000; 514/182.000; 552/625.000 <--
	ECLA	A61K031/57+M <--
WO 2001030355	ECLA	A61K031/565+M; A61K031/57; A61K031/57+M
US 2004220163	NCL	514/182.000; 514/170.000
	ECLA	A61K031/57+M <--

AB The invention relates to novel **contraceptive compns.**
 formed from a **progestogen** and an **estrogen**. The
 invention relates specifically to **contraceptive compns**
 ., characterized in that they contain, as active ingredients, a
 nomegestrol ester and estradiol, in **combination** or admixt. with
 an inert, nontoxic vehicle or a diluent which is suitable for oral
 administration. Thus, a tablet **formulation** contained estradiol
 2.50, Povidone 15.00, and lactose 82.50%.

ST **contraceptive progestogen estrogen**

IT Drug delivery systems
 (capsules; **contraceptives** based on **progestogens** and
estrogens)

IT **Contraceptives**
 Human
 Ovarian cycle
 (**contraceptives** based on **progestogens** and
estrogens)

IT **Estrogens**
Progestogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**contraceptives based on progestogens and estrogens**)

- IT Drug delivery systems
(oral; **contraceptives based on progestogens and estrogens**)
- IT Drug delivery systems
(powders; **contraceptives based on progestogens and estrogens**)
- IT Drug delivery systems
(tablets, coated; **contraceptives based on progestogens and estrogens**)
- IT Drug delivery systems
(tablets; **contraceptives based on progestogens and estrogens**)
- IT 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β) -
50-28-2D, Estradiol, esters 58652-20-3 853244-42-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**contraceptives based on progestogens and estrogens**)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Anon; FR 2754179 1998 HCAPLUS
- (2) Hesch; US 6500814 B1 2002 HCAPLUS
- (3) Jamin, C; Abstract of Revue Francaise De Gynecologie Et D Obsterique 1992, V87(6), P370 MEDLINE

- IT 50-28-2, Estra-1,3,5(10)-triene-3,17-diol (17 β) -
50-28-2D, Estradiol, esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**contraceptives based on progestogens and estrogens**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 2 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2005:122794 HCAPLUS
 DN 142:191646
 ED Entered STN: 11 Feb 2005
 TI Multistage preparation for **contraception** based on natural
estrogens
 IN Dittgen, Michael; Fricke, Sabine; Hoffmann, Herbert; Moore, Claudia;
 Oettel, Michael; Oster, Wald Monika
 PA Germany
 SO U.S. Pat. Appl. Publ., 4 pp., Cont.-in-part of U.S. Ser. No. 950,915.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-56
 INCL 514170000
 CC 2-3 (Mammalian Hormones)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005032756	A1	20050210	US 2004-891729	20040715 <--
	DE 19540253	A1	19970430	DE 1995-19540253	19951028 <--
	DE 19540253	C2	19980604		
	US 6133251	A	20001017	US 1996-738314	19961025 <--
	US 2002107229	A1	20020808	US 2001-950915	20010912 <--
	US 6884793	B2	20050426		
PRAI	DE 1995-19540253	A	19951028	<--	
	US 1996-738314	A1	19961025	<--	
	US 2000-648858	B3	20000825		
	US 2001-950915	A2	20010912		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005032756	ICM	A61K031-56
	INCL	514170000
US 2005032756	NCL	514/170.000
	ECLA	A61K031/57+M <--
DE 19540253	ECLA	A61K031/57+M <--
US 6133251	NCL	514/170.000; 514/178.000; 514/182.000; 514/843.000
	ECLA	A61K031/57+M <--
US 2002107229	NCL	514/170.000; 514/178.000; 514/182.000
	ECLA	A61K031/57+M <--

AB A multistage preparation for **contraception** based on a
combination of natural **estrogen** and synthetic
gestagen is described. The preferred preparation contains estradiol
 valerate as the natural **estrogen** and **dienogest** or
drospirenone as the synthetic **gestagen**. solution In

comparison to conventional multistage preps. the multistage preparation according to the invention has a higher **contraceptive** reliability over the entire cycle, improved cyclic bleeding behavior and minimizes or prevents side effects, such as breast tension, headaches, depressive moods and libido changes.

ST natural **estrogen** based multistage **contraception**

IT **Contraceptives**

(female; multistage preparation for **contraception** based on natural **estrogens**)

IT Human

(multistage preparation for **contraception** based on natural **estrogens**)

IT **Estrogens**

Progestogens

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multistage preparation for **contraception** based on natural **estrogens**)

IT 307334-58-3 350818-74-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(multistage preparation for **contraception** based on natural **estrogens**)

L61 ANSWER 3 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:712919 HCAPLUS

DN 137:226940

ED Entered STN: 19 Sep 2002

TI Oral **contraceptive progestin/estrogen combination**

IN Gast, Michael J.

PA Wyeth, John, and Brother Ltd., USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-56

INCL 514170000

CC 2-3 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6451778	B1	20020917	US 1997-886072	19970702 <--
PRAI	US 1996-22625P	P	19960726	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 6451778	ICM	A61K031-56	
	INCL	514170000	
US 6451778	NCL	514/170.000; 514/843.000	
	ECLA	A61K031/56+M; A61K031/57+M; A61K031/575+M	<--

AB This invention provides a monophasic **combination progestin/estrogen oral contraceptive regimen** for females of child bearing age that provides effective **contraception**, good cycle control, and minimal side effects while greatly reducing the total **contraceptive** steroid administered (particularly the **estrogenic** component) per 28-day cycle. More particularly, this invention provides a method of **contraception** which **comprises** administering to a female of child bearing age for a **combination** of a **progestin** at a daily dosage of

40-500 µg trimegestone, 250 µg-4 mg **dienogest**, or 250 µg-4 mg **drospirenone**, and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the **progestin** and **estrogen combination** is administered in each of the 23-25 days.

ST oral **contraceptive progestin estrogen**

IT **Estrogens**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated, **mixts.** with **progestin**; oral **contraceptive progestin/estrogen combination**)

IT **Progestogens**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**mixts.** with **estrogens**; oral **contraceptive progestin/estrogen combination**)

IT **Estrogens**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**mixts.** with **progestins**; oral **contraceptive progestin/estrogen combination**)

IT Human

(oral **contraceptive progestin/estrogen combination**)

IT **Contraceptives**

(oral; oral **contraceptive progestin/estrogen combination**)

IT 53-16-7D, Estrone, salts, **mixts.** with **progestin**

8060-43-3 65928-58-7D, **Dienogest**, **mixts.**

with **estrogens** 67392-87-4D, **Drospirenone**,

mixts. with **estrogens** 74513-62-5D, **Trimegestone**,

mixts. with **estrogens** 164017-31-6 170475-05-5

459452-70-1 459452-71-2 459452-72-3 459452-73-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral **contraceptive progestin/estrogen combination**)

IT 7439-89-6, Iron, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral **contraceptive progestin/estrogen**

combination containing a non-**contraceptive** placebo with an iron supplement)


RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; EP 0253607 1988 HCAPLUS
- (2) Anon; EP 0628312 1994 HCAPLUS
- (3) Anon; DE 4313926 1994 HCAPLUS
- (4) Anon; WO 9517194 1995 HCAPLUS
- (5) Anon; WO 9526730 1995 HCAPLUS
- (6) Anon; EP 0696454 1996 HCAPLUS
- (7) Barcomb; US 5547948 A 1996 HCAPLUS
- (8) Bennink; US 5418228 A 1995 HCAPLUS
- (9) Bergink; US 5262408 A 1993 HCAPLUS
- (10) Boissonneault; US 4962098 A 1990 HCAPLUS
- (11) Coussediere; US 4273771 A 1981 HCAPLUS
- (12) Edgren; US 4390531 A 1983 HCAPLUS
- (13) Ehrlich; US 5280023 A 1994 HCAPLUS


(14) Lachnit-Fixson; US 3957982 A 1976 HCAPLUS
 (15) Lachnit-Fixson; US 3969502 A 1976 HCAPLUS
 (16) Lachnit-Fixson; US 4621079 A 1986 HCAPLUS
 (17) Oettel; US 5633242 A 1997 HCAPLUS
 (18) Pasquale; US 4530839 A 1985 HCAPLUS
 (19) Pasquale; US 4628051 A 1986 HCAPLUS
 (20) Pasquale; US 4921843 A 1990 HCAPLUS
 (21) Ponsold; US 4248790 A 1981 HCAPLUS
 (22) Sartoretto; Clinica e Terapeutica 1974, V3, P399
 (23) Spona; US 5583129 A 1996 HCAPLUS
 IT 65928-58-7D, Dienogest, mixts. with
 estrogens 67392-87-4D, Drospirenone,
 mixts. with estrogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (oral contraceptive progestin/estrogen
 combination)
 RN 65928-58-7 HCAPLUS
 CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 67392-87-4 HCAPLUS
 CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
 furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
 hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 4 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2001:319730 HCAPLUS
 DN 134:316159
 ED Entered STN: 04 May 2001
 TI **Contraceptive** medicine based on a **progestational** agent
 and an **estrogen**
 IN Paris, Jacques; Thomas, Jean-Louis
 PA Laboratoire Theramex, Monaco
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 IC ICM A61K031-57
 ICS A61P005-30
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030355	A1	20010503	WO 1999-FR2587	19991025
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6906049	B1	20050614	US 1999-423108	19991025 <--
	CA 2388857	AA	20010503	CA 2000-2388857	20001024
	WO 2001030358	A1	20010503	WO 2000-FR2952	20001024
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1227815	A1	20020807	EP 2000-971488	20001024
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003518013	T2	20030603	JP 2001-532776	20001024
	BR 2000014952	A	20030729	BR 2000-14952	20001024
	NO 2002001948	A	20020625	NO 2002-1948	20020425
	ZA 2002003399	A	20040209	ZA 2002-3399	20020429
	US 2004220163	A1	20041104	US 2004-753073	20040108 <--
PRAI	FR 1996-12239	A	19961008	<--	
	WO 1997-FR1792	W	19971008		
	US 1999-284147	A2	19990317		
	US 1999-423108	A2	19991025		
	WO 1999-FR2587	W	19991025		
	WO 2000-FR2952	W	20001024		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001030355	ICM	A61K031-57
	ICS	A61P005-30
WO 2001030355	ECLA	A61K031/565+M; A61K031/57; A61K031/57+M
US 6906049	NCL	514/170.000; 514/171.000; 514/177.000; 514/178.000; 514/182.000; 514/841.000; 514/843.000 <--
WO 2001030358	ECLA	A61K031/565+M; A61K031/57+M
US 2004220163	NCL	514/182.000; 514/170.000
	ECLA	A61K031/57+M <--

- AB The invention concerns the field of chemical and more particularly the field of therapeutic chemical. More particularly, it concerns novel **contraceptive compns.** consisting of a **progestational agent** and an **estrogen**. It specifically concerns novel pharmaceutical **contraceptive compns.** characterized in that they contain as active principles a nomegestrol and estradiol ester **combined** or **mixed** with a pharmaceutically acceptable inert non-toxic carrier or support suited for oral administration. A tablet contained 2.5% estradiol premixt. 44.45, nomegestrol acetate 0.33, colloidal silica 0.55, Crospovidone 3.60, lactose 28.89, microcryst. cellulose 19.18, stearic acid 2.00, and talc 1.00%. Antigonadotropic efficacy of the **combination** was studied in female volunteers.
- ST oral **contraceptive progestational agent estrogen**; estradiol nomegestrol acetate tablet oral **contraceptive**
- IT Drug delivery systems
(capsules; **contraceptive medicine based on progestational agent and estrogen**)
- IT Lubricants
(**contraceptive medicine based on progestational agent and estrogen**)
- IT **Estrogens**
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**contraceptive medicine based on progestational agent and estrogen**)
- IT **Contraceptives**
(oral; **contraceptive medicine based on progestational agent and estrogen**)
- IT Drug delivery systems
(powders; **contraceptive medicine based on progestational agent and estrogen**)
- IT Drug delivery systems
(sachets; **contraceptive medicine based on progestational agent and estrogen**)
- IT Drug delivery systems
(tablets; **contraceptive medicine based on progestational agent and estrogen**)
- IT **50-28-2D**, Estradiol, ethers and esters 58652-20-3, Nomegestrol acetate 58691-88-6D, Nomegestrol, ethers and esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**contraceptive medicine based on progestational agent and estrogen**)
- RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Laboratoire Theramex; FR 2754179 A 1998 HCAPLUS
- IT **50-28-2D**, Estradiol, ethers and esters
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**contraceptive medicine based on progestational agent and estrogen**)
- RN 50-28-2 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 5 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:768958 HCAPLUS
 DN 133:340228
 ED Entered STN: 02 Nov 2000
 TI **Combined pharmaceutical estrogen-androgen-progestin for oral contraception and hormone replacement therapy**
 IN Hughes, Claude L., Jr.; Jayo, Manuel J.
 PA Cedars-Sinai Medical Center, USA; Wake Forest University
 SO U.S., 21 pp., Cont.-in-part of U.S. 5,962,021.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K009-20
 ICS A61K031-56
 INCL 424464000
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1, 2, 13

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6139873	A	20001031	US 1998-177866	19981023 <--
US 5770226	A	19980623	US 1996-679764	19960710 <--
US 5962021	A	19991005	US 1998-102707	19980622 <--
WO 2000024384	A1	20000504	WO 1999-US24854	19991022
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 1996-679764	A1	19960710	<--	
US 1998-102707	A2	19980622		
US 1998-177866	A2	19981023		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6139873	ICM	A61K009-20
	ICS	A61K031-56
	INCL	424464000
US 6139873	NCL	424/464.000; 424/423.000; 424/443.000; 424/449.000; 514/170.000; 514/841.000; 514/843.000
	ECLA	A61K031/565+M; A61K031/57+M <--

US 5770226 NCL 424/464.000; 424/400.000; 424/465.000; 514/841.000;
514/843.000

US 5962021 ECLA A61K031/565+M; A61K031/57+M <--
NCL 424/464.000; 424/449.000; 514/170.000; 514/841.000;
514/843.000

WO 2000024384 ECLA A61K031/565+M; A61K031/57+M <--

AB Disclosed are methods and **comps.** for oral **contraception**
and for hormone replacement therapy. Certain **comps.** of the
invention contain androgens, preferably methyltestosterone to be taken in
conjunction with **estrogens** and **progestins**. An oral
contraceptive formulation comprised 28 tablets
as follows: 6 tablets containing 0.03 mg ethinyl estradiol, 0.05 mg
levonorgestrel and 0.25 mg methyltestosterone to be taken on
consecutive days 8-13 of a menstrual cycle; 5 tablets containing about 0.075
mg **levonorgestrel** and about 0.040 mg: ethinyl estradiol to be
taken on consecutive days 14-18 of a menstrual cycle; 10 tablets containing
about 0.125 mg **levonorgestrel** and about 0.030 mg ethinyl
estradiol to be taken on consecutive days 19-28 of a menstrual cycle; and
7 placebo tablets containing no oral **contraceptive** hormones to be
taken on days 1-7 of the menstrual cycle.

ST pharmaceutical **estrogen** androgen **progestin** oral
contraceptive; hormone replacement therapy **estrogen**
androgen **progestin**; ethinyl estradiol **levonorgestrel**
methyltestosterone **contraceptive** tablet

IT Atherosclerosis
Bone
Bone formation
Drug delivery systems
Hormone replacement therapy
Menopause
(**combined** pharmaceutical **estrogen**-androgen-
progestin for oral **contraception** and hormone
replacement therapy)

IT Androgens
Estrogens
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(**combined** pharmaceutical **estrogen**-androgen-
progestin for oral **contraception** and hormone
replacement therapy)

IT Ovary
(loss or change in secretion by; **combined** pharmaceutical
estrogen-androgen-**progestin** for oral
contraception and hormone replacement therapy)

IT Drug delivery systems
(ointments; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception** and
hormone replacement therapy)

IT **Contraceptives**
(oral; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception**
and hormone replacement therapy)

IT Menopause
(premenopause; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception** and
hormone replacement therapy)

IT Drug delivery systems

- (subdermal; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception** and
hormone replacement therapy)
- IT Drug delivery systems
(tablets; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception** and
hormone replacement therapy)
- IT Drug delivery systems
(topical, skin patches; **combined** pharmaceutical
estrogen-androgen-**progestin** for oral
contraception and hormone replacement therapy)
- IT Drug delivery systems
(transdermal; **combined** pharmaceutical **estrogen**
-androgen-**progestin** for oral **contraception** and
hormone replacement therapy)
- IT 57-63-6, Ethinyl estradiol 58-18-4, Methyltestosterone 797-63-7
, **Levonorgestrel**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(**combined** pharmaceutical **estrogen**-androgen-
progestin for oral **contraception** and hormone
replacement therapy)


RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adams; Arterioscler Thromb Vasc Biol 1995, V15, P562 HCAPLUS
- (2) Adashi; Fertil Steril 1994, V62, P20 MEDLINE
- (3) Anon; WO 9218107 1992 HCAPLUS
- (4) Anon; PCT Search Report 1997
- (5) Anon; Supplementary European Search Report 1999
- (6) Barrett-Connor; Am J Med 1995, V98(Suppl 2A), P3S
- (7) Baylor College Of Medicine; The Contraception Report 1995, VVI(5)
- (8) Bubenik; Comp Biochem Physiol A Comp Physiol 1987, V87, P551 MEDLINE
- (9) Buchanan; J Clin Endocrinol Metab 1988, V67, P934
- (10) Carr; J Clin Endocrinol Metab 1995, V80, P1169 HCAPLUS
- (11) Castro; Proc Soc Exp Biol Med 1981, V168, P389 HCAPLUS
- (12) Cauley; Am J Epidemiol 1994, V139, P1035 MEDLINE
- (13) Clarkson; Obstet Gynecol 1990, V75, P217 MEDLINE
- (14) Colvard; Proc Natl Acad Sci USA 1989, V86, P864
- (15) Decherney; Am J Obstet Gynecol 1993, V174, P1
- (16) Duhper; J Clin Endocrinol Metab 1990, V71, P1083
- (17) Enzelberger; Maturitas 1988, V9, P375
- (18) Flanagan; J Bone Miner Res 1995, V10(Suppl I), PS349
- (19) Fortney; J Reprod Med 1994, V39, P105 MEDLINE
- (20) Frank; Acta Paediatr 1995, V84, P627 MEDLINE
- (21) Gallagher; American Physiological Society 1996, V270, PE407 HCAPLUS
- (22) Gallagher; Department of Histopathology, St George's Hospital Medical
School, London 1996
- (23) Gambacciani; Obstet Gynecol 1994, V83, P392 MEDLINE
- (24) Garnero; Bone 1995, V16(5), P499 HCAPLUS
- (25) Garnero; Journal of Clinical Endocrinology and Metabolism 1996, V81(1),
P140 HCAPLUS
- (26) Goldsmith; J Bone J Surg 1975, V57A, P657
- (27) Hickock; Obstet Gynecol 1993, V82, P919
- (28) Hreshchyshyn; Am J Obstet Gynecol 1988, V159, P318 MEDLINE
- (29) Hughes; US 5770226 1998 HCAPLUS
- (30) Hughes; US 5962021 1999 HCAPLUS
- (31) Hughes; Gynecol Oncol 1991, V40, P42
- (32) Jayo; Am J Obstet Gynecol 1990, V193, P614
- (33) Jayo; Calcif Tissue Int 1991, V49, P438 MEDLINE

- (34) Jayo; Calcif Tissue Int 1994, V54, P231 MEDLINE
(35) Jayo; Cross-Sectional Examination of Lumbar Bone Mineral by Dual Energy X-Ray Absorptiometry (DXA) in Female Cynomolgus Macaques 1990, PS170
(36) Jayo; J Bone Miner Res 1989, V4(Suppl 1), PS181
(37) Jayo; J Bone Miner Res 1995, V10, PS256
(38) Jerome; J Bone Miner Res 1994, V9, P527 MEDLINE
(39) Johnell; Calcif Tissue Int 1984, V36, P354 MEDLINE
(40) Kanders; J Bone Miner Res 1988, V3, P145 MEDLINE
(41) Kanis; Am J Med 1995, V98(Suppl 2A), P605
(42) Kasperk; J Clin Endocrinol Metab 1990, V71, P1322 HCAPLUS
(43) Kasra; Bone 1995, V17, P265 HCAPLUS
(44) Polatti; Contraception 1995, V51, P221 HCAPLUS
(45) Raisz; Journal of Clinical Endocrinology and Metabolism 1996, V81(1), P37 HCAPLUS
(46) Recker; JAMA 1992, V268, P2403 MEDLINE
(47) Register; J Bone Min Reser 1995, V10(Suppl 1), PS356
(48) Register; Osteoporosis Int 1997
(49) Riasz; The Female Patient 1996, P11
(50) Ribot; Acta Paediatr Suppl 1995, V411, P31 MEDLINE
(51) Shargil; Int J Fertil 1985, V30(1), P15 MEDLINE
(52) Shively; Arteriosclerosis 1987, V7, P226 MEDLINE
(53) Simberg; Journal of Clinical Endocrinology and Metabolism 1996, V81(2), P646 HCAPLUS
(54) Slemenda; J Clin Invest 1996, V97(1), P14 HCAPLUS
(55) Soule; Clinical Endocrinology 1995, V43, P671 MEDLINE
(56) Spicer; US 5211952 1993 HCAPLUS
(57) Spicer; US 5340584 1994 HCAPLUS
(58) Stevenson; Br Med J 1989, V298, P924 MEDLINE
(59) Teegarden; J Bone Miner Res 1995, V10(Suppl 1), PS456
(60) Tulli; J Histotechnol 1992, V15, P93
(61) Tuppurainen; Osteoporosis International 1994, V4, P93 MEDLINE
(62) Ursin; Contraception and Cancer Prevention, Advances in Contraceptive Delivery Systems 1994, V10(3-4), P369 MEDLINE
(63) van der Vies; US 4220599 1980 HCAPLUS
(64) Vanin; J Bone Miner Res 1995, V10(Suppl 1), PS250
(65) Watts; Obstet Gynecol 1995, V85, P529 HCAPLUS
(66) Wiegratz; Contraception 1995, V51, P341 HCAPLUS
(67) Wiren; J Bone Miner Res 1995, V10(Suppl 1), PS494
(68) Wright; US 5595759 1997 HCAPLUS
- IT 797-63-7, **Levonorgestrel**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined pharmaceutical **estrogen**-androgen-**progestin** for oral **contraception** and hormone replacement therapy)
- RN 797-63-7 HCAPLUS
CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 6 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2000:290824 HCAPLUS
 DN 132:313717
 ED Entered STN: 05 May 2000
 TI **Contraceptive estrogen-androgen-progestin combinations**
 IN Hughes, Claude L., Jr.; Jayo, Manuel J.
 PA Wake Forest University, USA; Cedars-Sinai Medical Center
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-20
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000024384	A1	20000504	WO 1999-US24854	19991022
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6139873	A	20001031	US 1998-177866	19981023 <--
PRAI	US 1998-177866	A2	19981023		
	US 1996-679764	A1	19960710	<--	
	US 1998-102707	A2	19980622		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000024384	ICM	A61K009-20
WO 2000024384	ECLA	A61K031/565+M; A61K031/57+M
US 6139873	NCL	424/464.000; 424/423.000; 424/443.000; 424/449.000; 514/170.000; 514/841.000; 514/843.000
	ECLA	A61K031/565+M; A61K031/57+M <--
AB	Disclosed are methods and comps. for oral contraception and for hormone replacement therapy. Certain comps. of the invention contain androgens , preferably methyltestosterone to be taken in conjunction with estrogens and progestins . An example tablet contained ethinylestradiol, levonorgestrel , and methyltestosterone. Other examples include oral contraceptive effects on bone metabolism in primates, estrogen effects on	

postmenopausal monkeys, and atherosclerosis-related studies in premenopausal monkeys.

ST **contraceptive estrogen androgen progestogen**

IT **Contraceptives**
Hormone replacement therapy
Menopause
 (contraceptive estrogen-androgen-progestin combinations)

IT Androgens
 Estrogens
 Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (contraceptive estrogen-androgen-progestin combinations)

IT Drug delivery systems
 (ointments; **contraceptive estrogen-androgen-progestin combinations**)

IT **Contraceptives**
Drug delivery systems
 (oral; **contraceptive estrogen-androgen-progestin combinations**)

IT Drug delivery systems
 (topical; **contraceptive estrogen-androgen-progestin combinations**)

IT Drug delivery systems
 (transdermal; **contraceptive estrogen-androgen-progestin combinations**)

IT 57-63-6, Ethinylestradiol 58-18-4, Methyltestosterone **797-63-7**, **Levonorgestrel**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (contraceptive estrogen-androgen-progestin combinations)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


(1) Spicer; US 5340584 A 1994 HCAPLUS

IT **797-63-7, Levonorgestrel**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (contraceptive estrogen-androgen-progestin combinations)

RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 7 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:527193 HCAPLUS

DN 129:166193

ED Entered STN: 21 Aug 1998

TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil

PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SO PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-52

ICS A61K047-30

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 15

FAN.CNT 17

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832427	A1	19980730	WO 1998-US1556	19980127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6309669	B1	20011030	US 1997-789734	19970127 <--
AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI US 1997-789734	A	19970127		
US 1984-590308	B1	19840316	<--	
US 1992-867301	A2	19920410	<--	
US 1995-446148	A2	19950522	<--	
US 1995-446149	B2	19950522	<--	
US 1996-590973	B2	19960124	<--	
WO 1998-US1556	W	19980127		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9832427	ICM	A61K009-52
	ICS	A61K047-30
WO 9832427	ECLA	A61K009/16H6D4; A61K038/17A2; A61K038/19; A61K039/00;

US 6309669 NCL A61K039/108; A61K039/29B
 424/486.000; 424/422.000; 424/423.000; 424/424.000;
 424/425.000; 424/484.000
 ECLA A61K009/16H6D4; A61K009/50H6B; A61K009/50H6D;
 A61K038/17A2 <--

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiol. environment. The microcapsules are **comprised** of a core of polypeptide or other biol. active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

ST infection microcapsule sustained release peptide copolymer

IT Hepatitis
 (B, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Hepatitis
 (C, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Trypanosoma cruzi
 (Chagas' disease from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Immunoglobulins
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (G, ampicillin-specific; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Nervous system
 (Huntington's chorea; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
 (Kaposi's sarcoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Sperm
 (acrosome, proteinase of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Diagnosis
 (agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Ragweed (Ambrosia)
 (allergy; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Ameba
 (amebiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antibiotics
 (aminoglycoside; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Absidia ramosa
 Actinobacillus equuli
 Actinobacillus seminis
 Arcanobacterium pyogenes
 Aspergillus fumigatus
 Babesia caballi
 Brucella melitensis
 Campylobacter fetus

Campylobacter fetus intestinalis
 Candida albicans
 Candida tropicalis
 Chlamydia psittaci
 Clostridium tetani
 Equid herpesvirus 1
 Equine arteritis virus
 Escherichia coli
 Gardnerella vaginalis
 Human herpesvirus 1
 Human herpesvirus 2
 Leptospira interrogans pomona
 Listeria monocytogenes
 Mycobacterium tuberculosis
 Mycoplasma bovis
 Mycoplasma hominis
 Neisseria gonorrhoeae
 Pneumocystis carinii
 Pseudomonas aeruginosa
 Rhodococcus equi
 Salmonella abortusovae
 Salmonella abortusovis
 Streptococcus group B
 Toxoplasma gondii
 Treponema pallidum
 Trichomonas vaginalis
 Tritrichomonas foetus
 Trypanosoma equiperdum
 (antigens of; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Mycobacterium
 (antimycobacterial agents; prevention of infections with bioactive
 material encapsulated within biodegradable-biocompatible polymeric
 matrix)
 IT Mouth
 (aphthous ulcer; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Drugs
 (appetite stimulants; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Heart, disease
 (arrhythmia; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Blood vessel
 (artificial, infections surrounding; prevention of infections with
 bioactive material encapsulated within biodegradable-biocompatible
 polymeric matrix)
 IT Dermatitis
 (atopic; prevention of infections with bioactive material encapsulated
 within biodegradable-biocompatible polymeric matrix)
 IT Babesia
 (babesiosis; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Skin, neoplasm
 (basal cell carcinoma, inhibitors; prevention of infections with
 bioactive material encapsulated within biodegradable-biocompatible
 polymeric matrix)
 IT Antitumor agents
 Skin, neoplasm
 (basal cell carcinoma; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)

IT Natural products, pharmaceutical
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(belladonna; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Prostate gland
(benign hyperplasia; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Polymers, biological studies
RL: DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Nervous system
(central, disease; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Polymers, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(co-; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Intestine, disease
(colitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antigens
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(colony factor; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Intestine, neoplasm
(colorectal, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
Intestine, neoplasm
(colorectal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Thrombosis
(coronary arterial; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Artery, disease
(coronary, thrombosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Vasodilators
(coronary; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Tapeworm (Cestoda)
(cysticercosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Bladder
(cystitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Mental disorder
(depression; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Eye, disease
(diabetic retinopathy; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)

IT Polyesters, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (dilactone-based; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Digestive tract
 (drugs for; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Brain, disease
 (edema, peritumoral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
 (emulsions; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT B cell (lymphocyte)
 T cell (lymphocyte)
 (epitopes of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Alkaloids, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (ergot; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Amino acids, biological studies
 Fats and Glyceridic oils, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (essential; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Fasciola
 (fascioliasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Filaria
 (filariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Anthelmintics
 (filaricides; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Digestive tract
 (gastroenteritis, virus causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Intestine, disease
 (giardiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Transplant and Transplantation
 (graft-vs.-host reaction; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Calymmatobacterium granulomatis
 (granuloma inguinale from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antigens
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (hepatitis B surface; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Liver, neoplasm
 - (hepatoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Antitumor agents
 - Liver, neoplasm
 - (hepatoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Human herpesvirus 2
 - (herpes genitalis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Human herpesvirus 3
 - (herpes zoster from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Parvovirus
 - Retroviridae
 - (human; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Globulins, biological studies
 - RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (hyperimmune; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Sexual behavior
 - (impotence; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Eye, disease
 - Mouth
 - Skin, disease
 - (infection; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Prosthetic materials and Prosthetics
 - (infections surrounding; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
 - (inhalants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Fertility
 - Ovary, neoplasm
 - Pancreas, neoplasm
 - (inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
 - (injections; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Diabetes mellitus
 - (insulin-dependent; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Leishmania
 - (leishmaniasis from, visceral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Antitumor agents
 - (lung small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antibiotics
(macrolide; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(mammary gland; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(melanoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(microcapsules; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(microspheres; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(nasal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Mammary gland
Prostate gland
(neoplasm, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Mammary gland
Prostate gland
(neoplasm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Meningitis
(neoplastic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Angiogenesis
(neovascularization, retinal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Diabetes mellitus
(non-insulin-dependent; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Anti-inflammatory agents
(nonsteroidal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Emulsions
(oil-in-water; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Drug delivery systems
(oral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Nitrites
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(organic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(ovary; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Antitumor agents
(pancreas; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

IT Anxiety
(panic disorder; prevention of infections with bioactive material

encapsulated within biodegradable-biocompatible polymeric matrix)

IT Paragonimus
(paragonimiasis; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric matrix)

IT Hormones, animal, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
(Device component use); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); PROC (Process); USES (Uses)
(peptide; prevention of infections with bioactive material encapsulated
within biodegradable-biocompatible polymeric matrix)

IT Periodontium
(periodontitis; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric matrix)

IT Mental disorder
(phobia; prevention of infections with bioactive material encapsulated
within biodegradable-biocompatible polymeric matrix)

IT Adhesion, biological
(postsurgical; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric matrix)

IT AIDS (disease)
Acinetobacter
Actinomycetales
Adenoviridae
Adrenoceptor agonists
Aerococcus
Aeromonas
Allergy inhibitors
Alzheimer's disease
Analgesics
Anesthetics
Angiogenesis
Angiogenesis inhibitors
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antibacterial agents
Antibiotics
Anticholesteremic agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antiserums
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Appetite depressants
Arbovirus

Arcanobacterium haemolyticum
Arenavirus
Asthma
Bacillus (bacterium genus)
Biocompatibility
Blood substitutes
Bordetella
Borrelia
Bronchodilators
Brucella
Cachexia
Calymmatobacterium
Campylobacter
Cardiopulmonary bypass
Cardiotonics
Cardiovascular agents
Cholinergic agonists
Clostridium
 Contraceptives
Coronavirus
Corynebacterium
Cryptosporidium parvum
Cystic fibrosis
Cytomegalovirus
Cytotoxic agents
Decongestants
Diagnosis
Diarrhea
Dissolution rate
Diuretics
Drug bioavailability
Drug dependence
Ebola virus
Echinococcus
Electrolytes, biological
Emulsifying agents
Enterobacteriaceae
Enterococcus
Enterovirus
Epitopes
Erysipelothrix
Expectorants
Filovirus
Flavobacterium
Freeze drying
Fungicides
Gardnerella
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Haemophilus ducreyi
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human immunodeficiency virus 1
Human parainfluenza virus

Human poliovirus
Hypercholesterolemia
Hypnotics and Sedatives
Immunization
Immunomodulators
Immunostimulants
Infection
Influenza virus
Kidney, disease
Lactococcus
Legionella
Leptospira
Leuconostoc
Listeria
Measles virus
Melanoma
Micrococcus
Molluscum contagiosum virus
Moraxella
Multiple sclerosis
Mumps virus
Muscle relaxants
Narcotics
Neisseria
Nervous system agents
Nutrients
Opioid antagonists
Osteoarthritis
Osteomyelitis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Papillomavirus
Parasitocides
Parkinson's disease
Pediococcus
Planococcus (bacterium)
Plesiomonas
Pneumonia
Poxviridae
Pseudomonas
Psoriasis
Psychotropics
Rabies virus
Reoviridae
Respiratory syncytial virus
Rheumatoid arthritis
Rhinovirus
Rhodococcus
Rotavirus
Rothia (bacterium)
Rubella virus
Salmonella typhi
Sexually transmitted diseases
Shigella boydii
Shigella dysenteriae
Shigella flexneri
Shigella sonnei
Spirillum
Staphylococcus

Streptobacillus
 Streptococcus
 Thrombosis
 Tranquilizers
 Treponema
 Vaccines
 Vasodilators
 Vibrio
 Vibrio cholerae
 Wolinella succinogenes
 Yersinia
 (prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)
 IT Alkaloids, biological studies
 Antibodies
 Antigens
 Enzymes, biological studies
 Estrogens
 Glycolipids
 Glycopeptides
 Growth factors, animal
 Lipopolysaccharides
 Peptides, biological studies
 Pheromones, animal
 Progestogens
 Prostaglandins
 Proteins, general, biological studies
 Steroids, biological studies
 Sulfonamides
 Tetracyclines
 Vitamins
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PROC (Process); USES (Uses)
 (prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)
 IT Drug delivery systems
 (prodrugs; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Proliferation inhibition
 (proliferation inhibitors; prevention of infections with bioactive
 material encapsulated within biodegradable-biocompatible polymeric
 matrix)
 IT Antitumor agents
 (prostate gland; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Pilus
 (proteins; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Scalp
 (psoriasis of; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Drug delivery systems
 (rectal; prevention of infections with bioactive material encapsulated
 within biodegradable-biocompatible polymeric matrix)
 IT Artery, disease
 (restenosis; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric matrix)
 IT Eye, disease
 (retina, neovascularization; prevention of infections with bioactive

- material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Schistosoma
(schistosomiasis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Lung, neoplasm
(small-cell carcinoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Lung, neoplasm
(small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Muscle relaxants
(spasmolytics; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT **Contraceptives**
(spermicidal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Brain, disease
(spongiform encephalopathy, agent causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Appetite
(stimulants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Brain, disease
(stroke; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Strongylus
(strongylodiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
(sustained-release, programmable; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Osteoporosis
(therapeutic agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Bile
(therapy with; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
(topical; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Muscle, disease
(torticollis, spasmodic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Toxocara
(toxocariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Toxoplasma gondii
(toxoplasmosis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
(transdermal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Head
(trauma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

- IT Trichinella
(trichinellosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Trichomonas
(trichomoniasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Drug delivery systems
(vaginal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Emulsions
(water-in-oil; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT Lactams
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β -, antibiotics; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 9002-72-6, Somatotropin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(deficiency; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 9005-49-6, Heparin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neutralization of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 9001-60-9, Lactate dehydrogenase 37326-33-3, Hyaluronidase
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(of sperm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephentyoin
50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,
Prednisolone 50-28-2, 17 β -Estradiol, biological studies
50-33-9, Phenylbutazone, biological studies 50-52-2, Thioridazine
50-55-5, Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological
studies 52-24-4, Thiotepe 52-76-6, Lynestrenol 53-03-2, Prednisone
53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-11-5,
Nicotine 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7,
Nitrogen mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol
57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital
57-42-1, Meperidine 57-53-4, Meproamate 57-63-6, Ethinyl estradiol
57-85-2, Testosterone propionate 57-92-1, Streptomycin a, biological
studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine
58-22-0 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-73-1,
Diphenhydramine 59-01-8, Kanamycin a 59-05-2, Methotrexate 59-92-7,
L-Dopa, biological studies 61-33-6, Penicillin g, biological studies
67-20-9, Nitrofurantoin 68-22-4, **Norethisterone**
68-23-5, Norethynodrel 69-09-0, Chlorpromazine hydrochloride 69-53-4,
Ampicillin 69-72-7D, Salicylic acid, derivs. 71-58-9,
Medroxyprogesterone acetate 72-33-3, Mestranol 76-57-3,
Codeine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 91-81-6,
Tripeleminamine 103-90-2, Acetaminophen 113-15-5, Ergotamine
114-07-8, Erythromycin 114-49-8, Hyoscine hydrobromide 121-54-0
122-09-8, Phentermine 125-29-1, Dihydrocodeinone 125-71-3,
Dextromethorphan 127-48-0, Trimethadione 128-62-1, Noscapiene
145-94-8, Chlorindanol 148-82-3, Melphalan 155-41-9, Methscopolamine
bromide 288-32-4D, Imidazole, derivs. 297-76-7, Ethynodiol diacetate
302-22-7, Chlormadinone acetate 305-03-3, Chlorambucil
309-43-3, Sodium secobarbital 315-30-0, Allopurinol 434-03-7,

Ethisterone 439-14-5, Diazepam 443-48-1, Metronidazole 469-62-5
 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium
 carbonate, biological studies 523-87-5, Dimenhydrinate 546-93-0,
 Magnesium carbonate 578-66-5D, 8-Aminoquinoline, derivs. 578-68-7D,
 4-Aminoquinoline, derivs. 595-33-5, Megestrol acetate 738-70-5,
 Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin b
 1397-94-0, Antimycin a 1403-66-3, Gentamicin 1404-26-8, Polymyxin b
 1404-90-6, Vancomycin 1406-05-9D, Penicillin, derivs. 4696-76-8,
 Kanamycin b 5588-33-0, Mesoridazine 5633-18-1, Melengestrol
 5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2,
Norgestrel 7447-40-7, Potassium chloride (KCl), biological
 studies 8063-07-8, Kanamycin 9000-83-3, Atpase 9000-92-4, Amylase
 9001-62-1, Lipase 9001-63-2, Muramidase 9001-67-6, Neuraminidase
 9001-78-9, Alkaline phosphatase 9001-99-4, Ribonuclease 9002-02-2,
 Succinic acid dehydrogenase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin
 9004-10-8, Insulin, biological studies 9025-82-5, Phosphodiesterase
 9029-12-3, Glutamic acid dehydrogenase 9035-74-9, Glycogen phosphorylase
 9046-27-9, γ -Glutamyltranspeptidase 9079-67-8 10118-90-8,
 Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin
 14271-04-6 21645-51-2, Aluminum hydroxide, biological studies
 22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate
 25447-66-9 26780-50-7, Poly(lactide co-glycolide) 26787-78-0,
 Amoxicillin 30516-87-1, Azt 32986-56-4, Tobramycin 35189-28-7
 , **Norgestimate** 37205-61-1, Proteinase inhibitor 37517-28-5,
 Amikacin 53678-77-6D, Muramyl dipeptide, derivs. 53994-73-3, Cefaclor
 55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem
 80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82419-36-1,
 Ofloxacin 85721-33-1, Ciprofloxacin

RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PROC (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

IT 9002-60-2, Adrenocorticotropin, biological studies 9007-12-9, Calcitonin
 9034-40-6, Lhrh 62229-50-9, Epidermal growth factor 115966-68-2,
 Histatin 5 (human parotid saliva) 123781-17-9, Histatin 127716-52-3,
 Histatin 9 (human parotid saliva) 146553-69-7 174270-18-9,
 5-25-Histatin 6 (human parotid saliva) 186138-55-6 186138-60-3
 194017-97-5 211118-03-5

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); THU (Therapeutic use); BIOL (Biological study); PROC
 (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

IT 9005-64-5, Tween 20 9005-65-6, Tween 80 9005-67-8, Tween 60
 106392-12-5, Pluronic

RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); USES (Uses)

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

IT 75-09-2, uses

RL: NUU (Other use, unclassified); USES (Uses)

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric matrix)

IT 146553-70-0 146553-71-1 146553-72-2 146553-73-3 146553-74-4
 146553-75-5 146553-76-6 146553-77-7 146553-78-8 146553-81-3
 146553-82-4 146553-83-5 146553-85-7 146553-86-8 146553-87-9
 146553-88-0 146553-89-1 146553-90-4 146553-91-5 146553-92-6
 164583-46-4 164583-50-0 164583-51-1 211118-14-8 211118-17-1

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Jeyanthi; Proceedings International Symposium on Controlled Release of Bioactive Materials 1996, P351 HCAPLUS
- (2) Oppenheim; US 5486503 A 1996 HCAPLUS
- (3) Syntex U S AInc; EP 0052510 B2 1994 HCAPLUS
- (4) Wang; J of Controlled Release 1991, V17, P23 HCAPLUS
- (5) Yan; J of Controlled Release 1994, V32(3), P231 HCAPLUS
- (6) Yeh; A Novel Emulsification-Solvent Extraction Technique for Production of Protein Loaded Biodegradable Microparticles for Vaccine and Drug Delivery 1995, V33(3), P437 HCAPLUS

IT 50-28-2, 17 β -Estradiol, biological studies 68-22-4,

Norethisterone 302-22-7, Chlormadinone acetate

35189-28-7, Norgestimate


RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L61 ANSWER 8 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:98330 HCAPLUS

DN 128:158938

ED Entered STN: 19 Feb 1998

TI Monophasic **contraceptive** method and kit **comprising a combination of a progestin and estrogen**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-58

ICS A61K031-57; A61K031-565

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804269	A1	19980205	WO 1997-US12795	19970723 <--
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,				

VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

CA 2261689	AA	19980205	CA 1997-2261689	19970723 <--
AU 9738887	A1	19980220	AU 1997-38887	19970723 <--
AU 726091	B2	20001102		
BR 9710566	A	19990817	BR 1997-10566	19970723 <--
CN 1226168	A	19990818	CN 1997-196763	19970723 <--
EP 956024	A1	19991117	EP 1997-936149	19970723 <--
EP 956024	B1	20040721		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV, FI, RO

NZ 333750	A	20000929	NZ 1997-333750	19970723 <--
JP 2000515890	T2	20001128	JP 1998-508924	19970723 <--
AT 271386	E	20040815	AT 1997-936149	19970723 <--
IL 127797	A1	20040831	IL 1997-127797	19970723 <--
ES 2223081	T3	20050216	ES 1997-936149	19970723 <--
KR 2000029515	A	20000525	KR 1999-700553	19990123 <--
HK 1022843	A1	20050107	HK 2000-101976	20000331 <--
PRAI US 1996-686790	A	19960726	<--	
WO 1997-US12795	W	19970723		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9804269	ICM	A61K031-58	
	ICS	A61K031-57; A61K031-565	
WO 9804269	ECLA	A61K031/565+M; A61K031/57+M; A61K031/58+M	<--
AB	A method of contraception is provided which comprises administering to a female of child bearing age a combination of a progestin at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg dienogest , or 250 µg-4 mg drospirenone , and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol for 23-25 days beginning on day 1 of the menstrual cycle, and wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days. An oral contraceptive composition contained trimegestone 125, ethinyl estradiol 15 µg, microcryst. cellulose, lactose, potassium polacrillin, magnesium stearate, Opadry pink, PEG-1500, was E, and water q.s.		
ST	oral contraceptive progestin estrogen ;		
IT	Estrogens		
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(conjugated; monophasic contraceptive method and kit comprising combination of progestin and estrogen)		
IT	Contraceptives		
	(female; monophasic contraceptive method and kit comprising combination of progestin and estrogen)		
IT	Ovarian cycle		
	(monophasic contraceptive method and kit comprising combination of progestin and estrogen)		
IT	Estrogens		
	Progestogens		
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES		

(Uses)

(monophasic **contraceptive** method and kit **comprising combination of progestin and estrogen**)IT **Contraceptives**(oral; monophasic **contraceptive** method and kit **comprising combination of progestin and estrogen**)

IT 50-28-2, Estradiol, biological studies 53-16-7, Estrone, biological studies 53-16-7D, Estrone, salts 57-63-6, Ethinyl estradiol 72-33-3, Mestranol 65928-58-7, **Dienogest** 67392-87-4, **Drospirenone** 74513-62-5, Trimegestone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monophasic **contraceptive** method and kit **comprising combination of progestin and estrogen**)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Kuhl, H; GYNAKOLOGE 1992, V25/4, P231
- (2) Oelkers, W; J CLIN ENDOCRINOL METAB 1995, V80(6), PP1816
- (3) Oelkers, W; STEROIDS 1996, V61(4), P166 HCAPLUS
- (4) Oettel, M; DRUGS OF TODAY 1995, V31/7, P517
- (5) Schering Ag; DE 4411585 A 1995 HCAPLUS
- (6) Schering Ag; WO 9517194 A 1995 HCAPLUS
- (7) Schering Ag; WO 9701342 A 1997 HCAPLUS

IT 50-28-2, Estradiol, biological studies 65928-58-7, **Dienogest** 67392-87-4, **Drospirenone**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monophasic **contraceptive** method and kit **comprising combination of progestin and estrogen**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'-(5'H)-furan]-3,5'-(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 9 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:98328 HCAPLUS

DN 128:158936

ED Entered STN: 19 Feb 1998

TI Progestin/estrogen oral contraceptives

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61K031-57

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804267	A1	19980205	WO 1997-US12789	19970723 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				

LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
 VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9738886 A1 19980220 AU 1997-38886 19970723 <--
 PRAI US 1996-687855 A 19960726 <--
 WO 1997-US12789 W 19970723

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9804267	ICM	A61K031-565
	ICS	A61K031-57
WO 9804267	ECLA	A61K031/565+M; A61K031/57+M
AB	<p>This invention provides a method of contraception which comprises administering to a female of child-bearing age a combination of a progestin at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg dienogest, or 250 µg-4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinylestradiol for 23-25 days beginning on day 1 of the menstrual cycle; wherein the same dosage of the progestin and estrogen combination is administered in each of the 23-25 days, followed by the administration of an estrogen at a daily dosage equivalent in estrogenic activity to 5-15 µg ethinylestradiol for 3-5 days, such that the number of days of administration of the progestin and estrogen combination plus the number of days of administration of estrogen is equal to 28 per menstrual cycle. For example, during the first 23-25 days of the menstrual cycle, a pill containing trimegestone 125 and ethinylestradiol 15 µg is administered and during the last 3-5 days of the menstrual cycle, a pill containing 15 µg ethinylestradiol is administered.</p>	
ST	<p>progestin estrogen oral contraceptive pill; trimegestone ethinylestradiol combination oral contraceptive</p>	
IT	<p>Estrogens RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (conjugated; progestin/estrogen oral contraceptives)</p>	
IT	<p>Contraceptives (oral; progestin/estrogen oral contraceptives)</p>	
IT	<p>Estrogens Progestogens RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (progestin/estrogen oral contraceptives)</p>	
IT	<p>Drug delivery systems (tablets; progestin/estrogen oral contraceptives)</p>	
IT	<p>50-28-2, 17β-Estradiol, biological studies 53-16-7, Estrone, biological studies 57-63-6, Ethinyl estradiol 72-33-3, Mestranol 65928-58-7, Dienogest 67392-87-4, Drospirenone 74513-62-5, Trimegestone RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES</p>	

(Uses)

(progestin/estrogen oral contraceptives)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Akzo N V; EP 0491415 A 1992 HCAPLUS
- (2) Akzo N V; EP 0491438 A 1992 HCAPLUS
- (3) Akzo N V; US 5262408 A 1992 HCAPLUS
- (4) Akzo N V; US 5418228 A 1992 HCAPLUS
- (5) Ehrlich, M; EP 0499348 A 1992 HCAPLUS
- (6) Ehrlich, M; DE 4104385 A 1992 HCAPLUS
- (7) Ehrlich, M; DE 4224534 A 1994 HCAPLUS
- (8) S A Pasquale; US 4921843 A 1990 HCAPLUS
- (9) S A Pasquale; WO 9004330 A 1990 HCAPLUS
- (10) Schering Ag; DE 4344462 A 1995 HCAPLUS
- (11) Schering Ag; DE 4411585 A 1995 HCAPLUS
- (12) Schering Ag; WO 9517194 A 1995 HCAPLUS
- (13) Schering Ag; WO 9526730 A 1995 HCAPLUS

IT 50-28-2, 17 β -Estradiol, biological studies 65928-58-7

, Dienogest 67392-87-4, Drospirenone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(progestin/estrogen oral contraceptives)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 10 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:98311 HCAPLUS

DN 128:158929

ED Entered STN: 19 Feb 1998

TI Oral **contraceptives** containing **combination** of a
progestin and an **estrogen**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804246	A2	19980205	WO 1997-US12785	19970723 <--
	WO 9804246	A3	20020926		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9738885	A1	19980220	AU 1997-38885	19970723 <--
PRAI	US 1996-690439	A	19960726	<--	
	WO 1997-US12785	W	19970723		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9804246	ICM	A61K031-00	
WO 9804246	ECLA	A61K031/565+M; A61K031/57+M; A61K031/58+M	<--
AB	A method of contraception is provided which comprises		

administering to a female of child bearing age for 23-25 consecutive days: a first phase **combination** of a **progestin** at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg **dienogest**, or 250 µg-4 mg µg **drospirenone**, and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the **progestin** and **estrogen combination** is administered in each of the 3-8 days; a second phase **combination** of a **progestin** at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg **dienogest**, or 250 µg-4 mg µg **drospirenone**, and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the first phase **combination**, wherein the same dosage of the **progestin** and **estrogen combination** is administered in each of the 4-15 days. A third phase **combination** of a **progestin** at a daily dosage of 40-500 µg trimegestone, 250 µg-4 mg **dienogest**, or 250 µg-4 mg µg **drospirenone**, and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase **combination**, wherein the same dosage of the **progestin** and **estrogen combination** is administered in each of the 4-15 days; and an **estrogen phase estrogen** at a daily dosage equivalent in **estrogenic** activity to 5-20 µg ethinyl estradiol, for 3-5 days beginning on the day immediately following the last day of administration of the third phase **combination**, wherein the same dosage of the **estrogen** is administered in each of the 3-5 days, provided that the daily dosage of the **combination** administered in the first phase is not the same as the daily dosage of the **combination** administered in the second phase and that the daily dosage of the **combination** administered in the second phase is not the same as the daily dosage of the **combination** administered in the third phase. An oral **contraceptive composition** contained trimegestone 125, ethinyl estradiol 15 µg, microcrystalline cellulose, lactose, potassium polacrillin, magnesium stearate, Opadry pink, PEG-1500, was E, and water q.s.

ST oral **contraceptive progestin estrogen**;

trimegestone ethinyl estradiol oral **contraceptive**

IT **Estrogens**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(conjugated; oral **contraceptives** containing **combination** of **progestin** and **estrogen**)

IT **Contraceptives**

(female; oral **contraceptives** containing **combination** of **progestin** and **estrogen**)

IT Ovarian cycle

(oral **contraceptives** containing **combination** of **progestin** and **estrogen**)

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral **contraceptives** containing **combination** of **progestin** and **estrogen**)

IT **Contraceptives**

(oral; oral contraceptives containing combination of progestin and estrogen)

IT 50-28-2, Estradiol, biological studies 53-16-7, Estrone, biological studies 53-16-7D, Estrone, salts 57-63-6, Ethinyl estradiol 72-33-3, Mestranol 65928-58-7, Dienogest 67392-87-4, Drospirenone 74513-62-5, Trimegestone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral contraceptives containing combination of progestin and estrogen)


IT 50-28-2, Estradiol, biological studies 65928-58-7, Dienogest 67392-87-4, Drospirenone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral contraceptives containing combination of progestin and estrogen)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17 α) - (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 11 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:65794 HCAPLUS

DN 128:132432

ED Entered STN: 04 Feb 1998

TI Combined pharmaceutical estrogen-androgen-progestin oral contraceptive

IN Hughes, Claude L., Jr.; Jayo, Manuel J.

PA Wake Forest University, USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-20

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9801115	A1	19980115	WO 1997-US11969	19970709 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5770226	A	19980623	US 1996-679764	19960710 <--
CA 2258525	AA	19980115	CA 1997-2258525	19970709 <--
AU 9736558	A1	19980202	AU 1997-36558	19970709 <--
EP 929295	A1	19990721	EP 1997-933353	19970709 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1225008	A	19990804	CN 1997-196255	19970709 <--
BR 9710198	A	20000111	BR 1997-10198	19970709 <--
JP 2000516576	T2	20001212	JP 1998-505351	19970709 <--
KR 2000023633	A	20000425	KR 1999-700082	19990108 <--
PRAI US 1996-679764	A	19960710 <--		
WO 1997-US11969	W	19970709		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 9801115 ICM A61K009-20

WO 9801115 ECLA A61K031/565+M; A61K031/57+M <--

US 5770226 NCL 424/464.000; 424/400.000; 424/465.000; 514/841.000;
514/843.000

ECLA A61K031/565+M; A61K031/57+M <--

AB Oral **contraceptive compns.** of the invention contain androgens, preferably methyltestosterone to be taken by younger users of the **contraceptives** to inhibit adverse effects of oral **contraceptive** use on bone mineral d. Data are given showing that the oral **contraceptives** that prevent unwanted pregnancies allow the normal accrual of bone mass in younger users so that optimal peak bone mass may be reached by the users. A series of 28 tablets were prepared containing varying concns. of ethinylestradiol, **levonorgestrel** and methyltestosterone.

ST **estrogen androgen progestin oral contraceptive**

IT Androgens

Estrogens

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

IT Bone

(mass; combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

IT **Contraceptives**

(oral; combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

IT Drug delivery systems

(tablets; combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

IT 57-63-6, Ethinylestradiol 58-18-4, Methyltestosterone 797-63-7, **Levonorgestrel**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Wright; US 5595759 A 1997 HCAPLUS

IT 797-63-7, **Levonorgestrel**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combined pharmaceutical **estrogen-androgen-progestin oral contraceptive**)

RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 12 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:745953 HCAPLUS

DN 128:26927

ED Entered STN: 27 Nov 1997

TI Oral **contraceptives**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61K031-565; A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741872	A1	19971113	WO 1997-US7089	19970428 <--
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9727460	A1	19971126	AU 1997-27460	19970428 <--
PRAI	US 1996-646900	A	19960508	<--	
	WO 1997-US7089	W	19970428		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741872	ICM	A61K031-565
	ICS	A61K031-565; A61K031-565
WO 9741872	ECLA	A61K031/565+M <--

AB This invention provides a method of **contraception** comprising administering to a female of child-bearing age for 23-25 consecutive days; a first phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-15 µg **ethinylestradiol** for 9-13 days beginning on day 1 of the menstrual cycle and a second phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 11-15 days, provided that the daily dosage of second phase **progestin**

is greater than the daily dosage of the first phase **progestin** and that the daily dosage of the second phase **estrogen** is greater than or equal to the daily dosage of the first phase **estrogen**.

- ST **progestin estrogen oral contraceptive kit;**
levonorgestrel ethinylestradiol oral contraceptive kit
- IT **Estrogens**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugated; **progestin-estrogen combination**
oral contraceptive kit for females)
- IT **Contraceptives**
 (oral; **progestin-estrogen**
combination oral contraceptive kit for
females)
- IT **Estrogens**
Progestogens
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- IT Drug delivery systems
 (tablets; **progestin-estrogen combination**
oral contraceptive kit for females)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 53-16-7, Estrone, biological
 studies 57-63-6, Ethinylestradiol 68-22-4, Norethindrone
 72-33-3, Mestranol 797-63-7, **Levonorgestrel**
 6533-00-2, **Norgestrel** 35189-28-7, **Norgestimate**
 54024-22-5, **Desogestrel** 54048-10-1,
 3-Ketodesogestrel 60282-87-3, **Gestodene**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 68-22-4, Norethindrone
 797-63-7, **Levonorgestrel** 35189-28-7,
Norgestimate 54024-22-5, **Desogestrel**
 54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- RN 50-28-2 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



- RN 51-98-9 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L61 ANSWER 13 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:745950 HCAPLUS

DN 128:26924

ED Entered STN: 27 Nov 1997

TI Oral **contraceptives**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741869	A1	19971113	WO 1997-US7083	19970428 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9729267	A1	19971126	AU 1997-29267	19970428 <--
PRAI	US 1996-643429	A	19960508	<--	
	WO 1997-US7083	W	19970428		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741869	ICM	A61K031-565
WO 9741869	ECLA	A61K031/565+M

AB This invention provides a method of **contraception** which **comprises** administering to a female of child-bearing age for 23-25 consecutive days; a first phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-15 µg **ethinylestradiol** for 9-13 days beginning on day 1 of the menstrual cycle; a second phase **combination** of a **progestin** at a daily dosage equivalent in **progestational** activity to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent in **estrogenic** activity to 10-20 µg **ethinylestradiol** for 11-15 days; and an **estrogen** phase for 3-5 days beginning on the day immediately following the last day of administration of the second phase the same dosage of the **estrogen** is administered. The daily

dosage of second phase **progestin** is greater than the daily dosage of the first phase **progestin** and that the daily dosage of the second phase **estrogen** is greater than or equal to the daily dosage of the daily dosage of the first phase **estrogen**.

- ST **progestin estrogen oral contraceptive kit;**
levonorgestrel ethinylestradiol oral contraceptive kit
- IT **Estrogens**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugated; **progestin-estrogen combination**
oral contraceptive kit for females)
- IT **Contraceptives**
 (oral; **progestin-estrogen**
combination oral contraceptive kit for
females)
- IT **Estrogens**
Progestogens
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- IT Drug delivery systems
 (tablets; **progestin-estrogen combination**
oral contraceptive kit for females)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 53-16-7, Estrone, biological
 studies 57-63-6, Ethinylestradiol 68-22-4, Norethindrone
 72-33-3, Mestranol 797-63-7, **Levonorgestrel**
 6533-00-2, **Norgestrel** 35189-28-7, **Norgestimate**
 54024-22-5, **Desogestrel** 54048-10-1,
 3-Ketodesogestrel 60282-87-3, **Gestodene**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 68-22-4, Norethindrone
 797-63-7, **Levonorgestrel** 35189-28-7,
Norgestimate 54024-22-5, **Desogestrel**
 54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**progestin-estrogen combination oral**
contraceptive kit for females)
- RN 50-28-2 HCAPLUS
- CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



- RN 51-98-9 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L61 ANSWER 14 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:745949 HCAPLUS

DN 128:26923

ED Entered STN: 27 Nov 1997

TI Oral **contraceptives**

IN Gast, Michael Jay

PA American Home Products Corporation, USA

SO PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

ICS A61K031-565; A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741868	A1	19971113	WO 1997-US7074	19970428 <--
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9728158	A1	19971126	AU 1997-28158	19970428 <--
PRAI	US 1996-647078	A	19960508	<--	
	WO 1997-US7074	W	19970428		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9741868	ICM	A61K031-565	
	ICS	A61K031-565; A61K031-565	
WO 9741868	ECLA	A61K031/565+M	<--

AB This invention provides a method of **contraception** which **comprises** administering to a female of child-bearing age for 28 days per menstrual cycle a **combination** of a **progestin** at a daily dosage equivalent to 40-125 µg **levonorgestrel** and an **estrogen** at a daily dosage equivalent to 10-15 µg ethinylestradiol for 23-25 days beginning on day 1 of the menstrual cycle, followed by administering an **estrogen** at a daily dosage equivalent to 5-15 µg ethinylestradiol for 3-5 days. For example, the daily dosage of **levonorgestrel** 75 µg and ethinylestradiol 15 µg **combination** is administered for 24 days per menstrual cycle beginning on day 1 of the cycle, followed by the administration ethinylestradiol at the daily dosage of 15 µg for 4 days.

ST oral contraceptive kit progestin estrogen;
levonorgestrel ethinylestradiol oral contraceptive kit

IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; progestin-estrogen combination
oral contraceptive kit for females)

IT Contraceptives
(oral; progestin-estrogen
combination oral contraceptive kit for
females)

IT Estrogens
Progestogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(progestin-estrogen combination oral
contraceptive kit for females)

IT Drug delivery systems
(tablets; progestin-estrogen combination
oral contraceptive kit for females)


IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 53-16-7, Estrone, biological
studies 57-63-6, Ethinylestradiol 68-22-4, Norethindrone
72-33-3, Mestranol 797-63-7, Levonorgestrel
6533-00-2, Norgestrel 35189-28-7, Norgestimate
54024-22-5, Desogestrel 54048-10-1,
3-Ketodesogestrel 60282-87-3, Gestodene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(progestin-estrogen combination oral
contraceptive kit for females)

IT 50-28-2, 17 β -Estradiol, biological studies 51-98-9,
Norethisterone acetate 68-22-4, Norethindrone
797-63-7, Levonorgestrel 35189-28-7,
Norgestimate 54024-22-5, Desogestrel
54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(progestin-estrogen combination oral
contraceptive kit for females)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L61 ANSWER 15 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:604135 HCAPLUS

DN 127:272926

ED Entered STN: 24 Sep 1997

TI A 12-month comparative investigation of reliability, cycle control and tolerance with low-dose oral **contraceptives** containing 20 µg ethinylestradiol and either 75 µg **gestodene** or 150 µg **desogestrel**

AU Short, M.; Endrikat, J.

CS Women's Medical Clinic, Dublin, Ire.

SO New Option in Low-Dose Oral Contraception: Expanding the Gestodene Choice, Proceedings of a Symposium, Montpellier, Fr., Sept. 1995 (1996), Meeting Date 1995, 37-47. Editor(s): Lopes, P.; Killick, S. R. Publisher: Parthenon Publishing, Carnforth, UK.
CODEN: 65BPAP

DT Conference

LA English

CC 2-3 (Mammalian Hormones)

AB The clin. profile of an oral **contraceptive** is influenced not only by the **estrogen** dose, but also by the **progestogen** present in the preparation. **Progestogens** are not all equal, especially with respect to cycle control, and therefore it can be of value to compare preps. with the same **estrogen** dose but different **progestogens**. In this study, **contraceptive** reliability, cycle control and tolerance of an oral **contraceptive** containing 20 µg ethinylestradiol and 75 µg **gestodene** were compared with a reference preparation containing the same dose of **estrogen** combined with 150 µg **desogestrel**. Interim data from 218 women/2495 cycles in the **gestodene** group and 219 women/2496 cycles in the **desogestrel** group have been analyzed from a multicenter study which is in progress in six European countries. **Contraceptive** reliability was found to be good with both preps. One pregnancy occurred in the **gestodene** group due to intake error and addnl. there was one non-study-related pregnancy which occurred after a volunteer stopped taking the pill. In the **desogestrel** group there were two pregnancies, one due to intake error and the other due to method failure. With respect to cycle control, there appeared to be a trend towards a lower incidence of intermenstrual bleeding the **gestodene** group, although this difference did not achieve statistical significance. The cumulative incidence of spotting during the important first three cycles was 3.5% lower in the **gestodene** group, and, over the first six cycles, it was 7.6% lower than in the **desogestrel** group. It was noted that the incidence of dysmenorrhea developing during treatment was less (5.5%) in the **gestodene** group than in the **desogestrel** group (15.1%). This statistically significant finding needs further evaluation. Body weight remained relatively constant in both

groups, as did blood pressure, with no hypertension being reported for any woman during the course of the study. The incidence of nuisance adverse events was similar in the two groups, with headache, breast tension and nausea the most frequently reported symptoms. In each treatment group, 19 women discontinued because of adverse events. It is concluded that both preps. are reliable and well-tolerated oral **contraceptives**. There is, however, evidence of a trend towards better cycle control in the **gestodene** group.

ST oral **contraceptive** ethinylestradiol **gestodene**
desogestrel
 IT **Contraceptives**
 (oral; reliability, cycle control and tolerance with low-dose
 oral contraceptives containing ethinylestradiol and
 gestodene or **desogestrel** in women)
 IT Blood pressure
 Body weight
 Dysmenorrhea
 Headache
 Menstrual disorder
 Nausea
 Ovarian cycle
 (reliability, cycle control and tolerance with low-dose oral
 contraceptives containing ethinylestradiol and **gestodene**
 or **desogestrel** in women)
 IT Mammary gland
 (tension; reliability, cycle control and tolerance with low-dose oral
 contraceptives containing ethinylestradiol and **gestodene**
 or **desogestrel** in women)
 IT 71138-35-7 109852-02-0, Ethinylestradiol-**gestodene** mixture
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (reliability, cycle control and tolerance with low-dose oral
 contraceptives containing ethinylestradiol and **gestodene**
 or **desogestrel** in women)

L61 ANSWER 16 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:465078 HCAPLUS

DN 127:86120

ED Entered STN: 25 Jul 1997

TI Method and kit for **contraception**

IN **Endrikat, Jan; Duesterberg, Bernd; Reilhac, Pia**

PA Schering A.-G., Germany

SO Ger. Offen., 7 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

ICI A61K031-57, A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19549264	A1	19970626	DE 1995-19549264	19951223 <--
	CA 2241192	AA	19970703	CA 1996-2241192	19961220 <--
	WO 9723228	A2	19970703	WO 1996-DE2486	19961220 <--
	WO 9723228	A3	19970828		

W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS,
 JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW,
 MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG,
 US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
 MR, NE, SN, TD, TG

AU 9719219 A1 19970717 AU 1997-19219 19961220 <--
 AU 716249 B2 20000224
 EP 868188 A2 19981007 EP 1996-946221 19961220 <--
 EP 868188 B1 20030709

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

CN 1205639 A 19990120 CN 1996-199301 19961220 <--
 BR 9612207 A 19990713 BR 1996-12207 19961220 <--
 JP 2000502108 T2 20000222 JP 1997-523223 19961220 <--
 NZ 330741 A 20000327 NZ 1996-330741 19961220 <--
 IL 124472 A1 20010724 IL 1996-124472 19961220 <--
 CZ 291743 B6 20030514 CZ 1998-2000 19961220 <--
 AT 244567 E 20030715 AT 1996-946221 19961220 <--
 PT 868188 T 20031128 PT 1996-946221 19961220 <--
 ES 2202498 T3 20040401 ES 1996-946221 19961220 <--
 PL 187180 B1 20040531 PL 1996-327182 19961220 <--
 NO 9802902 A 19980622 NO 1998-2902 19980622 <--
 PRAI DE 1995-19549264 A 19951223 <--
 WO 1996-DE2486 W 19961220 <--

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

DE 19549264 ICM A61K031-57
 ICS A61K031-565
 ICI A61K031-57, A61K031-565
 WO 9723228 ECLA A61K031/565+M; A61K031/57+M <--

AB A method for **contraception** in female mammals involves administration of an **ovulation**-inhibiting dose of a **gestagen** daily for ≥ 28 days, and of a natural **estrogen** for 5-10 days at the end of this 28-day period. This regimen allows regular menstruation-like bleeding combined with reliable control of the ovarian cycle. The **gestagen** may be administered orally and the **estrogen** transdermally, or vice versa. Alternatively, a kit may comprise a 1st phase of 18-23 daily oral doses of **gestagen** and a 2nd phase of 5-10 daily oral doses of a **gestagen-estrogen** combination. For example, **levonorgestrel** was administered for 56 days at 0.1 mg/day; during the last 10 days of this period, estradiol was addnl. administered at 2.5 mg/day.

ST **contraceptive estrogen gestagen**

IT **Contraceptives**

(method and kit for **contraception**)

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and kit for **contraception**)

IT Drug delivery systems

(oral; method and kit for **contraception**)

IT Drug delivery systems

(transdermal; method and kit for **contraception**)

IT 50-28-2, Estradiol, biological studies 51-98-9,

Norethisterone acetate 57-83-0,
 Progesterone, biological studies 68-22-4,
 Norethisterone 302-22-7, Chlormadinone acetate
 427-51-0, Cyproterone acetate 797-63-7
 , Levonorgestrel 35189-28-7, Norgestimate
 54024-22-5, Desogestrel 54048-10-1,
 3-Ketodesogestrel 60282-87-3, Gestodene
 65928-58-7, Dienogest 67392-87-4,
 Drospirenone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and kit for **contraception**)

IT 50-28-2, Estradiol, biological studies 51-98-9,
 Norethisterone acetate 57-83-0,
 Progesterone, biological studies 68-22-4,
 Norethisterone 302-22-7, Chlormadinone acetate
 427-51-0, Cyproterone acetate 797-63-7
 , Levonorgestrel 35189-28-7, Norgestimate
 54024-22-5, Desogestrel 54048-10-1,
 3-Ketodesogestrel 60282-87-3, Gestodene
 65928-58-7, Dienogest 67392-87-4,
 Drospirenone


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and kit for **contraception**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS


CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS
 CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 302-22-7 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 65928-58-7 HCAPLUS

CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17α)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2' (5'H)-furan]-3,5' (2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 17 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:319219 HCAPLUS

DN 127:33429

ED Entered STN: 19 May 1997

TI Analysis of the vitamin-balance under long-term application of different types of **estrogen-gestagen combinations**

AU Klinger, G.; Flachowsky, G.; Carlson, H.; Michels, W.; Matthey, Maria; Schubert, K.; Splinter, F. -K.; Winnefeld, K.

CS Univ.-Frauenklinik, Germany

SO Vitamine und Zusatzstoffe in der Ernaehrung von Mensch und Tier, Symposium, 5th, Jena, Sept. 28-29, 1995 (1995), 244-249.
Editor(s): Schubert, Rainer; Flachowsky, Gerhard; Bitsch, Roland.
Publisher: Friedrich-Schiller-Universitaet Jena, Biologisch-Pharmazeutische Fakultaet, Institut fuer Ernaehrung und Umwelt, Jena, Germany.
CODEN: 64JYAH

DT Conference

LA German

CC 18-2 (Animal Nutrition)
Section cross-reference(s): 2

AB The low-dosed synthetic sexual steroid TRISISTON and DIANE 35 showed similar results on the different vitamin levels. No disturbance of the balance of free radicals and the individual status of antioxidants could be detected. But noticeable was the increase of vitamin C at the same time vitamin B12, vitamin E and folic acid were not influenced. The necessity of vitamin substitution to application of oral **contraceptives** cannot be answered until now.

ST vitamin **estrogen progestins**

IT Antioxidants
Contraceptives
(anal. of the vitamin-balance under long-term application of different types of **estrogen-gestagen combinations**)

IT **Estrogens**
Hormones, animal, biological studies
Progestogens
Radicals, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(anal. of the vitamin-balance under long-term application of different types of **estrogen-gestagen combinations**)

IT 50-81-7, Vitamin c, biological studies 59-30-3, Folic acid, biological studies 68-19-9, Vitamin b12 1406-18-4, Vitamin e
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(anal. of the vitamin-balance under long-term application of different types of **estrogen-gestagen combinations**)

L61 ANSWER 18 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:307252 HCAPLUS

DN 126:338964

ED Entered STN: 14 May 1997

TI A twelve-month comparative clinical investigation of two low-dose oral **contraceptives** containing 20 µg ethinylestradiol/75 µg **gestodene** and 30 µg ethinylestradiol/75 µg **gestodene**, with respect to efficacy, cycle control, and tolerance

AU **Endrikat, J.**; Mueller, U.; **Duesterberg, B.**

CS Schering AG, Berlin, D-13342, Germany

SO Contraception (1997), 55(3), 131-137
CODEN: CCPTAY; ISSN: 0010-7824

PB Elsevier

DT Journal

LA English

CC 2-3 (Mammalian Hormones)

- AB The aim of this study was to compare **contraceptive** reliability, cycle control, and tolerance of an oral **contraceptive** containing 20 µg ethinylestradiol (EE2) and 75 µg **gestodene** (GSD), with a reference preparation containing a similar dose of **gestodene** but in combination with 30 µg ethinylestradiol. A higher incidence of intermenstrual bleeding was apparent under the 20 µg EE2 oral **contraceptive**. For the 20 µg EE2 preparation, 47.4% of all women reported spotting at least once over a period of 12 treatment cycles, whereas this figure was 35.5% for the 30 µg EE2 pill. However, the incidence was within a range that corresponds to that of other OCs. The cumulative breakthrough bleeding rates (at least once during the one year of treatment) of 14.5% (20 µg EE2) and 11.8% (30 µg EE2) of women were not significantly different. In relation to all cycles, the intermenstrual bleeding rates were remarkably lower, indicating that the majority of the volunteers experienced such events only in few cycles under treatment: the spotting rate was 11.5% (20 µg EE2) and 7.2% (30 µg EE2) of all cycles, and the break-through bleeding rate was 2.6% and 1.6% of all cycles, resp. Three pregnancies were recorded during the study (one in the 20 µg EE2+75 µg GSD group, two in the 30 µg EE2+75 µg GSD group). All three could be explained either by intake irregularities or by circumstances impairing the **contraceptive** effect. The influence of both treatments on the blood pressure and body weight proved to be extremely slight. Adverse events in both groups were rare and differences in the frequency of adverse events were not apparent. The discontinuation rate due to adverse events, including intermenstrual bleeding, was low (9.8% for 20 µg EE2+75 µg GSD, and 7.2% for 30 µg EE2+75 µg GSD) and was in the lower range known for other oral **contraceptives**. Both preps. were well accepted by the volunteers. The data obtained demonstrate clin. acceptable cycle control, good tolerance, and a high standard of **contraceptive** reliability for both drugs. Prescription of the 20 µg EE2 preparation could be the first-line therapy to provide the lowest amount of EE2 possible. In case of persistent cycle control problems, a switch to the 30 µg EE2 drug should be considered.
- ST oral **contraceptive** ethinylestradiol **gestodene**
- IT Blood pressure
Body weight
Ovarian cycle
(efficacy, cycle control, and tolerance of ethinylestradiol-
gestodene oral **contraceptive** in relation to
estrogen and **progestogen** dose in women)
- IT Menstrual disorder
(intermenstrual bleeding; efficacy, cycle control, and tolerance of
ethinylestradiol-**gestodene** oral **contraceptive** in
relation to **estrogen** and **progestogen** dose in women)
- IT **Contraceptives**
(oral; efficacy, cycle control, and tolerance of
ethinylestradiol-**gestodene** oral
contraceptive in relation to **estrogen** and
progestogen dose in women)
- IT 109852-02-0, Ethinylestradiol-**gestodene** mixture
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); BIOL
(Biological study)
(efficacy, cycle control, and tolerance of ethinylestradiol-
gestodene oral **contraceptive** in relation to
estrogen and **progestogen** dose in women)
- RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Akerlund, M; Br J Obstet Gynaecol 1993, V100, P832 MEDLINE

- (2) Brill, K; Adv Contracept 1994, V10, P237 MEDLINE
- (3) Dusterberg, B; Gynecol Endocrinol 1996, V10, P33 MEDLINE
- (4) Elomaa, K; Extension of the pill-free period by three days in oral contraceptive users, Abstract 04.27 1994
- (5) Endrikat, J; Contraception 1995, V52, P229 HCAPLUS
- (6) Fitzgerald, C; Adv Contracept 1994, V10, P5 HCAPLUS
- (7) Fotherby, K; Contraception 1994, V49, P1 HCAPLUS
- (8) Gerstman, B; Am J Epidemiol 1991, V133, P32 MEDLINE
- (9) Latin American Oral Contraceptive Study Group; Contraception 1994, V50, P201

L61 ANSWER 19 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:299716 HCAPLUS

DN 126:282790

ED Entered STN: 12 May 1997

TI Oral **ovulation**-inhibiting antiandrogenic **composition**

IN Umbreit, Klaus

PA Germany

SO Ger. Offen., 3 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-565

ICS A61K031-57

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2.

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19539233	A1	19970424	DE 1995-19539233	19951021 <--
PRAI	DE 1995-19539233		19951021	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19539233	ICM	A61K031-565
	ICS	A61K031-57

AB The title oral **contraceptive** means **comprises** a packaging unit containing sep. daily dosage units, each of which contains a **gestagen** and optionally a natural or synthetic **estrogen**. These dosage units are taken in 2 phases utilizing different **gestagens**: (1) chlormadinone acetate for the 1st .apprx.10 days, followed by a pregnane-type **gestagen** (e.g. **medroxyprogesterone** acetate, medrogestone) for the remainder of the 24-21 days of treatment and a 4-7 day pause. Chlormadinone acetate blocks cellular 5 α -dihydrotestosterone receptors in the skin and thus prevents undesirable androgenic effects such as acne and hair loss, whereas **medroxyprogesterone** acetate has a more favorable metabolic half-life. A suitable regimen **comprised** ethynylestradiol 10 μ g, estradiol valerate 2 mg, and chlormadinone acetate 2 mg/day for 10 days, followed by ethynylestradiol 10 μ g, estradiol valerate 2 mg, and **medroxyprogesterone** acetate 5 mg/day for 11 days and a pause of 7 days.

ST **ovulation** inhibitor chlormadinone **medroxyprogesterone** acetate; **contraceptive estrogen gestagen**

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral **ovulation**-inhibiting antiandrogenic **composition**)

IT **Contraceptives**(oral; oral ovulation-inhibiting
antiandrogenic composition)IT 50-28-2, Estradiol, biological studies 57-63-6, Ethynylestradiol
57-83-0D, Progesterone, derivs. 71-58-9,
Medroxyprogesterone acetate 302-22-7, Chlormadinone
acetate 977-79-7, Medrogestone 979-32-8, Estradiol valerate
4732-76-7D, Gonane, derivs. 24749-37-9D, Estrane, derivs. 24909-91-9D,
Pregnane, derivs.RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(oral ovulation-inhibiting antiandrogenic composition)


IT 50-28-2, Estradiol, biological studies 57-83-0D,
Progesterone, derivs. 302-22-7, Chlormadinone acetate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(oral ovulation-inhibiting antiandrogenic composition)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



L61 ANSWER 20 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1997:105218 HCAPLUS

DN 126:122465

ED Entered STN: 14 Feb 1997

TI **Contraceptive** hormonal **combination**, kit, and method

IN Schmidt-Gollwitzer, Karin; Klemann, Walter

PA Schering A.-G., Germany

SO Ger. Offen., 15 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-565

ICS A61K031-57

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19525017	A1	19970102	DE 1995-19525017	19950628 <--
	CA 2225724	AA	19970116	CA 1996-2225724	19960627 <--
	WO 9701342	A1	19970116	WO 1996-DE1192	19960627 <--
	W: AU, BR, CA, CN, CZ, FI, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9663528	A1	19970130	AU 1996-63528	19960627 <--
	EP 835114	A1	19980415	EP 1996-922739	19960627 <--
	EP 835114	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1189101	A	19980729	CN 1996-195091	19960627 <--
	BR 9609317	A	19990706	BR 1996-9317	19960627 <--
	JP 11508538	T2	19990727	JP 1997-504097	19960627 <--
	AT 239483	E	20030515	AT 1996-922739	19960627 <--
	PT 835114	T	20030930	PT 1996-922739	19960627 <--
	ES 2199293	T3	20040216	ES 1996-922739	19960627 <--
	ZA 9605547	A	19970127	ZA 1996-5547	19960628 <--
	NO 9706067	A	19980227	NO 1997-6067	19971223 <--
	US 6027749	A	20000222	US 1998-981488	19980603 <--
	US 6312722	B1	20011106	US 2000-476333	20000103 <--
	AU 726283	B2	20001102	AU 2000-14858	20000201 <--
PRAI	DE 1995-19525017	A	19950628	<--	
	WO 1996-DE1192	W	19960627	<--	
	US 1998-981488	A1	19980603		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
DE 19525017	ICM	A61K031-565	
	ICS	A61K031-57	
WO 9701342	ECLA	A61K031/565+M; A61K031/57+M; A61K031/585+M	<--
US 6027749	NCL	424/464.000; 514/170.000; 514/843.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K031/585+M	<--
US 6312722	NCL	424/464.000; 514/170.000; 514/843.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K031/585+M	<--
AB	<p>A 2-stage combination for hormonal contraception comprises 30-84 daily dosage units of a hormone combination administered to women in 2 stages; in stage 1, an estrogen is administered in combination with a gestagen in an amount at least sufficient to inhibit ovulation, and in stage 2, only the estrogen is administered. Stage 1 lasts 25-77 days, and begins on day 1 of the menstrual cycle; stage 2 lasts 5, 6, or 7 days. A dosage unit is thus taken on every day of the cycle. The hormones may also be administered continuously in equivalent amts., e.g. via a transdermal patch. This regimen provides highly effective contraception at very low estrogen and total hormone doses, complete control of the menstrual cycle, and a low incidence of follicle development, and minimizes breakthrough bleeding, spotting, and cardiovascular side effects... Suitable daily dosages in stage 1 are 1.0-6.0 mg 17β-estradiol and 0.05-0.075 mg Gestodene, and in stage 2, 1.0-6.0 mg 17β-estradiol.</p>		
ST	estrogen gestagen contraceptive ; ovarian cycle control estrogen gestagen		
IT	Contraceptives		
	(contraceptive hormonal combination , kit, and method)		
IT	Estrogens		
	Progestogens		
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)		
	(contraceptive hormonal combination , kit, and method)		
IT	Ovarian cycle		
	(regulation of; contraceptive hormonal combination , kit, and method)		
IT	<p>50-28-2, 17β-Estradiol, biological studies 57-63-6, Ethynylestradiol 68-22-4, Norethisterone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 979-32-8, 17β-Estradiol valerate 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4</p> <p>RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)</p> <p>(contraceptive hormonal combination, kit, and method)</p>		
IT	<p>50-28-2, 17β-Estradiol, biological studies 68-22-4, Norethisterone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4</p> <p>RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)</p> <p>(contraceptive hormonal combination, kit, and</p>		

method)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-
furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 21 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:718138 HCAPLUS

DN 125:339154

ED Entered STN: 07 Dec 1996

TI Combination preparation for hormonal **contraception**
 IN Spona, Juergen; **Duesterberg, Bernd**
 PA Schering A.-G., Germany
 SO Ger. Offen., 7 pp.
 CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

CC 63-8 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19513662	A1	19961010	DE 1995-19513662	19950408 <--
	CA 2217564	AA	19961017	CA 1996-2217564	19960404 <--
	WO 9632114	A1	19961017	WO 1996-EP1529	19960404 <--
	W: AU, CA, CN, JP, KR, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9656462	A1	19961030	AU 1996-56462	19960404 <--
	AU 713771	B2	19991209		
	CN 1181011	A	19980506	CN 1996-193156	19960404 <--
	CN 1077430	B	20020109		
	EP 871453	A1	19981021	EP 1996-913497	19960404 <--
	EP 871453	B1	20030521		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	JP 11503440	T2	19990326	JP 1996-530708	19960404 <--
	NZ 307178	A	20000128	NZ 1996-307178	19960404 <--
	RU 2165259	C2	20010420	RU 1997-118464	19960404 <--
	AT 240735	E	20030615	AT 1996-913497	19960404 <--
	PT 871453	T	20031031	PT 1996-913497	19960404 <--
	ES 2200062	T3	20040301	ES 1996-913497	19960404 <--
	NO 9704630	A	19971205	NO 1997-4630	19971007 <--
	NO 313269	B1	20020909		
	US 5980940	A	19991109	US 1998-930630	19980127 <--
PRAI	DE 1995-19513662	A	19950408	<--	
	WO 1996-EP1529	W	19960404	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19513662	ICM	A61K031-57
	ICS	A61K031-565
US 5980940	NCL	424/464.000; 514/170.000; 514/173.000; 514/177.000; 514/178.000; 514/182.000; 514/843.000
	ECLA	A61K031/565+A; A61K031/565+M; A61K031/57+M; A61K031/585+M

AB The title preparation consists of a series of oral dosage forms to be taken during the (approx.) 28-day human female reproductive cycle; these forms (pills, tablets, etc.) are in 3 different sets: the 1st set comprises a dosage form containing both an **estrogen** and a **gestagen**, and these are to be taken during the 1st 23-24 days of the menstrual cycle; the 2nd set comprises a placebo form to be taken on the following 1 or 2 days; the 3rd set comprises a dosage form containing **estrogen** only, to be taken on the remaining 2-4 days of the cycle. This system provides good **contraceptive** safety combined with the min. intake of drugs consonant with such safety, and a reduced risk of unwanted effects.

ST **estrogen gestagen combination contraceptive**

IT **Estrogens**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(combination preparation containing **estrogens** for hormonal
contraception in women)

IT **Progestogens**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(combination preparation containing **gestagens** for hormonal
contraception in women)

IT **Contraceptives**

(oral, combination preparation for hormonal **contraception**
in women)

L61 ANSWER 22 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:610036 HCAPLUS

DN 125:230857

ED Entered STN: 14 Oct 1996

TI Single monthly injection of **estrogen** and **gestagen** as
sustained-release **contraceptive** and for hormone replacement
therapy in peri- and premenopausal women

IN Lachnit-Fixson, Ursula; Aydinlik, Semiramis

PA Schering A.-G., Germany

SO Ger. Offen., 4 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 19510861	A1	19960919	DE 1995-19510861	19950316	<--
	CA 2215382	AA	19960919	CA 1996-2215382	19960315	<--
	WO 9628165	A1	19960919	WO 1996-EP1201	19960315	<--
	W: AU, BY, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9651108	A1	19961002	AU 1996-51108	19960315	<--
	AU 713258	B2	19991125			
	EP 814811	A1	19980107	EP 1996-907506	19960315	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
	CN 1178465	A	19980408	CN 1996-192615	19960315	<--
	JP 11501649	T2	19990209	JP 1996-527295	19960315	<--
	NZ 304027	A	20000526	NZ 1996-304027	19960315	<--
	IL 117516	A1	20000726	IL 1996-117516	19960317	<--
	ZA 9602177	A	19960729	ZA 1996-2177	19960318	<--
	NO 9704255	A	19971114	NO 1997-4255	19970915	<--
	US 2001006963	A1	20010705	US 1999-348232	19990706	<--
	US 2002193358	A1	20021219	US 2002-62569	20020205	<--
PRAI	DE 1995-19510861	A	19950316	<--		
	WO 1996-EP1201	W	19960315	<--		
	US 1998-913306	B1	19980130			
	US 1999-348232	B1	19990706			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19510861	ICM	A61K031-57
	ICS	A61K031-565
US 2001006963	NCL	514/171.000
	ECLA	A61K031/565+M; A61K031/57+M

<--

US 2002193358 NCL 514/170.000; 514/182.000
 ECLA A61K031/565+M; A61K031/57+M <--

AB The title injectable **composition** is suitable for women of peri- and premenopausal age who require both **contraception** and hormone replacement therapy to prevent osteoporosis and other manifestations of **estrogen** deficiency. The **composition** contains only natural **estrogens**, i.e. estradiol or an estradiol ester. Thus, an ampul contained **norethisterone** enanthate 50 and estradiol valerate 5 mg in 1 mL castor oil/BzOCH₂Ph (6:4 volume/volume).

ST **estrogen gestagen contraceptive injection**;
 menopause hormone replacement injection

IT **Contraceptives**
 Menopause
 (single monthly injection of **estrogen** and **gestagen** as sustained-release **contraceptive** and for hormone replacement therapy in peri- and premenopausal women)

IT **Estrogens**
Progestogens
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (single monthly injection of **estrogen** and **gestagen** as sustained-release **contraceptive** and for hormone replacement therapy in peri- and premenopausal women)

IT Pharmaceutical dosage forms
 (injections, single monthly injection of **estrogen** and **gestagen** as sustained-release **contraceptive** and for hormone replacement therapy in peri- and premenopausal women)


IT 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, esters 50-50-0, Estradiol 3-benzoate 51-98-9, **Norethisterone acetate** 71-58-9, **Medroxyprogesterone acetate** 313-06-4, Estradiol cypionate 427-51-0, **Cyproterone acetate** 979-32-8, Estradiol 17-valerate 3836-23-5, **Norethisterone** enanthate 4956-37-0, Estradiol enanthate 33613-02-4, Estradiol undecanoate 71615-27-5 99897-30-0 108116-22-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (single monthly injection of **estrogen** and **gestagen** as sustained-release **contraceptive** and for hormone replacement therapy in peri- and premenopausal women)

IT 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, esters 51-98-9, **Norethisterone acetate** 427-51-0, **Cyproterone acetate**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (single monthly injection of **estrogen** and **gestagen** as sustained-release **contraceptive** and for hormone replacement therapy in peri- and premenopausal women)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-28-2 HCAPLUS

CN Estradiol (Estra-1,3,5(10)-triene-3,17-diol (17 β)) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 23 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:557953 HCAPLUS

DN 125:204557

ED Entered STN: 19 Sep 1996

TI **Ovulation-inhibiting composition** for hormonal
contraception

IN Umbreit, Klaus

PA Germany

SO Ger. Offen., 3 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

ICI A61K031-57, A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19504227	A1	19960814	DE 1995-19504227	19950209 <--
	DE 19504227	C2	19990429		
PRAI	DE 1995-19504227		19950209	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19504227	ICM	A61K031-57
	ICS	A61K031-565
	ICI	A61K031-57, A61K031-565

AB An **ovulation-inhibiting** means for hormonal **contraception** comprises a packaging unit containing sep. individual daily dosage units, each containing a natural **estrogen** and a **gestagen**. The daily **estrogen** dose is uniform throughout the cycle, whereas the **gestagen** dose is graded, being extremely low (e.g. 0.03 mg) during the first 9 days and higher (≤ 0.2 mg) during the subsequent phase. Administration is interrupted after day 21 until the 3rd day of menstruation. This regimen provides effective **contraception**, reliable control of menstruation, and minimal side effects.

ST **contraceptive estrogen gestagen**

IT **Contraceptives**

(**ovulation-inhibiting composition** for hormonal
contraception)

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition for hormonal contraception)

IT 797-63-7, **Levonorgestrel** 979-32-8, Estradiol valerate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition for hormonal contraception)

IT 797-63-7, **Levonorgestrel**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition for hormonal contraception)

RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 24 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:380204 HCAPLUS

DN 125:50096

ED Entered STN: 02 Jul 1996

TI **Antiprogesterin** cyclophasic hormonal regimen

IN Grubb, Gary S.

PA Ortho Pharmaceutical Corporation, USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K031-56

INCL 514170000

CC 2-3 (Mammalian Hormones)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521166	A	19960528	US 1994-359159	19941219 <--
	CA 2208007	AA	19960627	CA 1995-2208007	19951215 <--
	WO 9619227	A1	19960627	WO 1995-US16561	19951215 <--
W:	AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
 BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9644730	A1	19960710	AU 1996-44730	19951215 <--
AU 711179	B2	19991007		
EP 799043	A1	19971008	EP 1995-943476	19951215 <--
EP 799043	B1	20040421		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10513152	T2	19981215	JP 1995-519952	19951215 <--
AT 264682	E	20040515	AT 1995-943476	19951215 <--
PT 799043	T	20040831	PT 1995-943476	19951215 <--
ES 2219673	T3	20041201	ES 1995-943476	19951215 <--
PRAI US 1994-359159	A	19941219	<--	
WO 1995-US16561	W	19951215	<--	


CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5521166	ICM	A61K031-56	
	INCL	514170000	
US 5521166	NCL	514/170.000; 514/171.000; 514/179.000; 514/863.000; 514/899.000	
	ECLA	A61K031/565+M; A61K031/567+M	<--
WO 9619227	ECLA	A61K031/565+M; A61K031/567+M	<--
AB	The present invention is directed to cyclophasic hormonal regimens which comprise antiprogesterin and progesterin for human contraception whereby progesterin is administered in the alternating presence and absence of an antiprogesterin in effective amts. to upregulate steroid receptor levels or is alternatively dosed with effective amts. of antiprogesterin to upregulate steroid receptor levels. The present invention also provides an estrogen containing cyclophasic hormonal regimen for climacteric or menopausal hormone replacement therapy comprising the administration of an effective hormone replacement amount of estrogen in alternating doses with a combined amount of estrogen and an effective amount of antiprogesterin to inhibit proliferation of endometrial tissue caused by the administration of the estrogen .		
ST	antiprogesterin progesterin cyclophasic regimen; contraceptive antiprogesterin progesterin cyclophasic regimen; menopause antiprogesterin progesterin cyclophasic regimen		
IT	Contraceptives Menopause (antiprogesterin and progesterin and estrogen cyclophasic regimen for contraception and menopause replacement therapy)		
IT	Estrogens Progestogens RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiprogesterin and progesterin and estrogen cyclophasic regimen for contraception and menopause replacement therapy)		
IT	Progestogens RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (inhibitors, antiprogesterin and progesterin and estrogen cyclophasic regimen for contraception and menopause replacement therapy)		
IT	57-63-6, Ethynylestradiol 68-22-4, Norethindrone 35189-28-7, Norgestimate 84371-65-3, RU 486 96346-61-1, Onapristone 97747-88-1, Lilo pristone RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)		

(antiprogesterin and progesterin and estrogen
cyclophasic regimen for contraception and menopause
replacement therapy)


IT 68-22-4, Norethindrone 35189-28-7, Norgestimate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiprogesterin and progesterin and estrogen
cyclophasic regimen for contraception and menopause
replacement therapy)
RN 68-22-4 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 35189-28-7 HCAPLUS
CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L61 ANSWER 25 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:224682 HCAPLUS
DN 124:251156
ED Entered STN: 17 Apr 1996
TI The effect of **estrogen** dose and **progesterin** type on
hemostatic changes in women taking low dose oral **contraceptives**
AU Norris, L. A.; Bonnar, J.
CS Department Obstetrics and Gynaecology, Coombe Women's Hospital, Dublin,
Ire.
SO British Journal of Obstetrics and Gynaecology (1996), 103(3),
261-7
CODEN: BJOGAS; ISSN: 0306-5456
PB Blackwell
DT Journal

LA English
 CC 2-3 (Mammalian Hormones)
 AB The effect of **estrogen** dose and **progestogen** type on the coagulation and fibrinolytic systems were determined in a group of normal healthy women taking three different oral **contraceptive combinations**. Plasma levels of factor VII, X, antithrombin III, protein C, fibrinogen, tissue plasminogen activator activity, plasminogen activator inhibitor I antigen and fibrin (D-dimer) degradation products were measured at pretreatment, 6, 14, 22 wk of treatment and at 6 wk post-treatment in a group of 67 women taking either 30 µg ethynylestradiol/150 µg **desogestrel**, 20 µg ethynylestradiol/150 µg **desogestrel**, 30 µg ethynylestradiol/75 µg **gestodene**. The participants were 67 healthy normal women, 18 to 34 yr, smoking fewer than 15 cigarettes per day. The subjects were within 10% of their normal body weight and had no history of thromboembolic disease. Factor VII and X levels were significantly raised on treatment with both the 30 µg ethynylestradiol/**desogestrel** and **gestodene combinations**. Higher levels of factor VII activity were observed in the 30 µg ethynylestradiol/**desogestrel combination** compared with the **gestodene combination**. Factor VII and X were not significantly affected by the 20 µg ethynylestradiol **combination**. Increased plasminogen, fibrinogen and D-dimer levels and decreased plasminogen activator inhibitor 1 antigen levels were observed during the treatment phases in all three groups. Antithrombin III and protein C activity did not change during treatment with any of the oral **contraceptives** studied. Low dose oral **contraceptives** cause an activation of the coagulation system which is balanced by an activation of the fibrinolytic system. Reducing the dose of ethynylestradiol from 30 µg to 20 µg reduces the effect on factor VII and X. This effect can be modified by the **progestogen**. The lesser effect of the 20 µg **combination** may make this a safer option for some women than pills containing a higher dose of **estrogen**.

ST **estrogen** dose hemostasis oral **contraceptive**
 IT Fibrins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (D dimer; degradation products **estrogen** dose in oral **contraceptives** effect on hemostasis in women modified by **progestogen**)

IT **Estrogens**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**estrogen** dose in oral **contraceptives** effect on hemostasis in women)

IT Blood coagulation
 Fibrinolysis
 (**estrogen** dose in oral **contraceptives** effect on hemostasis in women modified by **progestogen**)

IT Fibrinogens
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (**estrogen** dose in oral **contraceptives** effect on hemostasis in women modified by **progestogen**)

IT **Progestogens**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**estrogen** dose in oral **contraceptives** effect on hemostasis in women modified by **progestogen**)

IT **Contraceptives**
 (oral, **estrogen** dose in oral

contraceptives effect on hemostasis in women modified by
progestogen)

IT 9001-25-6, Blood-coagulation factor VII 9001-29-0, Factor X
139639-23-9, Tissue-type plasminogen activator 140208-23-7, Plasminogen
activator inhibitor I

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)

(**estrogen** dose in oral **contraceptives** effect on
hemostasis in women modified by **progestogen**)

IT 57-63-6, Ethynylestradiol 71138-35-7 109852-02-0, Ethynylestradiol-
gestodene mixture

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**estrogen** dose in oral **contraceptives** effect on
hemostasis in women modified by **progestogen**)

L61 ANSWER 26 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:194879 HCAPLUS

DN 124:242335

ED Entered STN: 05 Apr 1996

TI Pharmaceutical preparation for **contraception** and hormone
substitution with biogenic **estrogen** components

IN Oettel, Michael; Osterwald, Hermann; Moore, Claudia; Graeser, Thomas

PA Jenapharm GmbH, Germany

SO Ger., 8 pp.

CODEN: GWXXAW

DT Patent

LA German

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4429374	C1	19960201	DE 1994-4429374	19940812 <--
	EP 696454	A2	19960214	EP 1995-250153	19950628 <--
	EP 696454	A3	19960717		
	EP 696454	B1	19990929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 185072	E	19991015	AT 1995-250153	19950628 <--
	US 5633242	A	19970527	US 1995-511026	19950803 <--
	JP 08169833	A2	19960702	JP 1995-205801	19950811 <--
	JP 3002117	B2	20000124		
PRAI	DE 1994-4429374	A	19940812	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
DE 4429374	ICM	A61K031-565	
DE 4429374	ECLA	A61K031/565+M; A61K031/57+M	<--
EP 696454	ECLA	A61K031/565+M; A61K031/57+M	<--
US 5633242	NCL	514/170.000; 514/841.000; 514/843.000	<--

AB A 3-stage hormone treatment regimen effective for either
contraception or hormone replacement therapy in women
comprises (1) 3 or 4 daily dosage units of biogenic
estrogen (e.g. 17 β -estradiol), (2) 20-22 daily dosage units
of biogenic **estrogen**/C21 **gestagen combination**
, and (3) 3 or 4 daily dosage units of biogenic **estrogen**.
Continuation of **estrogen** administration throughout the 28-day
treatment cycle avoids the bleeding and other side effects of interruption
of **estrogen** administration seen in the prior art, and provides
excellent control of the ovarian cycle. Thus, suitable **compns**.

of tablets for the 3 treatment stages (1 tablet/day) were: (stage 1) micronized estradiol valerate 2.0, lactose 33.4, corn starch 17.2, PVP 2.1, and Mg stearate 0.3 mg (4 tablets); (stage 2) micronized estradiol 2.0, micronized **dienogest** 2.0, lactose 33.4, corn starch 17.2, PVP 2.1, and Mg stearate 0.3 mg (7 tablets), followed by micronized estradiol 4.0, micronized **dienogest** 2.0, lactose 33.4, corn starch 17.2, PVP 2.1, and Mg stearate 0.3 mg (14 tablets); (stage 3) micronized estradiol valerate 2.0, lactose 33.4, corn starch 17.2, PVP 2.1, and Mg stearate 0.3 mg (3 tablets).

ST **estrogen gestagen contraceptive hormone replacement**

IT Menopause
(hormone replacement therapy in; pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

IT **Estrogens**

Progestogens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

IT **Contraceptives**

(oral, pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

IT Menopause

(post-, hormone replacement therapy in; pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

IT 50-28-2, 17 β -Estradiol, biological studies 50-28-2D

, 17 β -Estradiol, derivs. 50-28-2D, 17 β -Estradiol, esters 51-98-9, **Norethisterone acetate**

57-83-0, **Progesterone**, biological studies

68-22-4, **Norethisterone** 152-62-5, **Dydrogesterone**

302-22-7, **Chlormadinone acetate** 797-63-7,

Levonorgestrel 979-32-8, **Estradiol valerate** 35189-28-7

, **Norgestimate** 54024-22-5, **Desogestrel**

54048-10-1, 3-Ketodesogestrel 60282-87-3,

Gestodene 65928-58-7, **Dienogest**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

IT 50-28-2, 17 β -Estradiol, biological studies 50-28-2D

, 17 β -Estradiol, derivs. 51-98-9, **Norethisterone**

acetate 57-83-0, **Progesterone**, biological

studies 68-22-4, **Norethisterone** 302-22-7,

Chlormadinone acetate 797-63-7, **Levonorgestrel**

35189-28-7, **Norgestimate** 54024-22-5,

Desogestrel 54048-10-1, 3-Ketodesogestrel

60282-87-3, **Gestodene** 65928-58-7,

Dienogest


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical preparation for **contraception** and hormone substitution with biogenic **estrogen** components)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS


CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 60282-87-3 HCAPLUS
 CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
 (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 65928-58-7 HCAPLUS
 CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17α)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 27 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:940912 HCAPLUS
 DN 124:45916
 ED Entered STN: 23 Nov 1995
 TI A twelve-month comparative clinical investigation of two low-dose oral
contraceptives containing 20 µg ethinylestradiol/75 µg
gestodene and 20 µg ethinylestradiol/150 µg
desogestrel, with respect to efficacy, cycle control and tolerance
 AU **Endrikat, J.**; Jaques, M. -A.; Mayerhofer, M.; Pelissier, C.;

Mueller, U.; **Duesterberg, B.**

CS Schering AG, Berlin, D-13342, Germany

SO Contraception (1995), 52(4), 229-35

CODEN: CCPTAY; ISSN: 0010-7824

PB Elsevier

DT Journal

LA English

CC 2-3 (Mammalian Hormones)

AB The aim of this study was to compare **contraceptive** reliability, cycle control and tolerance of an oral **contraceptive** containing 20 µg ethinylestradiol and 75 µg **gestodene**, with a reference preparation containing the same dose of **estrogen** combined with 150 µg **desogestrel**. This article presents interim data from centers in France and Austria, involving a total of 479 women and 4,991 cycles. **Contraceptive** reliability was good with both preps. With respect to cycle control, there is a trend towards a lower incidence of intermenstrual bleeding in the **gestodene** group. The incidence of spotting (scanty bleeding) during the important first three cycles was 3.5% lower in the **gestodene** group, and over the first six cycles, it was 7.6% lower. Amenorrhea was similar in both groups, but the incidence of dysmenorrhea was significantly lower in the **gestodene** group ($p = 0.001$). Adverse events were similar in both groups, with headache, breast tension and nausea the most frequently reported symptoms. Body weight remained relatively constant during treatment in both groups, and no hypertension was reported for any woman during the course of the study. In each treatment group, 19 women discontinued because of adverse events. It is concluded that both preps. are reliable and well tolerated oral **contraceptives**; however, there is a more favorable effect on dysmenorrhea by the **gestodene** formulation.

ST **gestodene** ethinylestradiol **desogestrel**
contraceptives

IT **Contraceptives**

(efficacy, cycle control and tolerance of low-dose oral **contraceptives** containing 20 µg ethinylestradiol/75 µg **gestodene** and 20 µg ethinylestradiol/150 µg **desogestrel** in humans)

IT 57-63-6, Ethinylestradiol 54024-22-5, **Desogestrel** 60282-87-3, **Gestodene**

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(efficacy, cycle control and tolerance of low-dose oral **contraceptives** containing 20 µg ethinylestradiol/75 µg **gestodene** and 20 µg ethinylestradiol/150 µg **desogestrel** in humans)

IT 54024-22-5, **Desogestrel** 60282-87-3, **Gestodene**


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(efficacy, cycle control and tolerance of low-dose oral **contraceptives** containing 20 µg ethinylestradiol/75 µg **gestodene** and 20 µg ethinylestradiol/150 µg **desogestrel** in humans)

RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L61 ANSWER 28 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:902894 HCAPLUS

DN 123:296590

ED Entered STN: 08 Nov 1995

TI **Estrogen-gestagen** combination for hormonal
contraception

IN Lachnit-Fixson, Ursula; Duesterberg, Bernd; Spona, Juergen

PA Schering A.-G., Germany

SO Ger. Offen., 7 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

CC 63-2 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4411585	A1	19951005	DE 1994-4411585	19940330 <--
	CA 2186739	AA	19951012	CA 1995-2186739	19950330 <--
	WO 9526730	A1	19951012	WO 1995-EP1190	19950330 <--
	W: AU, BG, BR, CA, CN, CZ, EE, FI, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SI, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9520735	A1	19951023	AU 1995-20735	19950330 <--
	EP 750501	A1	19970102	EP 1995-913171	19950330 <--
	EP 750501	B1	20020821		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

HU 75521	A2	19970528	HU 1996-2657	19950330 <--
BR 9507251	A	19970902	BR 1995-7251	19950330 <--
CN 1159161	A	19970910	CN 1995-193056	19950330 <--
CN 1108800	B	20030521		
JP 09511243	T2	19971111	JP 1995-525409	19950330 <--
RU 2165258	C2	20010420	RU 1996-119957	19950330 <--
AT 222494	E	20020915	AT 1995-913171	19950330 <--
PT 750501	T	20030131	PT 1995-913171	19950330 <--
ES 2181770	T3	20030301	ES 1995-913171	19950330 <--
CZ 291698	B6	20030514	CZ 1996-2879	19950330 <--
RO 118375	B1	20030530	RO 1996-1897	19950330 <--
FI 9603831	A	19961129	FI 1996-3831	19960925 <--
NO 9604089	A	19961107	NO 1996-4089	19960927 <--
BG 63192	B1	20010629	BG 1996-100940	19961028 <--
US 5756490	A	19980526	US 1996-718401	19961216 <--
AU 9912127	A1	19990325	AU 1999-12127	19990115 <--
AU 722362	B2	20000803		
PRAI DE 1994-4411585	A	19940330	<--	
AU 1995-20735	A3	19950330	<--	
WO 1995-EP1190	W	19950330	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4411585	ICM	A61K031-57
	ICS	A61K031-565
US 5756490	NCL	514/170.000; 514/843.000
	ECLA	A61K031/565+M; A61K031/57+M
AB	An oral contraceptive system comprises a series of 23-24 daily dosage units containing an estrogen and an ovulation -inhibiting amount of a gestagen , to be followed by a series of 4-10 daily dosage units containing an estrogen alone. The dosages are such as to minimize the estrogen and total hormone contents of each dosage unit while maintaining high contraceptive effectiveness and menstrual cycle control with low incidence of follicle development and side effects. Typical daily dosages are 1.0-4.0 mg 17 β -estradiol valerate and 0.05-0.075 mg Gestoden.	
ST	estrogen gestagen oral contraceptive	
IT	Estrogens	
	Progestogens	
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(estrogen-gestagen combination for hormonal contraception)	
IT	Contraceptives	
	(female, estrogen-gestagen combination for hormonal contraception)	
IT	50-28-2, 17 β -Estradiol, biological studies 57-63-6, Ethynylestradiol 68-22-4, Norethisterone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 979-32-8, 17 β -Estradiol valerate 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4	
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
	(estrogen-gestagen combination for hormonal contraception)	
IT	50-28-2, 17 β -Estradiol, biological studies 68-22-4,	

Norethisterone 427-51-0, Cyproterone
acetate 797-63-7, Levonorgestrel
35189-28-7, Norgestimate 54024-22-5,
Desogestrel 54048-10-1, 3-Ketodesogestrel
60282-87-3, Gestodene 67392-87-4


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(estrogen-gestagen combination for hormonal
contraception)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS


CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 797-63-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
 (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 54024-22-5 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2' (5'H)-furan]-3,5' (2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 29 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:696261 HCAPLUS

DN 123:65882

ED Entered STN: 25 Jul 1995

TI Low-dose **contraceptive composition** containing
estrogen and gestagen

PA Schering A.-G., Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4344462	A1	19950629	DE 1993-4344462	19931222 <--
	DE 4344462	C2	19960201		
	US 5583129	A	19961210	US 1994-268996	19940630 <--
	CA 2179728	AA	19950629	CA 1994-2179728	19941222 <--
	WO 9517194	A1	19950629	WO 1994-EP4274	19941222 <--
	W: CA, CN, CZ, HU, JP, KR, LT, LV, NO, NZ, PL, RU, SI, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 735883	A1	19961009	EP 1995-905574	19941222 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1142185	A	19970205	CN 1994-194888	19941222 <--
	HU 74877	A2	19970228	HU 1996-1750	19941222 <--
	RU 2169567	C2	20010627	RU 1996-115196	19941222 <--
	PL 187818	B1	20041029	PL 1994-315168	19941222 <--
	NO 9602676	A	19960822	NO 1996-2676	19960624 <--
	NO 316257	B1	20040105		
	US 5824667	A	19981020	US 1996-742147	19961031 <--
	US 37564	E	20020226	US 2000-503952	20000215 <--
	US 37838	E	20020910	US 2000-504084	20000215 <--
	US 38253	E	20030916	US 2002-80617	20020225 <--
PRAI	DE 1993-4344462	A	19931222	<--	
	US 1994-268996	A1	19940630	<--	
	WO 1994-EP4274	W	19941222	<--	
	US 1996-742147	A5	19961031	<--	
	US 2000-503952	A5	20000215		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
DE 4344462	ICM	A61K031-565	
DE 4344462	ECLA	A61K031/565+M; A61K031/57+M	<--
US 5583129	NCL	514/178.000; 514/173.000; 514/182.000	<--
US 5824667	NCL	514/170.000; 514/173.000; 514/178.000; 514/182.000	
	ECLA	A61K031/57+M; A61K031/58+M	<--
US 37564	NCL	514/170.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K031/58+M	<--
US 37838	NCL	514/170.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K031/58+M	<--
US 38253	NCL	514/170.000	
	ECLA	A61K031/565+M; A61K031/57+M; A61K031/58+M	<--
AB		Effective ovarian suppression is obtained in women of child-bearing age by daily administration for 23 or 24 days, beginning on the 1st day of menstruation, of a composition containing (1) an estrogen selected from 17 β -estradiol (2.0-6.0 mg) and ethynylestradiol (0.015-0.020 mg) and (2) a gestagen selected from gestodene (0.05-0.075 mg), levonorgestrel (0.075-0.125 mg), desogestrel (0.06-0.15 mg), 3-ketodesogestrel (0.06-0.15 mg), drospirenone (0.1-0.3 mg), cyproterone acetate (0.1-0.2 mg), norgestimate (0.2-0.3 mg), and norethisterone (>0.35-0.75 mg), followed by 5 or 4 days of no or placebo medication. This course of treatment decreases the incidence of follicle maturation, recruitment of dominant follicles during the shortened medication-free period, and endogenous secretion of 17 β -estradiol.	
ST		contraceptive estrogen gestagen	
IT		Estrogens	
		Progestogens	
		RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
		(low-dose contraceptive composition containing estrogen and gestagen)	
IT		Contraceptives	
		(female , low-dose contraceptive composition containing estrogen and gestagen)	
IT		50-28-2, Estradiol, biological studies 57-63-6, Ethynylestradiol 68-22-4, Norethisterone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4, Drospirenone	
		RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	
		(low-dose contraceptive composition containing estrogen and gestagen)	
IT		50-28-2, Estradiol, biological studies 68-22-4, Norethisterone 427-51-0, Cyproterone acetate 797-63-7, Levonorgestrel 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4, Drospirenone	
		RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)	

(low-dose contraceptive composition containing
estrogen and gestagen)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[alphenanthrene-17,2' (5'H) -
furan]-3,5' (2H) -dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-
hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 30 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:690164 HCAPLUS

DN 123:65884

ED Entered STN: 21 Jul 1995

TI **Ovulation-inhibiting composition** containing
estrogen and **gestagen** for hormonal **contraception**
 IN Ehrlich, Marika; Kuhl, Herbert
 PA Germany
 SO Ger. Offen., 4 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4344405	A1	19950629	DE 1993-4344405	19931224 <--
	DE 4344405	C2	19951207		
	CA 2179422	AA	19950706	CA 1994-2179422	19941124 <--
	WO 9517895	A1	19950706	WO 1994-DE1420	19941124 <--
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9510625	A1	19950717	AU 1995-10625	19941124 <--
	AU 703064	B2	19990311		
	EP 735881	A1	19961009	EP 1995-901345	19941124 <--
	EP 735881	B1	20030827		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 74428	A2	19961230	HU 1996-1714	19941124 <--
	JP 09502733	T2	19970318	JP 1994-517714	19941124 <--
	BR 9408513	A	19970819	BR 1994-8513	19941124 <--
	RU 2169566	C2	20010627	RU 1996-115165	19941124 <--
	PL 182544	B1	20020131	PL 1994-315119	19941124 <--
	AT 247969	E	20030915	AT 1995-901345	19941124 <--
	ES 2206487	T3	20040516	ES 1995-901345	19941124 <--
	FI 9602559	A	19960619	FI 1996-2559	19960619 <--
	NO 9602663	A	19960821	NO 1996-2663	19960621 <--
	NO 309843	B1	20010409		
PRAI	DE 1993-4344405	A	19931224	<--	
	WO 1994-DE1420	W	19941124	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4344405	ICM	A61K031-565
DE 4344405	ECLA	A61K031/565+M; A61K031/57+M <--
WO 9517895	ECLA	A61K031/565+M; A61K031/57+M <--

AB A kit for hormonal **contraception** consists of 2 series of spatially separated daily dosage units, of which the 1st series **comprises** 5-14 daily dosage units containing follicle maturation-inhibiting amts. of **estrogen** and the 2nd series **comprises** 23-14 daily dosage units containing **ovulation** -inhibiting amts. of **gestagen**. The 2nd series is to be taken beginning on the 1st day of menstruation, followed without a pause by the 1st series. Thus, daily dosage units containing 2 mg estradiol and 1 mg **norethisterone acetate** were taken for 21 days beginning on the 1st day of menstruation, followed by a dosage units containing 2 mg estradiol each day for 7 days; the same sequence was followed each month without interruption for 1 yr with excellent **contraceptive** protection and practically no side effects.

ST **ovulation** inhibition **estrogen gestagen** **contraception**

IT **Estrogens****Progestogens**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition containing estrogen and gestagen for hormonal contraception)

IT **Contraceptives**

(female, ovulation-inhibiting composition containing estrogen and gestagen for hormonal contraception)

IT 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 57-63-6, Ethynylestradiol 797-63-7, Levonorgestrel

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition containing estrogen and gestagen for hormonal contraception)

IT 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 797-63-7, Levonorgestrel


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ovulation-inhibiting composition containing estrogen and gestagen for hormonal contraception)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS


CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 797-63-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 31 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1995:559955 HCAPLUS
 DN 122:283164
 ED Entered STN: 19 May 1995
 TI **Progestogens and estrogens** for substitution therapy
 and oral **contraception**
 IN Koninckx, Philippe Robert Marie
 PA Saturnus AG, Luxembourg
 SO PCT Int. Appl., 12 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-57
 ICS A61K031-565
 CC 2-3 (Mammalian Hormones)
 Section cross-reference(s): 63
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9507081	A1	19950316	WO 1994-EP2997	19940908 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
NL 9301562	A	19950403	NL 1993-1562	19930909 <--
CA 2171460	AA	19950316	CA 1994-2171460	19940908 <--

AU 9476952	A1	19950327	AU 1994-76952	19940908 <--
AU 708881	B2	19990812		
EP 717626	A1	19960626	EP 1994-927583	19940908 <--
EP 717626	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1133011	A	19961009	CN 1994-193713	19940908 <--
CN 1076969	B	20020102		
HU 74452	A2	19961230	HU 1996-592	19940908 <--
JP 09502194	T2	19970304	JP 1994-508461	19940908 <--
AT 241362	E	20030615	AT 1994-927583	19940908 <--
FI 9601098	A	19960403	FI 1996-1098	19960308 <--
US 5827843	A	19981027	US 1996-605118	19960604 <--
AU 9918488	A1	19990429	AU 1999-18488	19990226 <--
PRAI NL 1993-1562	A	19930909	<--	
AU 1994-76952	A3	19940908	<--	
WO 1994-EP2997	W	19940908	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9507081	ICM	A61K031-57	
	ICS	A61K031-565	
NL 9301562	ECLA	A61K031/565+M; A61K031/57+M	<--
US 5827843	NCL	514/170.000	
	ECLA	A61K031/565+M; A61K031/57+M	<--

AB The invention relates to a preparation for substitution therapy and **contraception comprising at least one progestogen** and at least one **estrogen** in which the **estrogen** dose varies with a periodicity such that blood loss is substantially avoided, wherein the periodicity is preferably ≤ 10 days, more preferably ≤ 7 days, such as preps. containing the **progestogen** and/or **estrogen** in an oral, transdermal, parenteral and/or **implantable** application form. A tablet A containing ethinyl estradiol 15, estradiol valerianate 1, and **norethisterone** 1 mg and a tablet B containing 1.5 mg **norethisterone** were alternately administered with a periodicity of 4-7 days and an amenorrhea was induced without blood loss.

ST **progestogen estrogen contraceptive**
amenorrhea induction

IT Amenorrhea
(**progestogens** and **estrogens** for substitution therapy and **contraception**)

IT **Progestogens**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**progestogens** and **estrogens** for substitution therapy and **contraception**)

IT **Estrogens**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, **progestogens** and **estrogens** for substitution therapy and **contraception**)

IT Pharmaceutical dosage forms
(**implants**, **progestogens** and **estrogens** for substitution therapy and **contraception**)

IT **Contraceptives**
Pharmaceutical dosage forms
(oral, **progestogens** and **estrogens** for substitution therapy and **contraception**)

IT Pharmaceutical dosage forms
(parenterals, **progestogens** and **estrogens** for substitution therapy and **contraception**)

IT Pharmaceutical dosage forms

(transdermal, **progestogens** and **estrogens** for substitution therapy and **contraception**)

IT 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies 71-58-9, Medroxyprogesterone acetate 427-51-0, Cyproterone acetate 797-63-7 979-32-8, Estradiol valerianate 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4, Drospirenone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (progestogens and estrogens for substitution therapy and contraception)


IT 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 57-83-0, Progesterone, biological studies 427-51-0, Cyproterone acetate 797-63-7 35189-28-7, Norgestimate 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 60282-87-3, Gestodene 67392-87-4, Drospirenone

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (progestogens and estrogens for substitution therapy and contraception)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 67392-87-4 HCAPLUS

CN Spiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione, 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hexadecahydro-10,13-dimethyl-, (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 32 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:532413 HCAPLUS

DN 122:282287

ED Entered STN: 09 May 1995

TI The **combined oral contraceptive**. Risks and adverse effects in perspective

AU Bagshaw, Sue

CS Manager Medical Services, New Zealand Family Planning Association, Christchurch, N. Z.

SO Drug Safety (1995), 12(2), 91-6

CODEN: DRSAEA; ISSN: 0114-5916

DT Journal; General Review

LA English

CC 2-0 (Mammalian Hormones)

AB A review, with 15 refs.,. The risks and adverse effects of the low dose, new generation **progestogen combined oral contraceptives** (COCs) are much lower than original studies involving pills containing 50µg **estrogen**. The main effects are those on the cardiovascular system, lipid and glucose metabolism and cancer. Any effect of the COC on myocardial infarction is probably minimal if the woman has no other risk factors especially smoking. The third generation **progestogen**, low dose COCs have very little effect on lipid or

glucose metabolism There may be a slight increase in breast cancer if COCs are used under the age of 25 yr and for more than 4 to 8 yr, and in the risk of cervical cancer. It is too early to estimate long term cancer effects of the newer COCs. Adverse effects such as nausea and breast tenderness can be managed by changing the **estrogen** dose or the type of **progestogen**. Overall, the clin. benefits of the COC probably outweigh the risks and adverse effects.

ST review oral **contraceptive** risk adverse effect

IT Lipids, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolism; **progestogen combined oral contraceptive** risks and adverse effects)

IT Cardiovascular system

Neoplasm

(**progestogen combined oral contraceptive** risks and adverse effects)

IT **Estrogens**

Progestogens

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**progestogen combined oral contraceptive** risks and adverse effects)

IT Mammary gland

(neoplasm, **progestogen combined oral contraceptive** risks and adverse effects)

IT **Contraceptives**

(oral, **progestogen combined oral contraceptive** risks and adverse effects)

IT 50-99-7, D-Glucose, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(metabolism; **progestogen combined oral contraceptive** risks and adverse effects)

L61 ANSWER 33 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:294462 HCAPLUS

DN 122:64413

ED Entered STN: 14 Jan 1995

TI **Ovulation-inhibiting estrogen-gestagen combinations** for hormonal **contraception**

IN Umbreit, Klaus

PA Germany

SO Ger. Offen., 4 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K031-57

ICS A61K031-565

ICA A61K031-57; A61K031-565

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 4339934	A1	19941110	DE 1993-4339934	19931124 <--
	DE 4339934	C2	19950524		
PRAI	DE 1993-4315126	A1	19930507	<--	
	DE 1993-4338643	A1	19931112	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4339934	ICM	A61K031-57
	ICS	A61K031-565
	ICA	A61K031-57; A61K031-565
DE 4339934	ECLA	A61K031/57+M

AB A contraceptive kit comprises sep., equal or graded, daily doses of **estrogen-gestagen combinations** to be taken over 21-24 days, followed by a pause of 7-4 days. The **combinations** described provide adequate protection against conception and adequate control of menses with minimal side effects. Thus, a **combination** of ethynylestradiol 20 µg, estradiol valerate 1 mg, and chlormadinone acetate 2 mg to be taken daily for 22 days, followed by a pause of 6 days, was provided for hormonal **contraception** especially in young women.

ST **estrogen gestagen contraceptive**

IT **Contraceptives**
(ovulation-inhibiting **estrogen-gestagen combinations** for hormonal **contraception**)

IT **Estrogens**
Progestogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovulation-inhibiting **estrogen-gestagen combinations** for hormonal **contraception**)


IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 57-63-6, Ethynylestradiol 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 302-22-7, Chlormadinone acetate 797-63-7, Levonorgestrel 979-32-8, Estradiol valerate 54024-22-5, Desogestrel
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovulation-inhibiting **estrogen-gestagen combinations** for hormonal **contraception**)

IT 50-28-2, Estradiol, biological studies 51-98-9, Norethisterone acetate 302-22-7, Chlormadinone acetate 797-63-7, Levonorgestrel 54024-22-5, Desogestrel
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovulation-inhibiting **estrogen-gestagen combinations** for hormonal **contraception**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L61 ANSWER 34 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:613014 HCAPLUS

DN 121:213014

ED Entered STN: 29 Oct 1994

TI A process for the preparation of substantially alcohol-free pharmaceutical
compositions

IN Gala, Pankaj B.; D'Alonzo, Gary; Shah, Jatin J.; Weiss, Jay

PA Warner-Lambert Co., USA

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-14

ICS A61K009-20


CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418951	A1	19940901	WO 1994-US381	19940111 <--
	W: AU, CA, JP, NZ				
	RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2151260	AA	19940901	CA 1994-2151260	19940111 <--
	AU 9462291	A1	19940914	AU 1994-62291	19940111 <--
	AU 671536	B2	19960829		
	JP 08506831	T2	19960723	JP 1994-518960	19940111 <--
	US 5478571	A	19951226	US 1995-375077	19950117 <--
PRAI	US 1993-21428	A	19930223	<--	
	WO 1994-US381	W	19940111	<--	

CLASS	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 9418951	ICM	A61K009-14
		ICS	A61K009-20
	WO 9418951	ECLA	A61K009/14H6; A61K009/14H4; A61K009/20P <--
	US 5478571	NCL	424/464.000; 424/469.000; 424/484.000; 424/488.000; 424/489.000; 424/499.000 <--
AB	A novel process for the preparation of pharmaceutical compsns. involves the stabilization of the active drug(s) through the reduction of residual alc. present in a drug/carrier blend. The presence of residual alc. in dried pharmaceutical compsns. adversely affects many drugs which must be initially dissolved to achieve uniform distributions throughout the excipient carrier materials. Wherein not previously possible, its removal is achieved utilizing precise processing parameters in which water lost during the drying process is replenished during blending in a conventional solids processor. This method is especially suitable		
	for preparation of stabilized composition of water-insol. hormones.		
ST	hormone alc free oral solid form		
IT	Estrogens		
	Progestogens		
	Steroids, biological studies		
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(process for manufacturing substantially alc.-free oral compsns.)		
IT	Pharmaceutical dosage forms		
	(capsules, process for manufacturing substantially alc.-free oral compsns. of water-insol. hormones)		
IT	Contraceptives		
	(oral, process for manufacturing substantially alc.-free oral compsns.)		
IT	Pharmaceutical dosage forms		
	(tablets, process for manufacturing substantially alc.-free oral compsns. of water-insol. hormones)		
IT	51-98-9, Norethindrone acetate 57-63-6, Ethinyl estradiol		
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(process for manufacturing substantially alc.-free oral compsns.)		
IT	7732-18-5, Water, biological studies		
	RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(process for manufacturing substantially alc.-free oral compsns. of water-insol. hormones)		
IT	64-17-5, Ethanol, biological studies 67-56-1, Methanol, biological studies		
	RL: REM (Removal or disposal); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)		
	(process for manufacturing substantially alc.-free oral compsns. of water-insol. hormones)		
IT	51-98-9, Norethindrone acetate		
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(process for manufacturing substantially alc.-free oral compsns.)		
RN	51-98-9 HCAPLUS		
CN	19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)		

Absolute stereochemistry.



L61 ANSWER 35 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:491884 HCAPLUS
 DN 121:91884
 ED Entered STN: 20 Aug 1994
 TI **Combination** hormonal preparation for **contraception**
 IN Oettel, Michael; Dittgen, Michael; Osterwald, Hermann
 PA Jenapharm GmbH, Germany
 SO Ger., 5 pp.
 CODEN: GWXXAW
 DT Patent
 LA German
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4308406	C1	19940616	DE 1993-4308406	19930312 <--
	EP 628312	A1	19941214	EP 1994-250030	19940214 <--
	EP 628312	B1	20000426		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 192043	E	20000515	AT 1994-250030	19940214 <--
	RU 2122854	C1	19981210	RU 1994-7635	19940311 <--
PRAI	DE 1993-4308406	A	19930312	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4308406	ICM	A61K031-565
EP 628312	ECLA	A61K031/565+M; A61K031/57+M


AB The title preparation **comprises** ≥ 1 step consisting at least of a mixture of a biogenic **estrogen**, a synthetic **estrogen**, and a **gestagen**, and optional addnl. steps **comprising** placebo, biogenic or synthetic **gestagen**, biogenic or synthetic **estrogen**, or a **combination** thereof, applied orally, intravaginally, or transdermally. Thus, an ovulation-inhibiting preparation consisted of 21 daily doses each containing ethynylestradiol 0.005, micronized 17 β -estradiol 2, and **dienogest** 2 mg, followed by 7 daily doses of 2 mg micronized 17 β -estradiol.

ST **contraceptive estrogen gestagen**
 IT **Progestogens**
 RL: BIOL (Biological study)
 (contraceptive combinations containing estrogens and)

IT **Estrogens**
 RL: BIOL (Biological study)


- (contraceptive combinations containing gestagens and)
- IT Contraceptives
(female, estrogen-gestagen combinations)
- IT 51-98-9, Norethisterone acetate
57-83-0, Progesterone, biological studies
302-22-7, Chlormadinone acetate 427-51-0,
Cyproterone acetate 797-63-7,
Levonorgestrel 54024-22-5, Desogestrel
60282-87-3, Gestodene 65928-58-7,
Dienogest
RL: BIOL (Biological study)
(contraceptive combinations containing estrogens and)
- IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies
53-16-7, Estrone, biological studies 57-63-6, Ethynylestradiol
72-33-3, Mestranol 481-97-0, Estrone sulfate 979-32-8, Estradiol
valerate 24749-37-9, Estrane
RL: BIOL (Biological study)
(contraceptive combinations containing gestagens and)
- IT 51-98-9, Norethisterone acetate
57-83-0, Progesterone, biological studies
302-22-7, Chlormadinone acetate 427-51-0,
Cyproterone acetate 797-63-7,
Levonorgestrel 54024-22-5, Desogestrel
60282-87-3, Gestodene 65928-58-7,
Dienogest
RL: BIOL (Biological study)
(contraceptive combinations containing estrogens and)
- RN 51-98-9 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 302-22-7 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 427-51-0 HCAPLUS
 CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 797-63-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 65928-58-7 HCAPLUS


CN 19-Norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, Estradiol, biological studies
 RL: BIOL (Biological study)
 (contraceptive combinations containing
 gestagens and)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 36 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:474003 HCAPLUS
 DN 121:74003
 ED Entered STN: 20 Aug 1994
 TI Long-acting hormonal **contraceptive** methods for women
 AU d'Arcangues, C.
 CS Development and Research Training Human Reproduction, World Health
 Organization, Geneva, 1211/27, Switz.
 SO Frontiers in Endocrinology (1993), 2 (REPRODUCTIVE HEALTH), 163-9
 CODEN: FRENEZ; ISSN: 1124-1292
 DT Journal; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 AB A review, with 17 refs., of long-acting hormone **contraceptives**
 for women, including **progestogen**-only injectable preps.,
combined once-a-month **estrogen/progestogen**
 -injectable preps., **implantable contraceptives**, and
 vaginal rings.
 ST review hormone **contraceptive**
 IT **Estrogens**
Progestogens
 RL: BIOL (Biological study)
 (long-acting **contraceptives** containing, in women)
 IT **Contraceptives**

(long-acting, **estrogen** and **progestogen** containing, in women)

L61 ANSWER 37 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:253387 HCAPLUS

DN 120:253387

ED Entered STN: 14 May 1994

TI **Antiprogesterone-containing contraceptives**

IN Bergink, Engelbert Willem

PA AKZO N. V., Neth.

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-565

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9404156	A1	19940303	WO 1993-EP2139	19930810 <--
	W: AU, CA, FI, JP, KR, NO, NZ, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9305617	A	19940307	ZA 1993-5617	19930803 <--
	AU 9347089	A1	19940315	AU 1993-47089	19930810 <--
PRAI	EP 1992-202504	A	19920814	<--	
	WO 1993-EP2139	W	19930810	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 9404156	ICM	A61K031-565
------------	-----	-------------

AB An effective oral **contraceptive composition** is comprised of an **antiprogesterone** phase combined with a **progestogenic** phase. The **contraceptive composition** has a first phase of 5-20, especially 14, **sequential** daily dosage units containing an **antiprogesterone** at a daily dosage sufficient to inhibit **ovulation** in the female, and a second phase of 10 to 25, especially 14, **sequential** daily dosage units containing a **progestogen** at a dosage equivalent to 40-120 µg **desogestrel** administered orally. To the first phase is preferentially added an **estrogen** such as 17β-estradiol (I) (0.50-2.5 mg daily) to allow for the possibility of making a **sequential** regimen. A **contraceptive** tablets contained in the first phase (14 tablets) (6β,11β, 17β)-11-(4-dimethylaminophenyl)-6-methyl-4',5,-dihydrospro[estra-4,9-diene-17,2'(3'H)-furan]-3-one 20.00, I 1.00, corn starch 8.00, PVP 2.40, stearic 0.80, silica 0.08, dL-α-tocopherol 0.08, and lactose q.s. 80.00mg; and in the second phase (14 tablets) **desogestrel** 0.075, corn starch 8.000, PVP 2.400, stearic acid 0.0800, silica 0.0800, dL-α-tocopherol 0.0800, and lactose q.s. 80.000mg.

ST female **contraceptive antiprogesterone**
progestogen; estradiol **desogestrel**
antiprogesterone female **contraceptive** tablet

IT **Progestogens**

RL: BIOL (Biological study)
(female **contraceptives** containing **antiprogesterones** and)


IT **Estrogens**

RL: BIOL (Biological study)
(female **contraceptives** containing **antiprogesterones** and **progestogens** and)

IT Pharmaceutical dosage forms


- (capsules, **antiprogestogens** and **progestogens** in,
for female **contraception**)
- IT **Contraceptives**
(female, **antiprogestogens** and **progestogens**
in)
- IT **Progestogens**
RL: BIOL (Biological study)
(inhibitors, female **contraceptives** containing
progestogens and)
- IT Pharmaceutical dosage forms
(tablets, **antiprogestogens** and **progestogens** in, for
female **contraception**)
- IT 797-63-7, **Levonorgestrel** 35189-28-7,
Norgestimate 54024-22-5, **Desogestrel**
54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
RL: BIOL (Biological study)
(female **contraceptives** containing **antiprogestogens** and)
- IT 50-28-2, 17 β -Estradiol, biological studies 57-63-6, Ethinyl
estradiol 72-33-3, Mestranol 118968-41-5
RL: BIOL (Biological study)
(female **contraceptives** containing **antiprogestogens** and
progestogens and)
- IT 123916-70-1
RL: BIOL (Biological study)
(female **contraceptives** containing **progestogens** and)
- IT 797-63-7, **Levonorgestrel** 35189-28-7,
Norgestimate 54024-22-5, **Desogestrel**
54048-10-1, 3-Ketodesogestrel 60282-87-3,
Gestodene
RL: BIOL (Biological study)
(female **contraceptives** containing **antiprogestogens** and)
- RN 797-63-7 HCAPLUS
- CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 35189-28-7 HCAPLUS
- CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime,
(17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS


CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 50-28-2, 17β-Estradiol, biological studies
 RL: BIOL (Biological study)
 (female **contraceptives** containing **antiprogestogens** and **progestogens** and)
 RN 50-28-2 HCAPLUS
 CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 38 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1994:173484 HCAPLUS
 DN 120:173484
 ED Entered STN: 02 Apr 1994
 TI Ovulation-inhibiting agents for hormonal **contraception**
 IN Ehrlich, Marika; Kuhl, Herbert
 PA Germany
 SO Ger. Offen., 5 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4224534	A1	19940127	DE 1992-4224534	19920724 <--
	WO 9402103	A2	19940203	WO 1993-DE656	19930726 <--
	WO 9402103	A3	19940511		
	W: AU, BR, CA, FI, HU, JP, NO, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9345583	A1	19940214	AU 1993-45583	19930726 <--
	EP 651644	A1	19950510	EP 1993-915661	19930726 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				

JP 07509454 T2 19951019 JP 1993-504082 19930726 <--
 PRAI DE 1992-4224534 A 19920724 <--
 WO 1993-DE656 W 19930726 <--

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

DE 4224534 ICM A61K031-565


- AB A **contraceptive** kit contains 2 spatially separated hormonal components, each packaged as sep. unit doses: (1) an **estrogen** component which inhibits follicle maturation and (2) an **estrogen-gestagen combination** which inhibits ovulation. Each month, a unit dose of **estrogen** is taken on 5-14 successive days, followed by the **estrogen-gestagen combination** on the next 23-14 days, depending on the woman's normal cycle. Thus, **contraception** was achieved for 1 yr by administration of 2 mg estradiol/day for 7 days and an estradiol/**norethisterone acetate combination** (4 + 1 mg/day) for the next 21 days of each cycle.
- ST **contraceptive estrogen gestagen ovulation inhibition**
- IT **Estrogens**
 RL: BIOL (Biological study)
 (female **contraceptive** kit containing, for inhibition of ovary follicle maturation)
- IT **Ovulation**
 (inhibitors, **estrogen-gestagen combinations**, in female **contraceptive** kit)
- IT **Progestogens**
 RL: BIOL (Biological study)
 (mixts. with **estrogens**, female **contraceptive** kit containing, for **ovulation** inhibition)
- IT **Contraceptives**
 (female, follicle maturation-inhibiting **estrogens** and **ovulation-inhibiting gestagens** in kit of)
- IT Ovary
 (follicle, maturation of, **estrogen** for inhibition of, in female **contraceptive** kit)
- IT 50-28-2, Estradiol, biological studies 53-16-7, Estrone, biological studies 57-63-6, Ethynylestradiol 72-33-3, Mestranol 979-32-8, Estradiol valerate
 RL: BIOL (Biological study)
 (female **contraceptive** kit containing, for inhibition of ovary follicle maturation)
- IT 51-98-9D, **Norethisterone acetate**, mixts. with **estrogens** 57-63-6D, Ethynylestradiol, mixts. with **gestagens** 57-83-0D, **Progesterone**, mixts. with **estrogens** 72-33-3D, Mestranol, mixts. with **gestagens** 302-22-7D, Chlormadinone acetate, mixts. with **estrogens** 427-51-0D, **Cyproterone acetate**, mixts. with **estrogens** 797-63-7D, **Levonorgestrel**, mixts. with **estrogens** 54024-22-5D, **Desogestrel**, mixts. with **estrogens** 153655-34-6
 RL: BIOL (Biological study)
 (female **contraceptive** kit containing, for **ovulation** inhibition)
- IT 50-28-2, Estradiol, biological studies
 RL: BIOL (Biological study)
 (female **contraceptive** kit containing, for inhibition of ovary

follicle maturation)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 51-98-9D, Norethisterone acetate, mixts. with estrogens 57-83-0D, Progesterone, mixts. with estrogens 302-22-7D, Chlormadinone acetate, mixts. with estrogens 427-51-0D, Cyproterone acetate, mixts. with estrogens 797-63-7D, Levonorgestrel, mixts. with estrogens 54024-22-5D, Desogestrel, mixts. with estrogens


RL: BIOL (Biological study)

(female **contraceptive** kit containing, for **ovulation** inhibition)

RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L61 ANSWER 39 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:153798 HCAPLUS

DN 120:153798

ED Entered STN: 02 Apr 1994

TI Immunologic effects of **estrogens**, **progestins**, and **estrogen-progestin combinations**

AU Schuurs, A. H. W. M.; Geurts, T. B. P.; Goorissen, E. M.; Hazes, J. M. W.; Verheul, H. A. M.

CS Ordganon Sci. Dev. Group, Oss, 5340 BH, Neth.

SO Pharmacol. Contracept. Steroids (1994), 379-99. Editor(s):

Goldzieher, Joseph William; Fotherby, Kenneth. Publisher: Raven, New York, N. Y.

CODEN: 59SNAJ

DT Conference; General Review

LA English

CC 2-0 (Mammalian Hormones)

Section cross-reference(s): 15

AB A review, with approx. 190 refs., of effects of **estrogens**, **progestins** and **estrogen-progestin oral**

contraceptives on the immune system. Topics discussed were: effects of gender and physiolo. hormonal changes on immune responses; effects of **estrogens** on immune responses; effects of **progestins** on immune responses; and effects of oral **contraceptives** on immune responses, including oral **contraceptives** and autoimmune diseases.

ST review **estrogen progestin** immune system; oral **contraceptive** immune system review

IT Immunity

(estrogens and progestins and estrogen-progestin combinations effects on)

IT Immunomodulators
(estrogens and progestins and estrogen-progestin combinations in relation to)

IT **Progestogens**
RL: BIOL (Biological study)
(immunol. effects of **estrogens** and)

IT **Estrogens**
RL: BIOL (Biological study)
(immunol. effects of **progestins** and)

IT **Contraceptives**
(oral, **estrogen-progestin** containing, immunol. effects of)

L61 ANSWER 40 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:46149 HCAPLUS
DN 120:46149
ED Entered STN: 05 Feb 1994
TI A comparative metabolic study of two low-**estrogen**-dose oral **contraceptives** containing **desogestrel** or **gestodene progestins**

AU Crook, David; Godsland, Ian F.; Worthington, Melek; Felton, Carl V.; Proudler, Anthony J.; Stevenson, John C.
CS Wynn Inst. Metabolic Res., London, UK
SO American Journal of Obstetrics and Gynecology (1993), 169(5), 1183-9
CODEN: AJOGAH; ISSN: 0002-9378

DT Journal
LA English
CC 2-3 (Mammalian Hormones)

AB The authors' objective was to compare the effects of low-**estrogen**-dose oral **contraceptives** containing **desogestrel** or **gestodene progestins** on metabolic risk markers for coronary heart disease. A cross-sectional comparison of 70 women who used a **formulation** that contained 30 µg ethinyl estradiol and 150 µg **desogestrel**, 43 women who used a **formulation** that contained 30 µg ethinyl estradiol and 75 µg **gestodene**, and 54 women who did not use steroidal **contraceptives** was performed. Oral **contraceptive** users had higher concns. of high-d. lipoproteins than did women in the control group (+10% to 20%, $p < 0.001$) primarily because of increases in high-d. lipoprotein subfraction 3. High-d. lipoprotein subfraction 2 concns. were higher in users of the **desogestrel formulation**. Low-d. lipoprotein cholesterol concns. were normal in oral **contraceptive** users, but triglyceride concns. were high (+80% to +100%, $p < 0.001$). Fasting glucose, insulin, and C-peptide concns. were similar to the three groups, but their responses to a glucose load were higher in oral **contraceptive** users than in controls ($p < 0.01$ to $p < 0.001$). The late plasma insulin response to glucose was higher in women who used the **gestodene formulation** than in those who used the **desogestrel formulation**. The metabolic profiles induced by these oral **contraceptives** were remarkably similar and may reflect the activity of the **estrogen** component.

ST oral **contraceptive** low **estrogen progestin**;
desogestrel low **estrogen** oral **contraceptive**;
gestodene low **estrogen** oral **contraceptive**

IT **Progestogens**
RL: BIOL (Biological study)
(low-dose **estrogen** oral **contraceptives** containing,

- metabolic profile of, in women)
- IT **Estrogens**
RL: BIOL (Biological study)
(low-dose, oral **contraceptives** containing, metabolic profile of, in women)
- IT Lipoproteins
RL: BIOL (Biological study)
(apo-, A-I, of blood plasma, of women, low **estrogen/progestin** oral **contraceptives** increase of)
- IT Lipoproteins
RL: BIOL (Biological study)
(apo-, A-II, of blood plasma, of women, low **estrogen/progestin** oral **contraceptives** increase of)
- IT Lipoproteins
RL: BIOL (Biological study)
(apo-, B, of blood plasma, of women, low **estrogen/progestin** oral **contraceptives** increase of)
- IT Lipoproteins
RL: BIOL (Biological study)
(high-d., 2, of blood plasma, of women, low **estrogen/progestin** oral **contraceptives** increase of)
- IT Lipoproteins
RL: BIOL (Biological study)
(high-d., 3, of blood plasma, of women, low **estrogen/progestin** oral **contraceptives** increase of)
- IT **Contraceptives**
(oral, low **estrogen**, metabolic profile of, in women)
- IT 71138-35-7, **Marvelon** 109852-02-0, Femodene
RL: BIOL (Biological study)
(as low **estrogen/progestin** oral **contraceptive**, metabolic profile of, in women)
- IT 50-99-7, Glucose, biological studies
RL: BIOL (Biological study)
(insulin and C-peptide release response to, low **estrogen/progestin** oral **contraceptive** effect on, in women)
- IT 9004-10-8, Insulin, biological studies 59112-80-0, C-Peptide
RL: BIOL (Biological study)
(secretion of, glucose and low **estrogen/progestin** oral **contraceptive** effect on, in women)

L61 ANSWER 41 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:567765 HCAPLUS

DN 119:167765

ED Entered STN: 16 Oct 1993

TI **Contraceptive steroid formulations** containing **estrogen** analogs

IN Rzhaznikov, Vladimir M.; Ivanenko, Tatyana I.; Fedotov, Viktor P.; Grinenko, Galina S.; Popova, Elena V.

PA Institute of Experimental Endocrinology, USSR; All-Union Scientific-Research Pharmaceutical Institute

SO U.S.S.R.

From: Izobreteniya 1993, (3), 20.

CODEN: URXXAF

DT Patent

LA Russian

IC ICM A61K031-56

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	SU 1789216	A1	19930123	SU 1991-4902019	19910111 <--
PRAI	SU 1991-4902019		19910111	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
SU 1789216	ICM	A61K031-56

GI



I

AB **Contraceptive formulations comprise estrogen analogs (I) (R=H,Ac,Pr; R1=OH, OAc; R2=ethynyl) 19.36-37.5 and progestogens 62.5-80.65 weight%.**

ST **contraceptive estrogen progestogen**

IT **Progestogens**
RL: BIOL (Biological study)
(**contraceptives containing nitrated estrogens and**)

IT **Estrogens**
RL: BIOL (Biological study)
(**nitro-, contraceptives containing progestogens and**)

IT **Contraceptives**
(**female, nitrated estrogens and progestogens in**)

IT 150380-16-8D, derivs.
RL: BIOL (Biological study)
(**contraceptives containing progestogens and**)

L61 ANSWER 42 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1993:161077 HCAPLUS

DN 118:161077

ED Entered STN: 01 May 1993

TI Female sex hormones. **Estrogen-gestagen combinations**

AU Neumann, Friedmund

CS Berlin, W-1000/65, Germany

SO Pharmazeutische Zeitung (1992), 137(34), 9-15
CODEN: PHZIAP; ISSN: 0031-7136

DT Journal; General Review

LA German

CC 2-0 (Mammalian Hormones)

AB A review, with 8 refs., which described the applications of **estrogen-progestagen drug combination** in gynecol., both for **contraception** and for the treatment of various disorders such as premenstrual syndrome, endometriosis, abortion prophylaxis, etc. Historical events in the development of **contraceptives** and their mechanisms of action, application forms, and risks and side effects are also described.

ST **estrogen progestogen contraceptive pharmacol**
review

- IT **Progestogens**
RL: BIOL (Biological study)
(**estrogen combinations** with, gynecol. indications
and **contraceptive** pharmacol. of)
- IT Gynecology
(**estrogen-progestogen combinations**
indications in)
- IT Pharmacology
(of **estrogen-progestogen contraceptives**)
- IT **Estrogens**
RL: BIOL (Biological study)
(**progestogen combinations** with, gynecol.
indications and **contraceptive** pharmacol. of)
- IT **Contraceptives**
(oral, **estrogen-progestogen**
combinations in, pharmacol. of)
- L61 ANSWER 43 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:94398 HCAPLUS
DN 118:94398
ED Entered STN: 19 Mar 1993
TI **Contraceptive** vaginal rings: Efficacy and acceptability
AU Shoupe, Donna; Mishell, Daniel R., Jr.
CS Sch. Med., Univ. South. California, Los Angeles, CA, USA
SO Contraception (1992), 71-89. Editor(s): Sitruk-Ware, Regine;
Bardin, C. Wayne. Publisher: Dekker, New York, N. Y.
CODEN: 58RBAS
DT Conference; General Review
LA English
CC 2-0 (Mammalian Hormones)
AB A review, with 55 refs., of **contraceptive** vaginal rings,
including: the history of their development; their size, **composition**,
and placement; their pharmacokinetics; their use schedule; their
advantages over oral **contraceptives**; types of vaginal rings (**progestins** only for discontinuous use, **progestins** only
for continuous use, **estrogen** plus **progestin** rings for
discontinuous use); concerns e.g. vaginal infections, cervical changes,
expulsion, other vaginal-related problems; and their acceptability.
- ST review **contraceptive** vagina ring; **estrogen**
contraceptive vagina ring review; **progestin**
contraceptive vagina ring review
- IT **Estrogens**
RL: BIOL (Biological study)
(**contraceptive** vaginal rings containing **progestins** and,
efficacy and acceptability of, in women)
- IT **Progestogens**
RL: BIOL (Biological study)
(**contraceptive** vaginal rings containing, efficacy and
acceptability of, in women)
- IT **Contraceptives**
(intravaginal rings, **estrogen** and **progestin**
containing, efficacy and acceptability of, in women)
- L61 ANSWER 44 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:94397 HCAPLUS
DN 118:94397
ED Entered STN: 19 Mar 1993
TI Steroid injectable **contraception**: Current concepts and
perspectives
AU Garza-Flores, Josue; Cravioto, Maria del C.; Perez-Palacios, Gregorio

CS Natl. Inst. Nutr. S. Zubiran, Mexico City, Mex.
 SO Contraception (1992), 41-70. Editor(s): Sitruk-Ware, Regine;
 Bardin, C. Wayne. Publisher: Dekker, New York, N. Y.
 CODEN: 58RBA5
 DT Conference; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 AB A review, with 71 refs., of steroid injectable **contraception**
 including: **progestin-only injectable contraceptives**
 e.g. depot-**medroxyprogesterone** acetate and
norethisterone enanthate; **combined progestin-**
estrogen injectable contraceptives (current and new
 monthly **contraceptive formulations**); new directions in
 injectable **contraceptives** (new esters of synthetic
progestins, microencapsulated steroid suspensions, and macrocryst.
 steroid suspension); and injectable **contraceptives** in postpartum
 women.
 ST review steroid injectable **contraception**
 IT **Progestogens**
 Steroids, biological studies
 RL: BIOL (Biological study)
 (as injectable **contraceptives**, in women)
 IT **Estrogens**
 RL: BIOL (Biological study)
 (**progestins** and, as injectable **contraceptives** in
 women)
 IT **Contraceptives**
 (injectable, steroids as, in women)

L61 ANSWER 45 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:476531 HCAPLUS
 DN 117:76531
 ED Entered STN: 23 Aug 1992
 TI Low **estrogen** oral **contraceptives**
 IN Bergink, Engelbert Wilhelm
 PA AKZO N. V., Neth.
 SO Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 491415	A1	19920624	EP 1991-203182	19911205 <--
	EP 491415	B1	19960403		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	AT 136218	E	19960415	AT 1991-203182	19911205 <--
	ES 2087964	T3	19960801	ES 1991-203182	19911205 <--
	ZA 9109731	A	19920930	ZA 1991-9731	19911210 <--
	AU 9189647	A1	19920618	AU 1991-89647	19911211 <--
	AU 645382	B2	19940113		
	CA 2057528	AA	19920614	CA 1991-2057528	19911212 <--
	CA 2057528	C	20030204		
	FI 9105855	A	19920614	FI 1991-5855	19911212 <--
	FI 99083	B	19970630		
	FI 99083	C	19971010		
	NO 9104900	A	19920615	NO 1991-4900	19911212 <--

NO 179234	B	19960528		
NO 179234	C	19960904		
CN 1062290	A	19920701	CN 1991-111089	19911212 <--
CN 1036835	B	19971231		
US 5262408	A	19931116	US 1991-806966	19911212 <--
KR 187316	B1	19990501	KR 1991-22726	19911212 <--
PT 99782	B	20010531	PT 1991-99782	19911212 <--
JP 04290828	A2	19921015	JP 1991-330885	19911213 <--
PRAI EP 1990-203309	A	19901213	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 491415	ICM	A61K031-565	
EP 491415	ECLA	A61K031/565; A61K031/57+M	<--
US 5262408	NCL	514/182.000; 514/170.000; 514/179.000; 514/843.000	<--
AB		An oral contraceptive regimen comprises 24 daily sequential dosage units of a 1st phase comprising 7-9 sep. 1st dosage units containing a progestogen at a daily dosage equivalent in progestogenic activity to 100 µg desogestrel and an estrogen at a daily dosage equivalent in estrogenic activity to 25 µg ethinylestradiol. Phases 2 and 3 and 4 contain both progestogen and estrogen at different dosage units. Tablets were prepared containing different amts. of ethinylestradiol and desogestrel for different phases.	
ST		estrogen low oral contraceptive	
IT		Progestogens	
		RL: BIOL (Biological study) (oral contraceptive tablets containing lower concns. of estrogens and)	
IT		Estrogens	
		RL: BIOL (Biological study) (oral contraceptive tablets containing progestogens and lower concns. of)	
IT		Contraceptives	
		(oral, progestogens and lower concns. of estrogen tablets)	
IT		Pharmaceutical dosage forms (tablets, lower concns. of estrogens and progestogens , as oral contraceptives)	
IT		54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel	
		RL: BIOL (Biological study) (oral contraceptive tablets containing lower concns. of estrogens and)	
IT		50-28-2, Estradiol, biological studies 57-63-6, Ethinyl estradiol	
		RL: BIOL (Biological study) (oral contraceptive tablets containing progestogens and lower concns. of)	
IT		54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel	
		RL: BIOL (Biological study) (oral contraceptive tablets containing lower concns. of estrogens and)	
RN		54024-22-5 HCAPLUS	
CN		18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-(9CI) (CA INDEX NAME)	


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 50-28-2, Estradiol, biological studies


RL: BIOL (Biological study)

(oral **contraceptive** tablets containing **progestogens** and
lower concns. of)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 46 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:200917 HCAPLUS

DN 116:200917

ED Entered STN: 16 May 1992

TI Improvement of oral **contraceptive** formulations in
recent progress

AU Kobayashi, Takuro

CS Teikyo Univ., Japan

- SO Pharma Medica (1992), 10(1), 29-37
CODEN: PMEDEC; ISSN: 0289-5803
- DT Journal; General Review
- LA Japanese
- CC 63-0 (Pharmaceuticals)
Section cross-reference(s): 2
- AB A review, with 4 refs., of recent progress in preparation of oral **contraceptive** pills containing low doses of **estrogens** and/or **progestins**.
- ST review oral **contraceptive**
- IT **Estrogens**
Progestogens
RL: BIOL (Biological study)
(oral **contraceptive** pills containing low-dose, **formulation** of)
- IT **Contraceptives**
(oral, **formulation** of, low-dose **estrogen** and/or **progestins** in)
- IT Pharmaceutical dosage forms
(tablets, **contraceptive**, containing low-dose **estrogens** and/or **progestins**, **formulation** of)
- L61 ANSWER 47 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
- AN 1992:144098 HCAPLUS
- DN 116:144098
- ED Entered STN: 17 Apr 1992
- TI Hormonal content of **combined** oral **contraceptives** in relation to the reduced risk of endometrial carcinoma
- AU Rosenblatt, Karin A.; Thomas, David B.; Berry, Geoffrey; MacLennan, Robert; Shearman, Rodney; Jelihovsky, Tatiana; Booth, Joan Cooper; Molina, Ramiro; Martinez, Luis; et al.
- CS Dep. Public Health, Univ. Sydney, Sydney, Australia
- SO International Journal of Cancer (1991), 49(6), 870-4
CODEN: IJCNAW; ISSN: 0020-7136
- DT Journal
- LA English
- CC 2-3 (Mammalian Hormones)
- AB The relationship between the strength of the **estrogenic** and **progestational** components of **combined** oral **contraceptives** and risk of endometrial carcinoma was examined in a multinational hospital-based case-control study comparing 220 cases from 7 countries with 1,537 age- and hospital-matched controls. Oral **contraceptives** were classified according to their relative content of **estrogen** and **progestin**. The risk was not altered in women who used preps. containing high-dose **estrogen**/low-dose **progestin** compds. [odds ratio (OR) = 1.10, 95% CI = 0.13-9.96]. In contrast, the risk among users of low-dose **estrogen**/high-dose **progestin** oral **contraceptives** was greatly decreased (OR = 0, 95% CI = 0-1.08). Risks observed for users of high-dose **estrogen**/high-dose **progestin** (OR = 0.15, 95% CI = 0.045-0.50) and low-dose **estrogen**/low-dose **progesterone** (OR 0.59, 95% CI = 0.26-1.30) preps. were intermediate between those for users of the 2 other types of preparation A significantly lower risk was observed for high-dose **progestin** users than for low-dose users [ratio of odds ratios (ROR) = 0.21, 95% CI = 0.05-0.84]. Although the nos. are small, findings from this study suggest that **combined** oral **contraceptives** with varying strengths of **estrogen** and **progestin** have different effects on the risk of endometrial carcinoma.

ST oral **contraceptive** endometrial carcinoma
 IT **Estrogens**
 Progestogens
 RL: BIOL (Biological study)
 (content of, in oral **contraceptives** in women, endometrial
 carcinoma risk in relation to)
 IT **Uterus**, neoplasm
 (endometrium, carcinoma, risk of, with oral **contraceptive** use
 in women, hormonal content in relation to)
 IT **Contraceptives**
 (oral, endometrial carcinoma risk response to, in women,
 hormonal content in relation to)
 IT 8003-08-5 8015-12-1 8015-14-3 8015-29-0 8015-30-3 8056-51-7
 8056-92-6 8064-76-4 8075-78-3 37270-71-6 39366-37-5 67783-17-9
 RL: BIOL (Biological study)
 (endometrial carcinoma risk response to, in women, hormonal content in
 relation to)

L61 ANSWER 48 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1992:121110 HCAPLUS
 DN 116:121110
 ED Entered STN: 03 Apr 1992
 TI A multicenter study of coagulation and hemostatic variables during oral
 contraception: variations with four **formulations**
 CS World Health Organization, Geneva, Switz.
 SO British Journal of Obstetrics and Gynaecology (1991), 98(11),
 1117-28
 CODEN: BJOGAS; ISSN: 0306-5456
 DT Journal
 LA English
 CC 2-3 (Mammalian Hormones)
 AB The extents to which **progestogen** type and **estrogen** and
 progestogen dose may modify the effects of **combined** oral
 contraceptives (OC) on coagulation and hemostasis were examined
 Women were treated with one of the following OC preps. for at least 12
 mo: **norethisterone acetate** (NEA) 1 mg + ethinyl
 estradiol (EE) 50 µg; **levonorgestrel** (LNG) 250 µg + EE 50
 µg; LNG 250 µg + EE 30 µg; LNG 150 µg + EE 30 µg. At 12-mo
 follow-up, the women on each OC preparation showed acceleration of prothrombin
 time and increases in factor X and fibrinogen. With the OC containing NEA,
 there was also a persistent rise in factor VIIC and redns. of antithrombin
 III and α2-antiplasmin. The **formulation** which contained
 low doses of both LNG and EE showed the least adverse coagulation changes.
 Large increases in fibrinolysis were found in all OC groups. Thus, the
 adverse effects of **combined** OC on clotting are affected by the
 type and dose of **progestogen** as well as the dose of
 estrogen.

ST **contraceptive** oral blood coagulation; **estrogen**
 progestogen **contraceptive** hemostasis
 IT **Estrogens**
 Progestogens
 RL: BIOL (Biological study)
 (**contraceptives** containing, blood coagulation in women response
 to)
 IT Blood coagulation
 (oral **contraceptive** treatment effect on, in women)
 IT **Contraceptives**
 (oral, blood coagulation response to treatment with, in
 women)
 IT 51-98-9, **Norethisterone acetate** 57-63-6,

Ethinyl estradiol 797-63-7, Levonorgestrel

RL: BIOL (Biological study)

(contraceptives containing, blood coagulation in women response to)

IT 51-98-9, Norethisterone acetate

797-63-7, Levonorgestrel


RL: BIOL (Biological study)

(contraceptives containing, blood coagulation in women response to)

RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 49 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1991:69079 HCAPLUS

DN 114:69079

ED Entered STN: 23 Feb 1991

TI Osmotic dosage form comprising an estrogen and a progestogen

IN Wright, Jeri D.; Childers, Jerry D.; Barclay, Brian L.; Wong, Patrick S. L.; Atkinson, Linda E.

PA Alza Corp., USA

SO U.S., 14 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-22

INCL 424473000

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4948593	A	19900814	US 1989-351365	19890515 <--
	CA 2015709	AA	19901115	CA 1990-2015709	19900430 <--
	ZA 9003445	A	19910227	ZA 1990-3445	19900507 <--
	WO 9014075	A1	19901129	WO 1990-US2749	19900515 <--
	W: AU, JP, KR, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AU 9057414	A1	19901218	AU 1990-57414	19900515 <--
	AU 632824	B2	19930114		
	EP 472645	A1	19920304	EP 1990-908831	19900515 <--
	EP 472645	B1	19930714		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04505328	T2	19920917	JP 1990-508511	19900515 <--
	AT 91410	E	19930715	AT 1990-908831	19900515 <--
	ES 2057570	T3	19941016	ES 1990-908831	19900515 <--
	NO 9103961	A	19911010	NO 1991-3961	19911010 <--
PRAI	US 1989-351365	A	19890515	<--	
	EP 1990-908831	A	19900515	<--	
	WO 1990-US2749	A	19900515	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4948593	ICM	A61K009-22
	INCL	424473000
US 4948593	NCL	424/473.000; 424/422.000

AB An osmotic device for delivering **contraceptive** steroids **comprises**, (1) a wall permeable to the passage of fluid, (2) a compartment containing an **estrogen**, a **progestogen**, and a osmopolymer which increases in dimensions upon entering of the fluid, and (3) ≥ 1 exit passageway that connects the exterior of the device with the compartment. The invention device **simultaneously** delivers the **estrogen** and **progestogen** at a controlled rate. A 1st **composition** containing polyethylene oxide, hydroxypropyl Me cellulose, norethindrone, ethinyl estradiol, and Mg stearate and a 2nd **composition** containing polyethylene oxide, NaCl, hydroxypropyl Me cellulose, FD&C blue lake number 1, and Mg stearate were sep. granulated and pressed into a laminate form; 2 laminates were pressed into a contacting arrangement and surrounded with a semipermeable wall **comprising** cellulose acetate and polyethylene glycol dissolved in acetone/water. The wall-coated bilaminates were dried at room temperature and a 20 mil exit orifice

was laser drilled on the **contraceptive** laminate side. The product was dried in an oven at 50° for 1 h and given a color overcoat to enhance its esthetic appearance. Schematic drawings of the osmotic device are given.

ST osmotic device controlled release **contraceptive**; **estrogen progestogen contraceptive** osmotic device

IT **Progestogens**

RL: BIOL (Biological study)
(mixts., with **estrogens**, in osmotic devices, as **contraceptives**)

IT **Estrogens**

RL: BIOL (Biological study)
(mixts., with **progestogens**, in osmotic devices, as **contraceptives**)

- IT **Contraceptives**
 (oral, estrogens and progestogens
 mixture-containing osmotic devices for)
- IT **Pharmaceutical dosage forms**
 (osmotic devices, controlled-release, estrogens and
 progestogens in, as oral contraceptives)
- IT 50-27-1D, Estriol, mixts. with progestogen
 50-28-2D, Estradiol, mixture with progestogen
 50-50-0D, Estradiol benzoate, mixture with progestogen
 51-98-9D, Norethindrone acetate, mixts. with
 estrogen 53-16-7D, Estrone, mixts. with
 progestogen 57-63-6D, esters, mixts. with
 progestogen 57-63-6D, ethers, mixts. with
 progestogen 57-63-6D, mixture with progestogen
 57-83-0D, Progesterone, mixts. with
 estrogen 68-22-4D, 17 α -Ethinyl-19-nortestosterone,
 mixts. with estrogen 68-23-5D, Norethynodrel,
 mixts. with estrogen 68-96-2D, esters, mixts
 . with estrogen 68-96-2D, mixts. with
 estrogen 71-58-9D, Medroxyprogesterone acetate,
 mixts. with estrogen 79-64-1D, mixts. with
 estrogen 113-38-2D, Estradiol dipropionate, mixture with
 progestogen 297-76-7D, Ethynodiol diacetate, mixts.
 with estrogen 302-22-7D, mixts. with
 estrogen 313-06-4D, Estradiol cypionate, mixture with
 progestogen 434-03-7D, mixts. with estrogen
 481-97-0D, Estrone sulfate, mixts. with progestogen
 514-68-1D, Estriol succinate, mixts. with progestogen
 595-33-5D, Megestrol acetate, mixts. with estrogen
 600-57-7D, esters, mixts. with estrogen 793-55-5D,
 mixts. with estrogen 797-58-0D, mixts. with
 estrogen 797-63-7D, mixts. with
 estrogen 901-93-9D, Estrone acetate, mixts. with
 progestogen 979-32-8D, Estradiol valerate, mixture with
 progestogen 2284-32-4D, Estriol triacetate, mixts.
 with progestogen 3758-34-7D, Estradiol propionate,
 mixture with progestogens 5779-47-5D, mixts.
 with progestogen 5934-04-3D, mixts. with
 progestogen 6533-00-2D, DL-Norgestrel, mixts
 . with estrogen 8015-12-1 8056-51-7 20799-24-0D,
 mixts. with estrogen 35189-28-7D,
 mixts. with estrogen 37270-71-6 37370-73-3D,
 Estradiol acetate, mixture with progestogen 39366-37-5
 53568-84-6 54024-22-5D, mixts. with estrogen
 54048-10-1D, mixts. with estrogen
 60282-87-3D, Gestodene, mixts. with
 estrogen 71138-35-7 79871-54-8 109852-02-0 131540-90-4
 131562-23-7 131562-74-8
 RL: BIOL (Biological study)
 (contraceptive osmotic device containing)
- IT 50-28-2D, Estradiol, mixture with progestogen
 51-98-9D, Norethindrone acetate, mixts. with
 estrogen 57-83-0D, Progesterone, mixts
 . with estrogen 68-22-4D, 17 α -Ethinyl-19-
 nortestosterone, mixts. with estrogen
 302-22-7D, mixts. with estrogen
 797-63-7D, mixts. with estrogen
 35189-28-7D, mixts. with estrogen
 54024-22-5D, mixts. with estrogen
 54048-10-1D, mixts. with estrogen

60282-87-3D, Gestodene, mixts. with
estrogen


RL: BIOL (Biological study)

(contraceptive osmotic device containing)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 302-22-7 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17α)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



```
L61 ANSWER 50 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:453127 HCAPLUS
DN 113:53127
ED Entered STN: 17 Aug 1990
TI Two-stage contraception system and method using an estogren and
a progestin
IN Pasquale, Samuel A.
PA USA
SO U.S., 6 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-56
INCL 514170000
CC 2-3 (Mammalian Hormones)
Section cross-reference(s): 63
FAN.CNT 1
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4921843	A	19900501	US 1988-260447	19881020 <--
	WO 9004330	A1	19900503	WO 1989-US4697	19891019 <--
	W: AU, FI, JP, KR				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8944970	A1	19900514	AU 1989-44970	19891019 <--
	AU 620940	B2	19920227		
	HU 51899	A2	19900628	HU 1989-5364	19891019 <--
	EP 397823	A1	19901122	EP 1989-912312	19891019 <--
	EP 397823	B1	19990107		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03502932	T2	19910704	JP 1989-511457	19891019 <--
	JP 3001216	B2	20000124		
	AT 175353	E	19990115	AT 1989-912312	19891019 <--
	CA 2001144	AA	19900420	CA 1989-2001144	19891020 <--
	CA 2001144	C	19990720		
	ZA 8907977	A	19900725	ZA 1989-7977	19891020 <--
	FI 103951	B1	19991029	FI 1990-3106	19900620 <--
	US 35724	E	19980203	US 1995-369309	19950106 <--
PRAI	US 1982-875277	B1	19820428	<--	
	US 1988-260447	A	19881020	<--	
	WO 1989-US4697	A	19891019	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 4921843	ICM	A61K031-56
	INCL	514170000
US 4921843	NCL	514/170.000

- AU Koehler, G.; Goeretzlehner, G.
 CS Frauenklin., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
 SO Zentralblatt fuer Gynaekologie (1984), 106(17), 1173-81
 CODEN: ZEGYAX; ISSN: 0044-4197
 DT Journal; General Review
 LA German
 CC 2-0 (Mammalian Hormones)
 AB A review with 62 refs. on the use of **estrogen-gestagen combinations** as postcoital **contraceptives** in women. Possible mechanisms of action of these **contraceptives** were discussed, including problems of this **contraceptive** method.
 ST review steroid postcoital **contraceptive**; **estrogen progestogen** postcoital **contraceptive** review
 IT Steroids, biological studies
 RL: BIOL (Biological study)
 (as postcoital **contraceptives**, for women)
 IT **Progestogens**
 RL: BIOL (Biological study)
 (in postcoital **contraceptives** with **estrogens**, for women)
 IT **Estrogens**
 RL: BIOL (Biological study)
 (in postcoital **contraceptives** with **progestogens**, for women)
 IT **Contraceptives**
 (postcoital, **estrogen-progestogen** combination as, in women)
- L61 ANSWER 59 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:616238 HCAPLUS
 DN 101:216238
 TI **Formulation and noncontraceptive** uses of the new, low-dose oral **contraceptive**
 AU Batzer, Frances R.
 CS Philadelphia Fertil. Inst., Philadelphia, PA, 19107, USA
 SO Journal of Reproductive Medicine (1984), 29(7 (Suppl.)), 503-12
 CODEN: JRPMAP; ISSN: 0024-7758
 DT Journal; General Review
 LA English
 CC 63-0 (Pharmaceuticals)
 Section cross-reference(s): 2
 AB A review with 46 refs. on **estrogens, progestins**, their mode of action, side effects, and **noncontraceptive** uses.
 ST review **contraceptive** oral; **noncontraceptive** hormone review
 IT **Estrogens**
Progestogens
 RL: BIOL (Biological study)
 (oral **contraceptives** and **noncontraceptive** uses of)
 IT **Contraceptives**
 (oral, **formulation and noncontraceptive** uses of)
- L61 ANSWER 60 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:17738 HCAPLUS
 DN 100:17738
 ED Entered STN: 12 May 1984
 TI Oral **contraceptives** containing **estrogen** plus **progestogen**

AU Briggs, Michael; Briggs, Maxine
 CS Deakin Univ., Geelong, 3217, Australia
 SO Endocr. Mech. Fertil. Regul. (1983), 17-48. Editor(s):
 Benagiano, Giuseppe; Diczfalusy, Egon. Publisher: CNRS, Paris, Fr.
 CODEN: 5QKA7
 DT Conference; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 AB A review with 179 refs.
 ST oral contraceptive estrogen progestogen
 review
 IT **Progestogens**
 RL: BIOL (Biological study)
 (oral contraceptives containing estrogens and, for
 human)
 IT **Estrogens**
 RL: BIOL (Biological study)
 (oral contraceptives containing progestogens and, for
 human)
 IT **Contraceptives**
 (oral, estrogen-progestogen-containing, for
 human)

L61 ANSWER 61 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1980:34540 HCAPLUS
 DN 92:34540
 ED Entered STN: 12 May 1984
 TI **Estrogen and progestagen in contraception**
 AU Teter, Jerzy
 CS Pol.
 SO Lek. Horm.: Klin. Ter. (1979), 284-331. Editor(s): Teter,
 Jerzy. Publisher: Panst. Zakl. Wydawn. Lek., Warsaw, Pol.
 CODEN: 41YDAK
 DT Conference; General Review
 LA Polish
 CC 2-0 (Hormone Pharmacology)
 AB A review with 55 refs.
 ST review contraceptive estrogen progestogen
 IT **Estrogens**
Progestogens
 RL: BIOL (Biological study)
 (as contraceptives)
 IT **Contraceptives**
 (estrogens and progestogens as)

L61 ANSWER 62 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1979:180432 HCAPLUS
 DN 90:180432
 ED Entered STN: 12 May 1984
 TI **Combined oral contraceptives**
 AU Briggs, Michael H.
 CS Sch. Pure Appl. Sci., Deakin Univ., Geelong, Australia
 SO Regul. Hum. Fertil., Proc. Symp. Adv. Fertil. Regul. (1977),
 Meeting Date 1976, 253-82. Editor(s): Diczfalusy, E. Publisher: Scriptor,
 Copenhagen, Den.
 CODEN: 40FAAD
 DT Conference; General Review
 LA English
 CC 2-0 (Hormone Pharmacology)
 AB A review with 48 refs. is given on combined estrogen-

progestogen oral contraceptives.
ST review oral **contraceptive**; **estrogen**
progestogen contraceptive review
IT **Progestogens**
RL: BIOL (Biological study)
(**contraceptives** containing **estrogens** and)
IT **Estrogens**
RL: BIOL (Biological study)
(**contraceptives** containing **progestogens** and)
IT **Contraceptives**
(oral)

L61 ANSWER 63 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1978:417240 HCAPLUS
DN 89:17240
ED Entered STN: 12 May 1984
TI Effects of **estrogens** and **estrogen-progestogen**
combinations on liver function
AU Leclere, J.
CS Serv. Endocrinol. Med. E, Cent. Hosp. Univ. Nancy, Vandoeuvre-Nancy, Fr.
SO Annales d'Endocrinologie (1977), 38(6), 443-6
CODEN: ANENAG; ISSN: 0003-4266
DT Journal; General Review
LA French
CC 2-0 (Hormone Pharmacology)
AB A review with 8 refs.
ST review **contraceptive** liver function; **estrogen** liver
function review; **progestogen** liver function review
IT Liver
(function of, **estrogen-progestogen-containing**
contraceptives effect on)
IT **Contraceptives**
Estrogens
Progestogens
RL: BIOL (Biological study)
(liver function response to)

=>

IT **Progestogens**
 RL: BIOL (Biological study)
 (contraceptives containing benzamides and)

IT **Estrogens**
 RL: BIOL (Biological study)
 (contraceptives containing benzamides and **progestogens**
 and)

IT 52-76-6 68-22-4 6533-00-2
 RL: BIOL (Biological study)
 (contraceptives containing benzamides and)

IT 57-63-6
 RL: BIOL (Biological study)
 (contraceptives containing benzamides and **progestogens**
 and)


IT 55-21-0D, derivs. 15676-16-1 66644-81-3 71675-85-9 71675-88-2
 81982-32-3
 RL: BIOL (Biological study)
 (contraceptives containing **progestogens** and)

IT 68-22-4
 RL: BIOL (Biological study)
 (contraceptives containing benzamides and)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L61 ANSWER 57 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1985:39953 HCAPLUS

DN 102:39953

ED Entered STN: 09 Feb 1985

TI Oral **progesterone** and **estrogen/progestogen**
 therapy. Effects of natural and synthetic hormones on subfractions of HDL
 cholesterol and liver proteins

AU Ottosson, Ulla Britt

CS Dep. Obstetr. Gynecol., Univ. Umea, Umea, Swed.

SO Acta Obstetrica et Gynecologica Scandinavica, Supplement (1984
), 127, 37 pp.

CODEN: AGSSAI; ISSN: 0300-8835

DT Journal; General Review

LA English

CC 2-0 (Mammalian Hormones)

AB A review with 143 refs. on the effects of oral **progesterone** [
 57-83-0] or **estrogen-progestogen**
combination therapy on subfractions of high-d. lipoprotein
 cholesterol [57-88-5] and liver proteins.

ST review **estrogen progestogen** lipid metab; lipoprotein

cholesterol **estrogen** **progesterone** review; liver protein
estrogen **progesterone** review; **contraceptive**
 oral lipid metab review

IT **Progestogens**

RL: BIOL (Biological study)
 (lipoproteins of blood serum and proteins of liver response to
estrogen and, in women)

IT **Estrogens**

RL: BIOL (Biological study)
 (lipoproteins of blood serum and proteins of liver response to
progesterone and, in women)

IT **Proteins**

RL: BIOL (Biological study)
 (of liver; of women, **estrogen** and **progesterone**
 effect on)

IT **Liver, composition**

(proteins of, of women, **estrogen** and **progesterone**
 effect on)

IT **Lipoproteins**

RL: BIOL (Biological study)
 (high-d., cholesterol of, of blood serum of women, **estrogen**
 and **progesterone** effect on)

IT **Contraceptives**

(oral, **estrogen**-**progesterone**-containing,
 lipoproteins of blood serum and protein of liver response to, in women)

IT **57-83-0, biological studies**

RL: BIOL (Biological study)
 (lipoproteins of blood serum and proteins of liver response to, in
 women)

IT **57-88-5, biological studies**

RL: BIOL (Biological study)
 (of high-d. lipoproteins, of blood serum, **estrogen** and
progesterone effect on, in women)


IT **57-83-0, biological studies**

RL: BIOL (Biological study)
 (lipoproteins of blood serum and proteins of liver response to, in
 women)

RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 58 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1984:622785 HCAPLUS

DN 101:222785

ED Entered STN: 22 Dec 1984

TI Postcoital **contraception** with steroidal hormones

RL: BIOL (Biological study)

(buccal tablet containing, controlled-release)

IT 50-28-2, 17 β -Estradiol, biological studies 51-34-3,
Scopolamine 51-43-4, Epinephrine 52-53-9, Verapamil 55-16-3,
Scopolamine hydrochloride 57-63-6 59-42-7, Phenylephrine
68-22-4, Norethindrone 152-11-4, Verapamil hydrochloride
9004-10-8, Insulin, biological studies 9007-12-9, Calcitonin
9034-40-6, Gonadotropin-releasing hormone 16679-58-6, Desmopressin

RL: BIOL (Biological study)

(buccal tablets containing, controlled-release)

IT 9003-39-8, Poly(vinylpyrrolidone) 25322-68-3

RL: BIOL (Biological study)

(tablet matrix containing, buccal controlled-release)

IT 9003-01-4, Poly(acrylic acid) 9004-32-4, Carboxymethyl cellulose
9005-38-3, Sodium alginate

RL: BIOL (Biological study)

(tablet matrix, buccal controlled-release)

IT 50-28-2, 17 β -Estradiol, biological studies 68-22-4,
Norethindrone


RL: BIOL (Biological study)

(buccal tablets containing, controlled-release)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 55 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1987:642642 HCAPLUS

DN 107:242642

TI Buccal controlled-release drug dosage form
 IN Keith, Alec D.; Snipes, Wallace C.
 PA Zetachron, Inc., USA
 SO Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K009-26
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 232877	A2	19870819	EP 1987-101727	19870209 <--
	EP 232877	A3	19871202		
	EP 232877	B1	19911030		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4764378	A	19880816	US 1986-827615	19860210 <--
	AT 68966	E	19911115	AT 1987-101727	19870209 <--
	ES 2026469	T3	19920501	ES 1987-101727	19870209 <--
	CA 1302261	A1	19920602	CA 1987-529319	19870209 <--
	JP 62265235	A2	19871118	JP 1987-29481	19870210 <--
PRAI	US 1986-827615	A	19860210	<--	
	EP 1987-101727	A	19870209	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 232877	ICM	A61K009-26
US 4764378	NCL	424/435.000; 424/464.000; 424/486.000; 424/487.000 <--

AB A controlled-release buccal dosage **composition** consists of a pharmaceutically active compound dispersed in a noncryst. polymer matrix containing low-mol.-weight polyethylene glycol 30-75, medium- or high-mol.-weight polyethylene glycol 2-65, and an auxiliary high-mol.-weight polymer 1-40 weight%. A dosage form was prepared from melting of a **mixture** of polyethylene glycol (I) (mol. weight 1000) 20, I (mol. weight 1450) 38, I (mol. weight 3350) 3, I (mol. weight 8000) 3, propylene glycol 3, and poly(vinylpyrrolidone) 33 weight%. Dye distribution tests with the above **composition** indicated that the matrix adhered to an area of .apprx.10 cm² on the cheek and .apprx.10 cm² on the adjacent gum, and that it remained there for 10-30 min.

ST buccal controlled release tablet; polyethylene glycol buccal tablet; polyvinylpyrrolidone buccal tablet

IT **Estrogens**

Progestogens

RL: BIOL (Biological study)
 (tablet containing, buccal controlled-release)

IT Motion sickness

(treatment of, buccal controlled-release tablets for)

IT Mammary gland

(disease, Paget, treatment of, buccal controlled-release tablets for)

IT **Contraceptives**

(oral, buccal controlled-release tablets containing)

IT Menopause

(post-, **estrogen** supplements for, buccal controlled-release tablets for)

IT Pharmaceutical dosage forms


(tablets, buccal, controlled-release, containing polyethylene glycol-poly(vinylpyrrolidone) matrix)

IT 50-56-6, Oxytocin, biological studies 55-63-0, Nitroglycerin 87-33-2, Isosorbide dinitrate 1491-59-4, Oxymetazoline 11000-17-2, Vasopressin


maintained at 20-120 pg/mL. After 14 days, the 2nd delivery system replaces the 1st and maintains the previous activities and levels and also maintains 1-10 ng **progesterone**/mL serum. The 2 systems are **sequentially** administered for **contraception**.

- ST **estrogen progesterone LHRH female contraception**
- IT **Progestogens**
RL: BIOL (Biological study)
(LH-RH and **estrogenic** steroids and, in female **contraceptives**)
- IT **Estrogens**
RL: BIOL (Biological study)
(LH-RH and **progestational** steroids and, in female **contraceptives**)
- IT **Pregnancy**
(prevention of, LH-RH and **estrogenic** and **progestational** steroids in)
- IT **Contraceptives**
(female, LH-RH and **estrogenic** and **progestational** steroids in)
- IT 9034-40-6, LH-RH 9034-40-6D, LH-RH, derivs., analogs
RL: BIOL (Biological study)
(**estrogenic** and **progestational** steroids and, in female **contraceptives**)
- IT 57-83-0, **Progesterone**, biological studies
RL: BIOL (Biological study)
(in female **contraceptive** containing LH-RH)
- IT 9002-68-0
RL: BIOL (Biological study)
(suppression of, female **contraceptive** containing LH-RH and **estrogenic** and **progestational** steroids for)
- IT 9002-67-9, LH
RL: BIOL (Biological study)
(suppression of, female **contraceptive** containing LH-RH and **estrogenic** and **progestational** steroids for)
- IT 57-83-0, **Progesterone**, biological studies
RL: BIOL (Biological study)
(in female **contraceptive** containing LH-RH)
- RN 57-83-0 HCAPLUS
- CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 54 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:26978 HCAPLUS
DN 108:26978
ED Entered STN: 23 Jan 1988



L61 ANSWER 53 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 1988:88570 HCAPLUS
 DN 108:88570
 ED Entered STN: 19 Mar 1988
 TI Delivery system and method for continuous delivery of LH-RH
compositions in **combination** with sex steroid delivery
 for female **contraception**
 IN Crowley, William F., Jr.
 PA General Hospital Corp., USA
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K037-56
 ICS A61K037-00; A61K037-38
 CC 2-3 (Mammalian Hormones)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8705514	A1	19870924	WO 1987-US596	19870320 <--
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	EP 298990	A1	19890118	EP 1987-902913	19870320 <--
	EP 298990	B1	19941117		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 01502265	T2	19890810	JP 1987-502178	19870320 <--
	JP 2703243	B2	19980126		
	CA 1339345	A1	19970826	CA 1987-532566	19870320 <--
PRAI	US 1986-842643	A	19860321	<--	
	WO 1987-US596	W	19870320	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 8705514	ICM	A61K037-56
	ICS	A61K037-00; A61K037-38

AB A method for preventing pregnancy in a female mammal **comprises**
 (a) administering an effective amount of an LH-RH **composition** and an
 effective amount of an **estrogenic** steroid via a delivery system
 during the follicular phase of the menstrual cycle beginning at the onset
 of menses; and (b) administering an LH-RH **composition**,
estrogenic steroid, and **progestational** steroid via a 2nd
 delivery system during the luteal phase until the beginning of normal
 menses. The delivery system **comprises** means for administering
 the hormones in (a) and (b). An adult human female is treated with the
 1st delivery system during the follicular phase such that LH and FSH
 secretions are suppressed and the serum level of **estrogen** is

DT Patent
 LA English
 IC ICM A61K031-565
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 253607	A1	19880120	EP 1987-306174	19870713 <--
	EP 253607	B1	19920429		
	EP 253607	B2	20010523		
	R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE				
	DK 8703518	A	19880116	DK 1987-3518	19870708 <--
	DK 174724	B1	20031006		
	AU 8775379	A1	19880121	AU 1987-75379	19870709 <--
	AU 597084	B2	19900524		
	ZA 8705010	A	19890222	ZA 1987-5010	19870709 <--
	WO 8800469	A1	19880128	WO 1987-US1646	19870710 <--
	W: JP, KR				
	JP 01500431	T2	19890216	JP 1987-504480	19870710 <--
	JP 2645510	B2	19970825		
	GB 2192542	A1	19880120	GB 1987-16431	19870713 <--
	GB 2192542	B2	19900502		
	AT 75401	E	19920515	AT 1987-306174	19870713 <--
	ES 2033850	T3	19930401	ES 1987-306174	19870713 <--
PRAI	US 1986-885971	A	19860715	<--	
	WO 1987-US1646	W	19870710	<--	
	EP 1987-306174	A	19870713	<--	

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	EP 253607	ICM	A61K031-565
	EP 253607	ECLA	A61K031/565
AB	A method of providing hormonal replacement therapy and contraception for a premenopausal woman comprises administering a combination dosage form of an estrogen and a progestogen for 23-25 days beginning on day one of the menstrual cycle, followed by 2-5 pill-free or blank pill days, for a total 28 days in the administration cycle. The composition comprises an estrogen selected from 17 β -estradiol 0.5-2.0, ethinyl estradiol 0.008-0.030, and mestranol 0.015-0.060 mg and a progestogen selected from levonorgestrel 0.025-0.100, gestodene 0.010-0.070, desogestrel 0.0250-0.100, 3-ketodesogestrel 0.025-0.100, and norethindrone 0.085-0.35 mg.		
ST	estrogen progestogen hormone replacement contraceptive ; menopause pre contraceptive estrogen progestogen		
IT	Contraceptives (for premenopausal women, estrogen-progestogen combinations for)		
IT	Progestogens RL: BIOL (Biological study) (pharmaceutical pack containing estrogen and, for hormonal replacement and contraception)		
IT	Estrogens RL: BIOL (Biological study) (pharmaceutical pack containing progestogen and, for hormonal replacement and contraception)		
IT	Menopause (pre-, hormonal therapy and contraceptive protection in,		


- estrogen-progestogen combination for)**
- IT 68-22-4, Norethindrone 797-63-7, Levonorgestrel
 54024-22-5, Desogestrel 54048-10-1,
 3-Ketodesogestrel 60282-87-3, Gestodene
 RL: BIOL (Biological study)
 (pharmaceutical pack containing **estrogen** and, for hormonal
 replacement and **contraception**)
- IT 50-28-2, 17 β -Estradiol, biological studies 57-63-6, Ethinyl
 estradiol 72-33-3, Mestranol
 RL: BIOL (Biological study)
 (pharmaceutical pack containing **progestogen** and, for hormonal
 replacement and **contraception**)
- IT 68-22-4, Norethindrone 797-63-7, Levonorgestrel
 54024-22-5, Desogestrel 54048-10-1,
 3-Ketodesogestrel 60282-87-3, Gestodene
 RL: BIOL (Biological study)
 (pharmaceutical pack containing **estrogen** and, for hormonal
 replacement and **contraception**)
- RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




- RN 797-63-7 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 54024-22-5 HCAPLUS
 CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 54048-10-1 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-,
(17α)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-,
(17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 50-28-2, 17β-Estradiol, biological studies

RL: BIOL (Biological study)

(pharmaceutical pack containing **progestogen** and, for hormonal
replacement and **contraception**)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

US 35724 NCL 514/170.000; 514/843.000
ECLA A61K031/565+M; A61K031/57+M <--

AB A method of **contraception** comprises a 2-stage protocol in which an **estrogen** in a 1st **composition** is administered daily to a human female from days 2-7 of her menstrual cycle and a follow-up **composition** containing a **progestin** is administered daily through day 28. The follow-up **composition** can contain **progestin** alone or can contain a **combination** of **estrogen** and **progestin** in different weight ratios. A drug delivery system containing daily dosage units is also described. A placebo tablet is administered to a menstruating female for the first 2 days of the menstrual cycle, on days 3-7 0.02 mg ethinyl estradiol is administered daily, and on days 8-28 a daily dosage of 0.035 mg ethinyl estradiol and 0.5 mg norethindrone is administered.

ST **contraceptive estrogen progestin oral**
female; ethinyl estradiol norethindrone **contraceptive**

IT **Estrogens**
Progestogens
RL: BIOL (Biological study)
(two-stage female oral **contraceptives** containing)

IT **Contraceptives**
(female, two stage, **estrogens** and **progestins** in)

IT **Contraceptives**
(female oral, two stage, **estrogens** and **progestins** in)


IT 50-28-2, 17 β -Estradiol, biological studies 57-63-6, Ethinyl estradiol 68-22-4, Norethindrone 72-33-3, Mestranol 2137-18-0D, esters 6533-00-2 20799-27-3
RL: BIOL (Biological study)
(two-stage female oral **contraceptives** containing)

IT 50-28-2, 17 β -Estradiol, biological studies 68-22-4, Norethindrone
RL: BIOL (Biological study)
(two-stage female oral **contraceptives** containing)

RN 50-28-2 HCAPLUS


CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68-22-4 HCAPLUS
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L61 ANSWER 51 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1990:133193 HCAPLUS

DN 112:133193

ED Entered STN: 13 Apr 1990

TI **Estrogen-progestin combinations as contraceptives**

IN Casper, Robert F.

PA Jencap Research Ltd., Can.

SO Eur. Pat. Appl., 12 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K031-565

CC 2-3 (Mammalian Hormones)

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309263	A2	19890329	EP 1988-308840	19880923 <--
	EP 309263	A3	19890802		
	EP 309263	B1	19940309		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 1332227	A1	19941004	CA 1987-547743	19870924 <--
	CA 1332228	A1	19941004	CA 1987-547744	19870924 <--
	FI 8804378	A	19890325	FI 1988-4378	19880923 <--
	FI 101601	B1	19980731		
	NO 8804230	A	19890328	NO 1988-4230	19880923 <--
	NO 301689	B1	19971201		
	AU 8822760	A1	19890406	AU 1988-22760	19880923 <--
	AU 630334	B2	19921029		
	DK 8805296	A	19890525	DK 1988-5296	19880923 <--
	DK 174071	B1	20020521		
	ZA 8807127	A	19890628	ZA 1988-7127	19880923 <--
	HU 50043	A2	19891228	HU 1988-4989	19880923 <--
	HU 214598	B	19980428		
	EP 559240	A2	19930908	EP 1993-107794	19880923 <--
	EP 559240	A3	19931222		
	EP 559240	B1	20011205		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 102484	E	19940315	AT 1988-308840	19880923 <--
	ES 2061672	T3	19941216	ES 1988-308840	19880923 <--
	AT 209919	E	20011215	AT 1993-107794	19880923 <--
	ES 2169030	T3	20020701	ES 1993-107794	19880923 <--
	JP 01132523	A2	19890525	JP 1988-239566	19880924 <--
	JP 3314207	B2	20020812		
	CN 1041528	A	19900425	CN 1988-107593	19880924 <--
	CN 1042296	B	19990303		

KR 170764	B1	19990201	KR 1988-12403	19880924 <--
AU 9230448	A1	19930211	AU 1992-30448	19921224 <--
FI 9702370	A	19970604	FI 1997-2370	19970604 <--
JP 11286446	A2	19991019	JP 1998-344823	19981028 <--
JP 3208482	B2	20010910		
DK 200101066	A5	20010706	DK 2001-1066	20010706 <--
DK 174181	B1	20020819		
PRAI CA 1987-547743	A	19870924	<--	
CA 1987-547744	A	19870924	<--	
DK 1988-5296	L	19880923	<--	
EP 1988-308840	A	19880923	<--	
FI 1988-4378	A	19880923	<--	
JP 1988-239566	A3	19880924	<--	

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
EP 309263	ICM	A61K031-565	
CA 1332227	ECLA	A61K031/565+M; A61K031/57+M	<--
CA 1332228	ECLA	A61K031/565+M; A61K031/57+M	<--
EP 559240	ECLA	A61K031/565+M; A61K031/57+M	<--
AB		<p>A combination of estrogen and progestin is used for contraception, where a short period of relatively dominant estrogenic activity alternates with a short period of relatively dominant progestagenic activity. The combination is also used for hormone replacement therapy in menopausal or castrated women. A plurality of unit doses (preferably ≈ 3) of relatively dominant estrogenic activity is alternated with a similar plurality of unit doses of relatively dominant progestagenic activity, with each package containing 20-35 unit doses. This combination provides improved cycle control. Intermittent increases in estrogen activity stimulate endometrial growth and progestin receptors. This makes the endometrium more sensitive to subsequent progestin administration, which limits growth by decreasing estrogen receptors and increasing 17β-hydroxy steroid dehydrogenase. Interaction of progestin with progestin receptors induces secretory changes in the endometrium which results in a denser stroma and endometrial stability. A return to relatively dominant estrogenic activity then again stimulates estrogen and progestin receptors and renews endometrial sensitivity to progestin. This push-pull activity keeps endometrial activity within a narrow range depending on the number of days of estrogenic and progestagenic activity. Thus, 3-day phases of unit dosages of 0.035 mg 17α-ethynylestradiol and 0.5 mg norethindrone were alternated with 3-day phases of unit dosages of 0.035 mg ethynylestradiol and 0.75 mg norethindrone, beginning and ending with the 0.75 mg norethindrone combination, for 7 phases (21 days), beginning on day 5 after the onset of menstruation. This regimen was followed by a 7-day hormone-free interval. The subject had no bleeding or spotting while taking the test formulation, and had a withdrawal bleed starting on the 2nd day of the hormone-free interval and lasting 5 days.</p>	
ST		<p>contraceptive estrogen progestagen combination</p>	
IT		<p>Progestogens RL: BIOL (Biological study) (-estrogen combinations, as contraceptives and for hormone replacement therapy)</p>	
IT		<p>Estrogens RL: BIOL (Biological study) (-progestagen combinations, as</p>	

- contraceptives and for hormone replacement therapy)
- IT **Contraceptives**
(estrogen-progestagen combinations)
- IT Menopause
Ovariectomy
(hormone replacement therapy in, with **estrogen-progestagen combinations**)
- IT 50-27-1D, Estriol, mixts. with **progestagens**
50-28-2D, 17 β -Estradiol, mixts. with
progestagens 51-98-9D, Norethindrone acetate,
mixts. with **estrogens** 52-76-6D, mixts. with
estrogens 53-16-7D, Estrone, mixts. with
progestagens 53-16-7D, polyphosphates, mixts. with
progestagens 57-63-6D, 17 α -Ethinylestradiol, mixts
. with **progestagens** 57-83-0D, Progesterone,
mixts. with **estrogens** 68-22-4D, Norethindrone,
mixts. with **estrogens** 68-23-5D, Norethynodrel,
mixts. with **estrogens** 68-96-2D, esters, mixts
. with **estrogens** 71-58-9D, Medroxyprogesterone
acetate, mixts. with **estrogens** 72-33-3D, Mestranol,
mixts. with **progestagens** 79-64-1D, Dimethisterone,
mixts. with **estrogens** 152-62-5D, Dydrogesterone,
mixts. with **estrogens** 297-76-7D, Ethynodiol diacetate,
mixts. with **estrogens** 427-51-0D,
Cyproterone acetate, mixts. with
estrogens 432-60-0D, Allylestrenol, mixts. with
estrogens 434-03-7D, Ethisterone, mixts. with
estrogens 481-97-0D, Estrone sulphate, mixts. with
progestagens 514-68-1D, Estriol succinate, mixts. with
progestagens 797-63-7D, Levonorgestrel,
mixts. with **estrogens** 797-64-8D, mixts. with
estrogens 848-21-5D, mixts. with **estrogens**
977-79-7D, Medrogestone, mixts. with **estrogens**
979-32-8D, Estradiol valerate, mixts. with **progestagens**
1169-79-5D, mixts. with **progestagens** 2098-66-0D,
Cyproterone, mixts. with **estrogens**
3000-39-3D, Quingestanol acetate, mixts. with **estrogens**
6533-00-2D, DL-Norgestrel, mixts. with
estrogens 7280-37-7D, mixts. with **progestagens**
35189-28-7D, Norgestimate, mixts. with
estrogens 37270-71-6 54024-22-5D, Desogestrel
, mixts. with **estrogens** 60282-87-3D,
Gestodene, mixts. with **estrogens** 62057-27-6
125670-28-2
RL: BIOL (Biological study)
(as contraceptives and for hormone replacement therapy)
- IT 50-28-2D, 17 β -Estradiol, mixts. with
progestagens 51-98-9D, Norethindrone acetate,
mixts. with **estrogens** 57-83-0D,
Progesterone, mixts. with **estrogens**
68-22-4D, Norethindrone, mixts. with **estrogens**
427-51-0D, Cyproterone acetate, mixts
. with **estrogens** 797-63-7D, Levonorgestrel,
mixts. with **estrogens** 35189-28-7D,
Norgestimate, mixts. with **estrogens**
54024-22-5D, Desogestrel, mixts. with
estrogens 60282-87-3D, Gestodene,
mixts. with **estrogens**
RL: BIOL (Biological study)
(as contraceptives and for hormone replacement therapy)

RN 50-28-2 HCAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol (17 β) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 51-98-9 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-(acetyloxy)-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-83-0 HCAPLUS

CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 α) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 427-51-0 HCAPLUS

CN 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1 β ,2 β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797-63-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 35189-28-7 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 54024-22-5 HCAPLUS

CN 18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17 α)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+):



RN 60282-87-3 HCAPLUS

CN 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17 α)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-):



L61 ANSWER 52 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:597190 HCAPLUS

DN 109:197190

ED Entered STN: 25 Nov 1988

TI **Combination** dosage form containing **estrogens** and **progestogens** for pre-menopausal women

IN Upton, Gertrude Virginia

PA American Home Products Corp., USA

SO Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

ED Entered STN: 25 Dec 1987
 TI **Contraceptives** containing an **estrogen** and a
progestogen, which are prophylactic for hormone-dependent tumors
 IN Beillon, Xavier
 PA Fr.
 SO Fr. Demande, 7 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 IC ICM A61K031-57
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 2

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2589735	A1	19870515	FR 1985-16516	19851107 <--
PRAI FR 1985-16516		19851107	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
FR 2589735	ICM	A61K031-57

AB **Contraceptives** which protect against breast and endometrial cancer contain an **estrogen** and a **progestogen**. The **estrogen** is at a normal dosage and the **progestogen** is at a dose 1.5-3 times higher than in classic **contraceptives**. A mode of administration is: 7 days, 0.05 mg ethynylestradiol and 1 mg **norgestrel**; 14 days, 0.05 mg ethynylestradiol and 1.5 mg **norgestrel**; 7 days off. The biol. efficiency ratio of **progestogen** to **estrogen** is 627.

ST **progestogen estrogen contraceptive cancer prevention**

IT **Progestogens**

RL: BIOL (Biological study)
 (contraceptives containing **estrogens** and, for hormone-dependent tumor prevention)

IT **Estrogens**

RL: BIOL (Biological study)
 (contraceptives containing **progestogens** and, for hormone-dependent tumor prevention)

IT **Contraceptives**

(**estrogen-progestogen**, with prophylactic activity against hormone-dependent tumors)

IT **Uterus, neoplasm**

(endometrium, hormone-dependent, prophylaxis of, **estrogen-progestogen contraceptive** for)

IT **Neoplasm**

(hormone-dependent, prophylaxis of, **estrogen-progestogen contraceptive** for)

IT **Mammary gland**

(neoplasm, hormone-dependent, prophylaxis of, **estrogen-progestogen contraceptive** for)

IT 8056-51-7 8056-92-6 8075-78-3 67956-64-3

RL: BIOL (Biological study)
 (contraceptive containing, with prophylactic activity against hormone-dependent tumors)

L61 ANSWER 56 OF 63 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:412136 HCAPLUS

DN 105:12136

ED Entered STN: 13 Jul 1986

TI **Contraceptive composition**
 IN Howie, Peter William; McNeilly, Alan
 PA Societe d'Etudes Scientifiques et Industrielles de l'Ile-de-France, Fr.
 SO Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM A61K031-565
 ICS A61K031-165; A61K031-40
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	DE 3535396	A1	19860410	DE 1985-3535396	19851003	<--
	EP 177654	A1	19860416	EP 1984-402033	19841010	<--
	EP 177654	B1	19890531			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	AT 43499	E	19890615	AT 1984-402033	19841010	<--
	IN 162049	A	19880319	IN 1985-MA739	19850923	<--
	IL 76470	A1	19881031	IL 1985-76470	19850923	<--
	BE 903341	A1	19860401	BE 1985-11343	19850930	<--
	FI 8503768	A	19860411	FI 1985-3768	19850930	<--
	FI 83593	B	19910430			
	FI 83593	C	19910812			
	FR 2571254	A1	19860411	FR 1985-14432	19850930	<--
	FR 2571254	B1	19900112			
	ZA 8507524	A	19860528	ZA 1985-7524	19850930	<--
	AU 8548159	A1	19860417	AU 1985-48159	19851001	<--
	AU 573158	B2	19880526			
	JP 61093119	A2	19860512	JP 1985-225948	19851008	<--
	DD 238921	A5	19860910	DD 1985-281523	19851008	<--
	DK 8504614	A	19860411	DK 1985-4614	19851009	<--
	DK 164442	B	19920629			
	DK 164442	C	19921116			
	NO 8504009	A	19860411	NO 1985-4009	19851009	<--
	NO 169322	B	19920302			
	NO 169322	C	19920610			
	GB 2165750	A1	19860423	GB 1985-24891	19851009	<--
	GB 2165750	B2	19890301			
	HU 39601	A2	19861029	HU 1985-3921	19851009	<--
	HU 194494	B	19880229			
	CH 665953	A	19880630	CH 1985-4351	19851009	<--
	US 4639439	A	19870127	US 1985-786328	19851010	<--
	CA 1256802	A1	19890704	CA 1985-492672	19851010	<--
PRAI	EP 1984-402033	A	19841010			<--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
DE 3535396	ICM	A61K031-565	
	ICS	A61K031-165; A61K031-40	
US 4639439	NCL	514/171.000	<--

AB **A synergistic contraceptive composition** contains a hyperprolactinemic benzamide (e.g. the psychotropic, sulpiride), a **gestagen** or **progestogen**, and optionally an **estrogen**. For example, 500-mg tablets or capsules were prepared containing 150 µg **norethisterone**, 10 mg sulpiride, and excipient.
 ST **contraceptive benzamide gestagen; sulpiride gestagen contraceptive**
 IT **Contraceptives**
 (benzamide-progestogen compns.)